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Infections with alphaviruses such as RRV or CHIKV often induce severe myalgia 
and arthritic joint conditions in affected patients. Currently, treatment of these 
infections is only symptomatic with NSAIDs and analgesic drugs that often cause 
side effects on long term use. 
Macrophages and macrophage derived cytokines are thought to be major 
contributors to the inflammatory conditions during RRV infection and this study 
investigated the involvement of various cytokines, such as TNFα, MIF and NO. We 
could further establish a role of IL-6, IL-18, IL-33 and IL-10 and we were able to 
exclude the involvement of PGE2 in the pathogenesis of RRVD. With this extended 
knowledge several inhibitors of cytokine production were tested for their ability to 
inhibit transcription or release of pro-inflammatory cytokines. These inhibitors 
included erythromycin, clarithromycin, roxithromycin, ethyl pyruvate, pentoxifylline 
and resveratrol. Varying inhibitory effects on cytokine production were detected for 
all tested compounds during RRV infection with erythromycin and ethyl pyruvate 
showing strongest inhibition on most pro-inflammatory cytokines. 
The second part of the thesis highlights a possible role of muscle cells during 
alphavirus infections. We could show that RRV is able to undergo a cytolytic 
replication cycle in muscle cells, which likely contributes to the initial viraemia in the 
acute phase of the infection. We further investigated the role of muscle cell derived 
myokines as contributors to RRVD pathogenesis and we could show increased 
transcription or release of the inflammatory cytokines TNFα, IL-6, MIF, IL-18 and IL-
33. The cytokine inhibitors from previous experiments were trialled on RRV-infected 
myoblast cells and we were able to show a small inhibitory effect on IL-6 for 
macrolides but not ethyl pyruvate or resveratrol.   
The last set of experiments briefly investigated the role of adipocytes in RRV 
infection. We could show that unlike most cells RRV can infect adipocytes without 
causing immediate cytolysis. Furthermore we found the cytokines IL-6, IL-33 and 
MCP-1 to be increasingly expressed or released. No change in transcription or 
secretion of TNFα, NO, MIF or IL-18 was detected, whereas expression of HMGB3 
mRNA was found to be down-regulated in RRV infected adipocytes. 
In summary, these results add more knowledge to the understanding of the 




Several compounds have been tested and found to inhibit pro-inflammatory cytokine 
production at varying levels, with erythromycin and ethyl pyruvate showing the 
strongest effects, suggesting their use in clinical trials or animal models of 
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1. Literature Review 
1.1 Rheumatoid arthritis and viral arthritis 
Arthritis is an inflammatory condition of the joint that is associated with pain, heat, 
swelling and loss or limitation of function of the affected joint (Stein, 2003). Due to 
the rather broad definition, arthritic conditions are classified into several categories. 
Degenerative arthritis or osteoarthritis is a common form of joint abnormality 
characterised by loss of cartilage followed by mechanical degradation of the joint. 
This arthritic condition is commonly found in the elderly due to increased wear and 
tear of the joint cartilage. Rheumatoid arthritis (RA) in contrast is a chronic 
inflammatory autoimmune disorder affecting approximately 1% of the population in 
most countries. Although the aetiology of RA is still not fully understood, much 
progress has been made in understanding the mechanisms that lead to the 
characteristic symptoms. Inflammatory processes play a crucial role in disease 
pathogenesis, characterised by hypertrophy of the synovial lining and infiltration of 
inflammatory cells such as fibroblasts, lymphocytes and macrophages (Firestein, 
2003; McInnes & Schett, 2011).  
Similar pathological processes, namely the involvement of the synovium and 
infiltration of immune cells have been found to contribute to the inflammation in a 
form of infectious arthritis, triggered by a number of viruses, such as the human 
immunodeficiency virus or hepatitis virus B and C (Tarkowski, 2006), although 
manifestation of arthritis is not a predominant symptom of the infection with these 
pathogens (Holland et al., 2013). Other viruses however are classified as 
arthritogenic pathogens, with joint inflammation being one of the characteristic 
symptoms of infection. These viruses include parvovirus B19, dengue virus, rubella 
virus and members of the alphavirus genus such as Chikungunya virus or Ross 
River virus (Franssila & Hedman, 2006; Suhrbier & Mahalingam, 2009). 
Current research on arthritis focuses mainly on autoimmune conditions and their 
treatments, while research in the field of infectious arthritis is still lagging (Tarkowski, 
2006). Considering the economic burden and health impact of viral arthritis, with 
some localised virus outbreaks affecting more than 1 million people (Schwartz & 
Albert, 2010), it is important that effective and economical treatment options, 
including antiviral compounds or alternative treatments for the symptomatic 




arthritis focuses primarily on symptomatic pain relief using analgesics and/or non-
steroidal anti-inflammatory drugs, which do however often come with significant 
risks of adverse effects after prolonged administration (Suhrbier et al., 2012).  
Although it is not believed that the occurrence of viral arthritis increases the 
likelihood of developing autoimmune arthritis, the acute disease symptoms have a 
significant impact on physical health. Considering the duration of inflammatory joint 
conditions in viral arthritis, which for most alphaviruses generally lasts more than 6 
months, sometimes up to two years (Mylonas et al., 2002), it is possible that some 
lasting damage to joint and cartilage might occur, which may hasten the onset of 
osteoarthritis. A recent report (W. Chen et al., 2014) supports this idea, with results 
showing that significant bone loss can be present in joints of mice infected with Ross 
River virus, an arthritogenic virus. These findings further highlight the strong 
similarities between viral arthritis and RA (Ryman & Klimstra, 2014).  
1.2 Alphavirus infections as a cause of arthritis and myalgia 
Suhrbier and Mahalingam (Suhrbier & Mahalingam, 2009) have reviewed viral 
causes of arthritis and discussed the array of viruses inducing arthritic conditions. 
While the risk of developing arthralgia (joint pain) or arthritis is small for most 
viruses, it is almost always predominant in infections with certain members of the 
alphavirus genus, namely Ross River virus (RRV), Chikungunya virus (CHIKV), 
Barmah Forest virus (BFV), Mayaro virus, O’nyong-nyong virus and the Sindbis 
virus group. Due to the disease presentation, with inflammation generally affecting 
multiple joints, the symptoms of RRV infections were initially diagnosed as epidemic 
polyarthritis (EPA) and only after the discovery of alphaviruses as the causative 
agent the term viral arthritis was used (Jacups et al., 2008). Affected joints often 
show severe swelling with large numbers of macrophages found in the synovial 
lining. The infiltration of these immune cells and the subsequent release of 
inflammatory cytokines are believed to be the major contributor to the development 
of joint inflammation (Assuncao-Miranda et al., 2013). The resulting arthralgia and 
arthritis often last for several months and in some cases up to two years, despite the 
initial viraemia period of only 4-7 days. 
Apart from the severe arthritic symptoms, alphaviruses frequently cause 
excruciating muscle pain during the acute phase of infection. This myalgia often 
resolves within 7-10 days after onset, but prolonged pain has been reported to 




myalgia is still not fully understood and it has been suggested that infiltrating 
macrophages release inflammatory cytokines and thereby induce painful muscle 
inflammation (Lidbury et al., 2008). A more recent study (K. S. Burrack et al., 2015) 
found increasing numbers of activated T-cells in the muscle tissue of RRV infected 
mice, which may further contribute to the reported muscle pain. Apart from the 
involvement of immune cells, several studies have shown that alphaviruses can 
induce necrosis in muscle tissue of infected mice (Morrison et al., 2011; Morrison et 
al., 2006) and it is likely that all of these factors contribute to the severe muscle pain. 
Besides the discussed arthritis and myalgia, several other but less debilitating 
symptoms are commonly present in infections with alphaviruses, including fatigue, 
maculopapular rash and fever (Suhrbier et al., 2012).  
Although disease symptoms are self-limiting in alphaviral infections, the impact on 
health and economy is considerable, with approximately 4400-4800 infections 
recorded per year in Australia. A financial estimate (Woodruff & Bambrick, 2008) 
has calculated an average annual cost of A$4.3 to A$4.9 million for the Australian 
health system caused by RRV alone. Considering the cost for such a relatively small 
patient group and given that previous alphavirus outbreaks have affected up to 1.5 
million people, such as the 2006 Chikungunya epidemic in India (Schwartz & Albert, 
2010), the potential cost and impact on the population’s health in a large scale 
outbreak is substantial. 
Treatment of alphavirus induced arthritis mainly focuses on symptomatic relief using 
analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) such as 
paracetamol, naproxen or ibuprofen (Suhrbier & La Linn, 2004). Corticosteroids 
have previously been used, with patient recovery rates reportedly similar to other 
therapy options. Due to the immunosuppressive effect of steroids and possible 
gastrointestinal side effects however many prescribers are reluctant to use this 
therapy option (Mylonas et al., 2004; Suhrbier et al., 2012). Recent research efforts 
have focused on antiviral therapy or alternative treatment of symptoms. Various 
compounds such as chloroquine and ribavirin have been tested for the treatment of 
alphavirus infections in vitro, however most do not appear to be viable options for 
future treatments in vivo (Parashar & Cherian, 2014). Anti-TNFα therapy with 
etanercept has unsuccessfully been trialled in acute RRV infection as it has 
exacerbated disease progression in a mouse model (Zaid et al., 2011). It appears 
that TNFα is important in the initial antiviral response and an exhaustive anti-TNFα 





Apart from symptomatic or antiviral treatment of the infection some research efforts 
have targeted the control of mosquito vectors responsible for viral transmission. The 
natural cycle of alphaviruses occurs between susceptible vertebrate hosts and 
hematophageous arthropod vectors, hence these viruses are commonly referred to 
as arthropod-borne viruses or arboviruses (Suhrbier et al., 2012). Transmission 
cycles in the wild usually involve non-symptomatic vertebrates such kangaroos, 
wallabies, horses and possums acting as viral reservoirs in Australia (Atkins, 2013; 
Boyd & Kay, 2000), however direct transmission from human to human via mosquito 
vectors has been reported in large alphavirus outbreaks such as the 2004 CHIKV 
outbreak on La Reunion island or the 2006 outbreak in India (Pialoux et al., 2007). 
1.2.1 Ross River virus (RRV) 
Ross River virus (RRV), a single stranded positive sense RNA virus of the 
alphavirus genus, is endemic to Australia and the Pacific islands region and was first 
isolated in 1959 from Aedes vigilax (northern salt marsh mosquito) around the Ross 
River in northern Queensland (R. Doherty et al., 1963). Aedes (Ochlerotatus) vigilax 
is the most common vector of RRV in Australia, besides other mosquito species 
such as Aedes (Ochlerotatus) camptorhynchus and Culex annulirostris (Atkins, 
2013). Further Aedes species have shown to be susceptible to virus transmission 
and the rather recent increase of Aedes albopictus populations within Australia has 
raised public health concerns of increased transmissions of RRV (C. R. Williams, 
2012). So far, no human-mosquito-human transmission has been recorded for RRV 
yet, however a single case is known of RRV transmission through a contaminated 
blood transfusion (Hoad et al., 2015). 
Early reports of infections with RRV or the similar Barmah Forest virus (BFV) refer to 
the condition as epidemic polyarthritis (EPA) since alphaviruses were initially not 
recognised as the causative agent and arthritic symptoms generally affect multiple 
joints of infected patients (R. Doherty et al., 1963). Diagnosis was based solely on 
clinical symptoms and therefore RRV infections were indistinguishable from BFV 
infections until the latter virus was first isolated from an infected patient (Phillips et 
al., 1990). RRV is by far the most common alphavirus in Australia and in the last 
decade, approximately 4400-4800 cases of infection have been recorded annually, 
however outbreaks in the South Pacific with more than 50,000 patients have been 




A previous report (Sammels et al., 1995) described the geographic distribution of 
genomically differing RRV strains within Australia, but no evidence has been found 
for the genetic diversity of various RRV isolates to correlate with symptomatic 
manifestations of the infection (Suhrbier & Mahalingam, 2009). The influence of the 
RRV genome on disease development has been further investigated (Jupille et al., 
2011) and it was reported that gene sequences encoding the viral replicase non-
structural protein 1 (nsP1) and precursor to envelope 2 protein (pE2) determine the 
development of arthritic symptoms in infections. Mutations in the coding sequence of 
these proteins resulted in avirulent strains such as RRV DC5692 and fully virulent 
strains such as RRV T48 and substitution of the nsP1 and pE2 gene region in 
DC5692 with the corresponding sequence of T48 restored full virulence. A mutation 
in these genes may hence potentially increase virulence in current RRV strains and 
possibly lead to longer lasting and more severe symptomatic manifestations.  
Even though trials into RRV vaccination appear promising in current clinical phase 3 
studies (Wressnigg et al., 2014), it is important to continue research into treatment 
options for RRV disease (RRVD). The cost of vaccinations might likely only be 
viable for high risk personnel or people living in high risk areas. In addition, research 
into the pathogenesis of RRVD could potentially help to understand infections with 
other alphavirus, such as CHIKV (Srivastava et al., 2008). 
1.2.2 Chikungunya virus (CHIKV) 
Chikungunya virus (CHIKV) is a single-stranded positive-sense RNA virus and the 
most common alphavirus worldwide, with localised outbreaks affecting up to 1.5 
million people, such as the 2006 outbreak in India, or up to 50% of the population, 
such as the 2004 outbreak on La Reunion island (Schwartz & Albert, 2010; Suhrbier 
et al., 2012).  
CHIKV was initially discovered in Tanzania in 1952 with small outbreaks recorded in 
other parts of Africa and Asia in the following decades (Powers et al., 2000; 
Robinson, 1955). A more recent outbreak of CHIKV in 2004 in Kenya has spread 
globally, affecting several millions of people by 2011 (Caglioti et al., 2013). Disease 
manifestation is similar to other arthritogenic alphaviruses however symptom 
presentation is significantly more severe. The name ‘chikungunya’ is derived from 
the Makonde language and means ‘that which bends up’, referring to the often 
stooped posture of infected patients due to excruciating joint and muscle pain 




frequently present in the joints of extremities but can affect almost any joint. Further 
symptoms of CHIKV disease (CHIKVD) include high fever, fatigue and severe 
myalgia. As with RRV, the initial acute phase of infection lasts for 7-10 days, after 
which most symptoms slowly subside. Relapsing joint stiffness and arthralgia 
however often last for months or even years (Caglioti et al., 2013). Although 
mortalities in CHIKV infections have been reported in some instances, it is believed 
that underlying conditions were contributory factors (Bandyopadhyay et al., 2009; 
Economopoulou et al., 2009). 
The transmission vectors for CHIKV are mosquitoes of the Aedes family found 
throughout Africa, Asia and more recently also in the Americas and Australia (Higgs 
& Vanlandingham, 2015; C. R. Williams, 2012). Genetic comparison of various 
CHIKV isolates found a mutation in the viral envelope protein gene (E1-A226V), 
which led to increased infectivity for Aedes albopictus (Asian tiger mosquito) and 
Aedes aegypti (Yellow fever mosquito) (Schuffenecker et al., 2006). This contributed 
to the larger scale outbreak occurring on La Reunion island in 2004, since urban 
transmission cycles of CHIKV rely on the presence of these mosquito species for 
successful human-mosquito-human transmission without the need for a reservoir 
(Caglioti et al., 2013; Tsetsarkin et al., 2007). The mosquito species Aedes 
albopictus is geographically widespread, which has facilitated the expansion of 
CHIKV in the last decade (Higgs & Vanlandingham, 2015). Several Australian 
mosquito species have been investigated as possible vectors for CHIKV 
transmission and the populations of Aedes aegypti and Aedes albopictus were 
found to be highly susceptible to virus infection and transmission (van den Hurk et 
al., 2009). With ongoing reports of CHIKV infections in travellers returning from 
affected regions (Viennet et al., 2013) and suitable vectors within Australia, we 
believe it is only a matter of time before a CHIKV outbreak will occur in Australia. 
Very similar conditions have previously led to a small outbreak in Italy in 2007 
(Bonilauri et al., 2008; Rezza et al., 2007).   
1.3 Cellular response in alphavirus infection and inflammation 
It has been known for some time that a number of different cells and cell types are 
susceptible to alphavirus infection and La Linn et al. (La Linn et al., 2005) identified 
the importance of the α1β1-integrin collagen receptor for successful cellular binding 
(Aaskov et al., 1994; Wahlfors et al., 2000). Alphaviruses appear to interact with this 




(Leung et al., 2011). However, studies with other alphaviruses have also reported a 
less common, clathrin-independent pathway (Paredes et al., 2004).  
After entering the blood stream the initial path of the virus is unknown. It has been 
suggested that alphaviruses may undergo an early replication cycle in leukocytes 
and are then distributed through the lymph system (Assuncao-Miranda et al., 2013). 
Although there is no evidence of their involvement as yet, thrombocytes or platelets 
could potentially be involved in initial replication or distribution of the virus. Platelets 
are found at the site of virus entry into the blood stream and they have previously 
been reported to bind various viruses such as adenoviruses or dengue virus among 
others (Shimony et al., 2009). Thrombocytes can also internalise and shelter viruses 
as has been shown for the human immunodeficiency virus 1 (Flaujac et al., 2010), 
which could potentially facilitate the transfer of the virus to various target tissues or 
organs. With more recent reports highlighting the role of platelets in immune 
responses and as a source of inflammatory cytokines such as MIF, thrombocytes 
may also contribute to the hosts immune response upon virus infection (Semple et 
al., 2011; Strüßmann et al., 2013). More research is however necessary to 
investigate a possible role of thrombocytes in the infection of alphaviruses such as 
RRV or CHIKV. 
Although a variety of other cells may contribute to the pathogenesis of alphavirus 
induced arthritis and myalgia, this research project has focused on macrophages 
and myocytes and has briefly investigated a possible role of adipocytes in RRV 
infections. 
1.3.1 Macrophages in alphavirus infections 
The important role of macrophages and their secretory products in rheumatoid 
arthritis is well established (Kinne et al., 2000). A previous study (Linn et al., 1996) 
confirmed the susceptibility of macrophages to RRV and demonstrated the ability of 
the virus to infect RAW264.7 macrophages and induce production of active virus 
particles for a period of more than 60 days post infection in vitro. RRV has been 
shown to persist in another macrophage cell line for as long as 170 days and 
despite the virus concentration falling below detectable levels in culture, a 
spontaneous relapse of cytolytic replication could be observed (Way et al., 2002). 
Virus entry into macrophages is thought to occur via either an integrin receptor 
pathway or via antibody-dependent enhanced (ADE) infection, which is mediated by 




Following in vivo infection, viral titres reach high plasma levels initially but drop 
below the serological detection limit within approximately one week. In contrast, viral 
RNA is detectable in the macrophage infiltrated synovium of infected patients for up 
to 5 weeks post-infection (Soden et al., 2000). This persistent, non-cytolytic infection 
and the possibility of a spontaneous relapse strongly indicate that macrophages play 
a major role in the prolonged duration of the infection. 
Another indication that macrophages are pivotal cells in RRV infection is their 
increased migration into tissues that exhibited pathological symptoms during 
infection, such as joints and muscles. Macrophages have previously been shown to 
accumulate in the synovial lining of affected joints in RRVD (J. R. Fraser, 1986). 
Depletion of those macrophage infiltrates in vivo with disodium clodronate liposome 
treatment resulted in decreased levels of TNFα and MCP-1 in the affected tissues 
and a reduction in necrotic damage and local inflammation (Lidbury et al., 2008; 
Rooijen & Sanders, 1994). In addition to the infiltration into the synovium, 
macrophage migration into the striated muscles of RRV-infected mice has been 
observed previously. A study of RRV-infected mice (Lidbury et al., 2000) confirmed 
the primary role of macrophages in the muscle damage and found the declining 
presence of macrophages in the muscle correlated with the disappearance of 
symptoms. 
To our knowledge, apart from macrophage-depletion with clodronate no treatment 
options targeting these immune cells or their cytokine release have been 
investigated in RRV infection.  
1.3.2 Involvement of muscle cells in RRV infection 
Due to the myalgia present in most patients, some studies have focused on the 
involvement of muscle tissue in the pathogenesis of RRVD, however initial research 
into the role of muscle cells has produced contradictory results. Murphy et al. 
(Murphy et al., 1973) observed severe muscle fibre damage and cytolysis in infected 
mice whereas later studies (Eaton & Hapel, 1976) reported a non-cytolytic 
alphavirus infection in primary mouse muscle cell cultures. It was later suggested 
that infiltrating macrophages and subsequent cytokine release as well as other host 
specific processes appear to be responsible for the necrotic processes leading to 
the myalgia and myositis experienced by many patients during RRV infection 




research focus towards macrophages thereafter and away from the possible 
involvement of myocytes in disease pathology (Lidbury et al., 2008). 
Using a mouse model it was shown that RRV and CHIKV undergo cytolytic 
replication cycles in muscles after initial infection (Morrison et al., 2011; Morrison et 
al., 2006; Murphy et al., 1973). It has also been reported that CHIKV can persist in 
human satellite muscle cells for prolonged periods of time (Ozden et al., 2007) and 
more recent work (Sane et al., 2012) has confirmed the in vitro susceptibility of 
human myoblasts and myocytes to Sindbis Virus, another member of the 
arthritogenic alphavirus genus. Despite these advances in research, the role of 
muscle cells in alphavirus infections is still poorly understood. The apparent viral 
replication cycle as well as a possible prolonged dormant infection in muscle cells 
both indicate that muscle tissue may be involved in the pathogenesis of RRVD.  
Myocytes possess the ability to produce and secrete an array of cytokines such as 
Interleukin 6, which are often referred to as myokines, and hence are known to 
contribute to inflammatory processes (Muñoz-Cánoves et al., 2013; Pedersen et al., 
2007). As Frost et al. (Frost et al., 2002, 2004) have reported, the secretion of pro-
inflammatory cytokines can be induced by various stimuli in vitro, but to our 
knowledge it has never been shown if RRV can induce a cytokine response from 
myocytes in vivo or in vitro. The possible production of pro-inflammatory mediators 
secreted by muscle cells could very well exacerbate the myopathy and myositis 
induced by macrophage infiltrates and therefore offer a possible target for future 
treatment regimens. 
1.3.3 A possible role of adipocytes in alphavirus infection 
Earlier studies (Murphy et al., 1973) examined tissue samples of RRV-infected mice 
and found the highest viral titres in adipose tissue at 36 hr post infection. The 
average viral load in adipose tissue in the first 7 days was similar to the virus 
concentration found in muscles and exceeded titres in the blood. Cytolytic foci were 
detectable by 3 days post-infection in adipose tissue and necrosis continued even 
after virus levels dropped below the detection level. Despite these early reports little 
data is available on the effect of alphaviruses on either primary adipose tissue or 
adipocyte cell lines. Piper et al. (Piper et al., 1994) only refer to their unpublished 
data and mention the possibility to use Sindbis virus as an alphavirus vector for 
differentiated 3T3-L1 adipocytes, which could indicate the susceptibility of 3T3-L1 




Considering the limited information available, the possibility exists that the virus may 
undergo replication cycles in adipocytes within the first week of infection. 
Research on adipocytes has highlighted their important role in inflammatory 
processes as producers of cytokines, such as the pro-inflammatory mediators TNFα 
and IL-6. Various stimulants like lipopolysaccharide (LPS) or several cytokines have 
been shown to induce production and secretion of these adipokines, often initiating 
further signalling cascades (Berg & Scherer, 2005; Coppack, 2001). Adipocytes 
have previously been shown to secrete macrophage migration inhibitory factor 
(MIF), which is known to play a role in the pathogenesis of RRV infection (Herrero et 
al., 2011; Hirokawa et al., 1997). A review of the contributing role of adipocytokines 
in rheumatic arthritis has however also highlighted the importance of considering 
other non-adipocyte cells present in adipose tissue as sources of inflammatory 
mediators, such as infiltrated immune cells (Schäffler et al., 2006). 
A more recent focus on adipocyte biology has demonstrated their important role in 
the immune system as producers of various complement factors, such as C1 and 
C3a (Pattrick et al., 2009; Schaffler & Scholmerich, 2010). This is interesting and 
warrants further investigations, since both RRV as well as CHIKV have been shown 
to trigger immune reactions in which complement component C3 contributes to the 
destructive phase of the inflammation (Morrison et al., 2007; Morrison et al., 2008).  
1.4 Cytokines in viral arthritis 
Elevation of inflammatory cytokine levels such as TNFα and IL-6 are known to 
contribute to both the inflammation and pain in the joints of patients with rheumatoid 
arthritis (RA) (McInnes & Schett, 2011). Research into alphavirus induced arthritis 
has shown the pathological processes to be similar in RA and EPA, with cytokines 
thought to be the main contributors to disease progression in both conditions 
(Lidbury & Mahalingam, 2000a). A more recent study (Nakaya et al., 2012) 
confirmed this similarity by comparing the inflammatory processes of CHIKV 
induced arthritis with those present in RA. A significant overlap in the gene 
expression profile of numerous cytokines was apparent for both arthritic conditions 
and it was concluded that current RA treatments targeting cytokines may be 
beneficial for the treatment of alphavirus induced arthritis.  
Besides cytokines, other factors are known to contribute to arbovirus induced 




Morrison et al. (Morrison et al., 2011; Morrison et al., 2008) have shown the 
involvement of complement factors, such as C3, in disease progression and 
pathogenesis of alphavirus induced arthritis and more recently the influence of 
myeloid differentiation primary response gene 88 (Myd88)-dependent TLR7 
signalling on symptom manifestation and protection from disease was confirmed 
(Neighbours et al., 2012). These reports highlight the complex pathology in 
alphaviral arthritis.  We believe however that pro-inflammatory cytokines secreted by 
various cells upon infection remain the major contributors to disease progression. 
The experiments described in this thesis focused on the involvement of following 
cytokines and may suggest future therapy options for EPA, based on inhibition of 
cytokine production. 
1.4.1 Tumor necrosis factor alpha (TNFα)  
TNFα is recognised as a major pro-inflammatory cytokine and numerous treatments 
for inflammatory diseases currently target the TNFα pathway. TNFα can be released 
by a variety of cells, in most inflammatory conditions however the main TNFα 
producers are thought to be monocytes and macrophages (Oppenheim et al., 2001). 
TNFα production is regulated by a complex network of cytokines and adipokines 
and as such presents many possible targets for treatment of rheumatoid arthritis 
(Tarner et al., 2007). The contribution of TNFα to disease progression in alphavirus 
infections has previously been confirmed (Lidbury et al., 2008). Elevated TNFα 
levels were detected in the synovial fluid of patients with RRV induced arthritis as 
well as in the serum of RRV infected mice. Infection of mice pre-treated with 
disodium clodronate liposomes to deplete macrophages resulted in lower serum 
levels of TNFα, MCP-1 and IL-1b, which indicates the macrophage origin of these 
cytokines in RRV infection. 
The importance of TNFα as a key regulator in the production of further inflammatory 
cytokines is well established (Brennan & McInnes, 2008; Oppenheim et al., 2001), 
and since anti-TNFα treatments are successfully used in the management of RA it 
was concluded that they may be beneficial in the treatment of alphavirus infections 
(Suhrbier & Mahalingam, 2009). Exhaustive anti-TNFα therapies with etanercept or 
monoclonal antibodies such as infliximab however are expensive and may not be 
considered economical in a self-limiting disease with moderate sequaele. Patients 
often also experience adverse effects such as increased susceptibility to infections 
(van Dartel et al., 2012), which may make these treatment options less suitable for 




immune responses during viral infection has been reported previously and 
excessive anti-TNFα therapy was suggested to negatively influence the host’s ability 
to counteract such infections (Suhrbier & Mahalingam, 2009). This concept was later 
confirmed when TNFα inhibition with etanercept exacerbated disease symptoms in 
RRV-infected mice (Zaid et al., 2011). 
Our investigations focused on compounds that are known to reduce but not 
completely halt TNFα secretion in macrophages, thereby inhibiting excessive 
inflammatory processes without supressing basic immune reactions. Table 1 shows 
a list of compounds that have been tested in various macrophage cells or animal 
models. The list is not exhaustive and focused on inhibitors that were initially 
considered for our experiments due to availability and affordability.  
1.4.2 Nitric oxide (NO) and inducible Nitric oxide synthase (iNOS) 
Nitric oxide (NO) is a gaseous signalling molecule with crucial roles in immune 
responses, the regulation of inflammatory processes, neuronal communication and 
vasoregulation (Bogdan, 2015). It can be produced in most cell types via activation 
of one of three different NO-synthases (NOS): neuronal NOS (nNOS, NOS-1), 
inducible NOS (iNOS, NOS-2) and endothelial NOS (eNOS, NOS-3) (Pautz et al., 
2010). Both nNOS and eNOS are pre-formed enzymes that produce NO depending 
on intracellular calcium levels with generally slow production rate. In contrast, iNOS 
is synthesized de-novo upon stimulation and output of NO is calcium-independent 
with higher production rates as compared to eNOS or nNOS. It appears that the NO 
produced during inflammatory and host defence mechanisms is almost exclusively 
derived from iNOS (Nagy et al., 2010; Schmitz et al., 2005). Expression of iNOS can 
be induced by various cytokines or other mediators in a wide range of cell types 
including macrophages (Kobayashi, 2010).  
The central role of NO in the pathogenesis of rheumatoid arthritis has been 
established with increased levels of NO found in the serum and synovial fluid of 
patients with rheumatoid arthritis (RA) as compared to patients with osteoarthritis or 
healthy individuals (Ueki et al., 1996). It was later suggested that elevated systemic 
NO levels in inflammatory arthritis are likely due to increased iNOS expression in 





Table 1: TNFα inhibitors in macrophages or macrophage cell lines  
  
  
Inhibitor Cells / animal model References 
Thalidomide RAW264.7 macrophages (Noman et al., 2009) 
Pentoxifyline 
RAW264.7 macrophages, human 
alveolar macrophages  
(Loftis et al., 1997),   
(Marques et al., 1999) 
Erythromycin Human monocytes (PBMCs) 
(Bailly et al., 1991; Iino et al., 
1992) 
Clarithromycin Mouse model (Tkalcevic et al., 2008) 
Roxithromycin Human monocytes (PBMCs) (Bailly et al., 1991) 
SM905  
(artemisinin derivative) 
RAW264.7 macrophages (J. Wang, 2009) 
Pyrrolidine 
dithiocarbamate 
Rat model (Z.  Zhang et al., 2009) 
Ethyl pyruvate 
RAW264.7 macrophages, mouse 
model 
(Shang et al., 2009),  
(Ulloa et al., 2002) 
Gabexate mesilate 
Rat model,  
human monocytes 
(Yuksel et al., 2003) 
Dasatinib 
RAW264.7 macrophages, mouse 
model 
(C. Fraser et al., 2009) 
Curcumin 
RAW264.7 macrophages,  
rat model 
(D. Chen et al., 2008),  
(Xiao et al., 2012) 
Plant derived 
polyphenols  
RAW264.7 macrophages (Chandler et al., 2010) 
Flavocoxid  
(baicalin and catechin) 
Rat peritoneal macrophages (Altavilla et al., 2009) 
Resveratrol Murine microglial cell line N9 





A review on the role of NO in viral infections concluded that NO participates in the 
antiviral host response by interfering with the replication of DNA and RNA viruses 
(Reiss & Komatsu, 1998). Double stranded RNA is produced during virus synthesis 
in infected cells and is thought to induce iNOS and thus trigger antiviral responses 
(Steer & Corbett, 2003). A study investigating the expression of iNOS in RRV 
infection found that RRV is able to suppress important antiviral genes such as TNFα 
and iNOS in LPS-stimulated macrophages when infection occurred through an 
antibody-dependent enhanced pathway (Lidbury & Mahalingam, 2000b). 
Considering the role of NO as both a pro-inflammatory molecule as well as a 
mediator in antiviral responses, a limiting however not exhaustive inhibition may be 
preferred in the treatment of RRVD. This would avoid excessive inflammatory 
processes but still allow basic antiviral immune responses. 
1.4.3 Interleukin 6 (IL-6)  
Interleukin 6 (IL-6) is involved in many metabolic and regulatory processes and acts 
as an important activator of immune responses. As a cytokine, it can have both pro-
inflammatory as well as anti-inflammatory functions. Similar to TNFα, IL-6 is 
involved in most inflammatory processes and has been investigated as a target for 
anti-inflammatory intervention (Scheller et al., 2011). Although numerous cell types 
have the ability to produce IL-6, the primary source in inflammatory processes are 
monocytes and macrophages. The release of IL-6 can be induced by a variety of 
inflammatory stimuli, including TNFα, Interleukin-1 (IL-1), LPS or viruses. In the 
latter two cases toll-like receptor (TLR) activation appears to be involved in the 
activation of the cell to release IL-6 (Naugler & Karin, 2008).  
After secretion IL-6 may initiate further responses via two pathways. The classic 
signalling pathway involves interaction with the membrane-bound IL-6 receptor and 
membrane glycoprotein 130, leading to the activation of the target cell. Trans-
signalling involves a soluble IL-6 receptor that forms a complex with IL-6 which then 
activates glycoprotein 130 and induces further signalling cascades. This pathway 
can be utilized in an autocrine or paracrine manner by cells lacking the membrane-
bound IL-6 receptor, but still produce glycoprotein 130 (Scheller et al., 2011). 
The role of IL-6 as a myokine – a cytokine released by muscle cells – is usually 
associated with anti-inflammatory processes. Increased IL-6 concentrations are 
found in skeletal muscle and plasma during and after prolonged exercise and it 




and IL-10 (Pedersen et al., 2007). Apart from exercise induced release, myoblasts 
are however also known to release IL-6 upon inflammatory stimulation, which in turn 
can induce the release of further chemokines and other pro-inflammatory mediators 
(Gallucci et al., 1998; Scheller et al., 2011). Increased monocyte infiltration into 
muscles during RRV-infection has been reported previously (Lidbury et al., 2000) 
and IL-6 released from muscles during infection could possibly contribute to the 
characteristic myopathy as well as arthritic symptoms observed in RRVD. 
IL-6 plays an important role in the inflammatory processes in RA, with elevated 
levels found in synovial fluids and plasma of affected patients. Targeted anti-IL-6 
therapy, such as treatment with IL-6 antibodies has been trialled successfully to 
reduce disease progression and symptom manifestation in patients with RA 
(Brennan & McInnes, 2008; McInnes & Schett, 2007). Increased IL-6 levels have 
also been found in viral arthritides such as parvovirus B19 induced arthritis (Kerr et 
al., 2004) and a correlation between peripheral blood IL-6 concentration and 
CHIKVD symptom severity in patients was observed (Ng et al., 2009). Elevated IL-6 
levels were detected in patients with severe arthritic symptoms while reduced levels 
related to mild symptom presentation. IL-6 was therefore suggested as a suitable 
biomarker for the prediction of disease manifestation in CHIKVD.  
IL-6 inhibitors such as the monoclonal antibody tocilizumab have been successfully 
trialled for the treatment of RA (Hennigan & Kavanaugh, 2008), however to our 
knowledge no compound has so far been investigated for a potential IL-6 lowering 
effect in alphavirus infection. 
1.4.4 Macrophage migration inhibitory factor (MIF)  
Macrophage migration inhibitory factor (MIF) was the first cytokine to be discovered, 
and has been found to play a seminal role in the pathogenesis of several diseases 
including rheumatoid arthritis (H. R. Kim et al., 2007; Santos & Morand, 2006). MIF 
is produced by activated macrophages and is able to maintain macrophage 
activation by inhibiting p53 through interaction with CD74. This results in an 
autocrine loop which leads to continued macrophage activation and secretion of pro-
inflammatory products, thereby maintaining the inflammatory response. MIF plays 
an important role in RA and it therefore warrants to be investigated as a possible 
target in the therapeutic treatment of RA (Morand, 2005). Apart from its role as a 
cytokine MIF is known to possess enzyme activity as a keto-enol-tautomerase 




potential anti-inflammatory agents could therefore either reduce MIF secretion or 
inhibit its enzyme activity (Garai & Lorand, 2009). 
Herrero et al. (Herrero et al., 2011) established the critical role of MIF in RRV 
infection and showed that MIF-/- mice developed less severe disease symptoms 
with reduced transcription of several pro-inflammatory cytokines, despite reaching 
plasma viral titres similar to those found in infected wild type mice. Reconstitution of 
MIF in MIF-/- mice increased symptom presentation whereas treatment of infected 
wild type mice with ISO-1, a MIF inhibitor, reduced disease progression. With this 
recent evidence of MIF contributing to the symptoms in RRV infection it might be 
possible to find cheap and effective agents to relieve both the joint and muscle 
symptoms and hence reduce the impact of infection on patients. Recent findings 
have highlighted the importance of MIF in dengue virus infections (Chuang et al., 
2015) which could indicate a possible role of MIF inhibitors in the treatment of other 
viral infections. 
A number of small molecules and plant derived anti-inflammatory compounds such 
as caffeic acid, curcumin, and resveratrol have been investigated for potential anti-
MIF activity (Molnar & Garai, 2005). These non-toxic constituents of fruits and 
vegetables are present in the diet, it is however not known if they are active when 
administered in vivo at these concentrations. Besides these naturally occurring 
molecules there is continuing research for synthetic agents such as ISO-1 (Al-Abed 
et al., 2005) and other synthetic compounds (L. Xu et al., 2013) capable of inhibiting 
MIF. 
Table 2 shows a list of MIF inhibitors that were initially considered for our 
experiments. The list is not exhaustive and focused on inhibitors in regards to 
availability or affordability.  
1.4.5 High mobility group box (HMGB) protein family  
The high mobility group box (HMGB) protein family contains four members 
(HMGB1-4) of abundant non-histone proteins conserved across species which bind 
double stranded DNA without sequence specifity (Stros, 2010; Stros et al., 2007). 
They have previously been recognized as important effectors in nucleic-acid 
mediated innate immune responses by activating various toll-like receptors (TLRs), 
however most work in this field has focused on HMGB1 (Yanai et al., 2009). HMGB1 
is known to act as an extracellular mediator that can be secreted to function as a 




suggested that HMGB2 may possess similar functions (Stros, 2010). Due to the 
limited data available on HMGB2 and HMGB3 our research project has focused on 
the role of HMGB1 in alphavirus infections and only briefly investigated the 
involvement of HMGB2 and HMGB3.  
Within the nucleus, HMGB1 is responsible for stabilizing nucleosomes and 
presenting DNA to enable gene transcription. Constitutively present in most nuclei, it 
can be passively released by necrotic cells or actively secreted by monocytes, 
macrophages or neutrophils and further stimulate the release of pro-inflammatory 
cytokines (Andersson et al., 2014). In monocytes, HMGB1 is secreted via a non-
classical vesicle mediated secretory pathway that may differ from the method of 
secretion by other cells (Gardella et al., 2002).  
There are numerous reports highlighting the pivotal role of HMGB1 in the 
pathogenesis of RA as a possible target for directed therapy (Ulloa et al., 2003). 
HMGB1 is found in higher levels in synovial fluid of RA patients and when applied to 
synovial macrophages is able to stimulate production of TNFα, IL-6 and IL-1β 
(Taniguchi et al., 2003). Administration of HMGB1 into normal joints causes 
development of inflammation and arthritis, inhibition of HMGB1 prevents the 
progress of the arthritis (Andersson & Erlandsson-Harris, 2004).  
Besides its function as pro-inflammatory mediator, a pathogenic role in viral 
infections has been suggested for HMGB1 previously (H. Wang et al., 2006). Active 
HMGB1 secretion has been reported for herpes simplex virus-2 infected epithelial 
HEC-1 cells (Borde et al., 2011) and increased HMGB1 levels were found in the 
lungs of H5N1 influenza-infected mice (Hou et al., 2014), which likely contributes to 
pulmonary inflammation. Human dendritic cells actively release HMGB1 in dengue 
virus infection, which initiates release of pro-inflammatory cytokines and modulates 
virus replication in vitro (Kamau et al., 2009). More recent data showed comparable 
HMGB1-release from dengue virus infected peripheral blood mononuclear cells 
(Ong et al., 2012) and HMGB1 has therefore been suggested as auxiliary biomarker 
for the diagnosis of dengue virus infections (Allonso et al., 2013). Given the 
importance of HMGB1 in RA it is surprising that no work has attempted to relate it to 
arthritogenic virus infections.  
Much of the work on HMGB1 inhibitors has focused on possible treatment options of 
inflammatory processes and sepsis (Nogueira-Machado & de Oliveira Volpe, 2012; 
H. Wang, M. F. Ward, et al., 2009). No study has however considered the use of 




inexpensive, readily available and non-toxic and may therefore potentially offer 
economic and effective therapy options. Table 3 shows inhibitors that were initially 
considered for our experiments. The list is not exhaustive and the main selection 
criteria were availability and affordability. 
 
Table 2: MIF inhibitors  
Inhibitor Cell line/ animal References 
Curcumin Rat model 
(Molnar & Garai, 2005; Xiao 
et al., 2012) 
Umbelliferon Rat model (Molnar & Garai, 2005) 
Resveratrol Rat model (Molnar & Garai, 2005) 




(Al-Abed et al., 2005; Cho et 
al., 2010; Herrero et al., 
2011) 
Benzylisothiocyanate * 
(Ouertatani-Sakouhi et al., 
2009) 
AV411 (Ibudilast) * (Cho et al., 2010) 
Epoxy-azadiradione RAW264.7 macrophages (Alam et al., 2012) 




Table 3: Inhibitors of HMGB1 release 
  
Inhibitor Cell line/ animal References 
Ethyl pyruvate Mouse model 
(Hollenbach et al., 2008; 
Shang et al., 2009; H. Wang 
et al., 2008; Q. Wang et al., 
2009) 




(Girard, 2007; Vitali et al., 
2013; Wu et al., 2014) 








(Jiang et al., 2009) 




(H. Wang et al., 2004) 
Chinese medicinal herbs: 
Danggui (Angelica sinensis), 
Green tea (Camellia sinensis), 
Danshen (Salvia miltorrhiza) 
Mouse models  
(H. Wang, M. F. Ward, et al., 
2009; H. Wang, T. Xu, et al., 
2009; H. Wang et al., 2008)  
Curcumin HUVECs (D. C. Kim et al., 2011) 
Minocycline 
Rat phaeochromo-
cytoma (PC12) cells 












1.4.6 Interleukin 18 (IL-18)  
Interleukin 18 (IL-18) is a member of the IL-1 cytokine superfamily initially 
discovered in endotoxemic mice as interferon gamma inducing factor and later 
renamed to IL-18 (Okamura et al., 1995). It is widely recognised as a pro-
inflammatory mediator and regulator of immune responses amongst other 
physiological and pathological roles. IL-18 is constitutively synthesized as an 
inactive precursor by a wide variety of cells and requires enzymatic cleaving by 
caspase-1 to transform into its active form. Macrophages and dendritic cells have 
been identified as the main sources for active IL-18, although cleavage can also 
occur in other cells (Dinarello et al., 2013) . 
Once activated, IL-18 can form a trimeric complex with the two subunits of the IL-18 
receptor (IL-18Rα and IL18Rβ) to initiate signalling pathways similar to IL-1, hence 
resulting in similar molecular responses, such as activation of NFκB, JNK or p38 
MAP kinase pathways. This ultimately leads to increased production of nitric oxide, 
interferon gamma (IFNγ) and further chemokines (Arend et al., 2008). IL-18 binding 
protein (IL-18 BP) is an endogenous regulator of IL-18 that binds IL-18 with high 
affinity thus inhibiting its biological activity. IL-18BP secretion is upregulated by IFNγ 
and therefore provides a regulatory feedback loop for IL-18 (Arend et al., 2008). 
The role of IL-18 as pro-inflammatory mediator in rheumatoid arthritis was reported 
previously (Gracie et al., 1999), with increased concentrations of both IL-18 mRNA 
and protein found in synovial tissues of patients with rheumatoid arthritis as 
compared to osteoarthritis controls. IL-18 has since been shown to independently 
induce NO and TNFα secretion by macrophages and contribute to the inflammatory 
processes present in RA (Arend et al., 2008). 
IL-18 is involved in the immune response to viral infections, partly due to the 
activation of cytotoxic T cells that clear the virus (Gracie et al., 2003). A more recent 
investigation (Chirathaworn et al., 2010) has found increased IL-18 and IL-18BP 
serum levels in Chikungunya virus infections which promote the T helper-1 immune 
response. Both IL-18 and IL-18BP have thus been suggested as potential 
therapeutic targets for the treatment of CHIKVD. It is likely that IL-18 and IL-18BP 
concentrations are also elevated in other alphavirus infections such as RRVD and 
potential treatment options targeting the IL-18 signalling chain might therefore 





1.4.7 Interleukin-33 (IL-33)  
Interleukin-33 (IL-33) was identified  as a new member of the IL-1 cytokine family 
(Schmitz et al., 2005) and similar to other IL-1 cytokines it was found to activate NF-
kB and MAP kinase pathways thereby triggering further inflammatory responses via 
the T1/ST2 receptor (also referred to as ST2L). This receptor is commonly found on 
mast cells and lymphocytes and activation initiates expression and secretion of pro-
inflammatory cytokines and chemokines. IL-33 can be synthesized in a variety of 
cells including macrophages, mast cells and endothelial cells in which it is stored as 
a nuclear bound IL-33 precursor that can be cleaved and secreted as the active IL-
33 upon exposure to stimuli (Arend et al., 2008). Cleavage is thought to be 
catalysed by caspase-1 or caspase-1-activated proteases, however the exact 
mechanism is still not fully understood. More recent data has shown that nuclear IL-
33 itself possesses biological activity and can act as transcriptional regulator. 
Activation of epithelial and endothelial cells with pro-inflammatory stimuli results in 
inhibited expression of nuclear IL-33 (Kuchler et al., 2008). This indicates a pro- as 
well as anti-inflammatory role of IL-33, depending on the physiological and 
pathological processes.  
The nuclear rather than cytoplasmic storage of IL-33 and the active secretion upon 
stimulation remind of the previously discussed HMGB1 (Haraldsen et al., 2009). 
Similar to HMGB1, IL-33 can act as an ‘alarmin’ when released from necrotic cells 
and alert or activate the immune system (Miller, 2011).  
IL-33 has been investigated for its role in RA and increased IL-33 expression as well 
as secretion has been found in synovial tissues during RA, promoting local 
inflammation through mast cell activation (D. Xu et al., 2008). In vitro tests with 
fibroblasts showed increased expression upon exposure to inflammatory cytokines 
(Matsuyama et al., 2010). IL-33 has been shown to exacerbate symptoms in CIA, 
whereas blockage of its ST2 receptor reduced inflammation in CIA (Liew et al., 
2010), which makes both molecules potential targets for future treatments.  
IL‑33 was referred to as T1 prior to its classification as interleukin and early reports 
suggested a role of T1 in the defence against viral infection. Respiratory syncytial 
virus-infected mice showed reduced lung inflammation when treated with 
monoclonal ST2-specific antibody and TH2-associated immunopathology was 
observed to be less severe (Walzl et al., 2001). To our knowledge, this is the only 




1.4.8 Interleukin 10 (IL-10)  
Interleukin-10 (IL-10) is, in contrast to the previously reviewed cytokines, an anti-
inflammatory cytokine with a crucial role in infection and inflammation. IL-10 has a 
limiting effect on the host’s immune response in infections in order to avert tissue or 
cell damage (Saraiva & O'Garra, 2010). Similarly, it is an important regulator that 
prevents overshooting inflammatory reactions and autoimmune pathologies by 
down-regulating pro-inflammatory cytokine production. IL-10 was initially thought to 
be exclusively expressed in TH2 and T regulator cells, however more recent data 
has confirmed its expression in a variety of other cells including macrophages, mast 
cells and myeloid dendritic cells upon stimulation (Saraiva & O'Garra, 2010).  
The induction of IL-10 is a complex network of cell signalling pathways that can 
greatly differ from cell to cell. In macrophages its transcription is induced by 
pathogen derived products through pattern recognition receptors (PPRs) which 
generally involve TLR activation followed by activation of the MyD88 pathway. Once 
released, IL-10 can interact with the IL-10 receptor (IL-10R) which in turn activates 
the signal transducer and activator of transcription 3 (STAT3) pathway. Since the IL-
10R is also expressed by macrophages and dendritic cells, IL-10 can act as an 
autocrine inhibitor on these cells and inhibit the synthesis of various pro-
inflammatory cytokines (Mosmann, 1994). In general, IL-10 is released after 
secretion of pro-inflammatory cytokines to prevent an overshooting reaction 
(Trinchieri, 1997). Macrophages have been identified as the main producers of 
circulating IL-10 in LPS challenged mice (Haskó et al., 1996).  
The involvement of IL-10 in the immune response to viral infection is widely 
acknowledged (Saraiva & O'Garra, 2010). Analysis of patient sera during dengue 
virus infection found a clear correlation between IL-10 plasma levels and disease 
severity with highest IL-10 levels detected on day 0 of fever onset (S. Green et al., 
1999). Analysis of cytokine expression during RRV-ADE infection of macrophage 
cultures showed increased transcription of IL-10 as well as elevated IL-10 
concentrations in the supernatant of infected cells as compared to controls 
(Mahalingam & Lidbury, 2002). Due to its regulatory effect in inflammation as well as 
its potent immunosuppressive properties IL-10 has been considered as a potential 
target for the treatment of RA (Keystone et al., 1998) and it was suggested that 
reduction of IL-10 levels in alphavirus infections might potentially lead to better 




1.5 Cytokine inhibitors for the treatment of RRV induced arthritis 
As previously discussed, current treatment options for alphavirus infections are 
limited and usually target symptomatic relief with aspirin, paracetamol or non-
steroidal anti-inflammatory drugs (Rulli et al., 2005). Corticosteroids have been used 
in the treatment of RRVD without significant disease exacerbation, however due to 
concerns in regards to their immunomodulatory effects they are used cautiously 
(Mylonas et al., 2004).  
To this date there is no antiviral treatment available for RRV or CHIKV infections. 
Research projects have investigated several compounds, however none has 
successfully completed clinical trials (Parashar & Cherian, 2014). A recently 
developed RRV vaccine has entered phase 3 clinical trials and outcomes so far look 
very promising (Wressnigg et al., 2014). Considering the early stages of vaccine 
development and the likelihood that vaccination will only be used in high risk areas 
or by high risk personnel, we believe it is important to continue research into 
alternative treatment options for alphavirus infections. 
The role of various cytokines has been investigated in alphavirus infection and offers 
many possible targets for future treatments. Our experiments have focused on the 
possible inhibition of several of these cytokines with inexpensive and readily 
available compounds. As previously mentioned, it was suggested that current 
treatment options for RA may be applicable for use in alphaviral athritides (Nakaya 
et al., 2012). We believe that, vice versa, agents with promising results in the 
treatment of EPA could potentially open the door for alternative treatment options in 
patients with RA. 
The drug bindarit has previously been trialled in a RRV mouse model and treatment 
significantly reduced levels of monocyte chemoattractant protein 1 and TNFα in 
infected mice (Rulli et al., 2009). Similarly, macrophage infiltration into synovial 
tissues and muscles as well as disease severity was reduced, without affecting 
viraemia. This once more suggests that macrophages and macrophage derived 
cytokines are major contributors to RRVD progression and could be targeted for 
alternative treatment options.   
Potential inhibitors of TNFα, (Table 1), HMGB1 (Table 3) and MIF (Table 2) were 
initially screened for affordability and availability. Following is a brief review on 




1.5.1 Macrolide antibiotics  
The anti-inflammatory effect of macrolide antibiotics has been investigated 
extensively in the last decades. Early investigations (Bailly et al., 1991) reported of 
an IL-6-inhibiting effect of erythromycin (ERY) and spiramycin on LPS-stimulated 
monocytes and similarly ERY was found to inhibit TNFα secretion from stimulated 
monocytes (Iino et al., 1992). Further studies (Ianaro et al., 2000) showed reduced 
production of TNFα, IL-1b, IL-6 and NO in LPS-challenged macrophages when 
treated with macrolide antibiotics such as ERY, clarithromycin (CLA) and 
roxithromycin (RXM). ERY as well as CLA also inhibited NO secretion in stimulated 
rat pulmonary alveolar macrophages (Kohri et al., 2000). An inhibitory effect on 
chemotaxis and infiltration of neutrophils into the airways in vivo has been reported 
for ERY, CLA, RXM and azithromycin (Tamaoki et al., 2004). The use of RXM as an 
anti-inflammatory agent in collagen induced arthritis (CIA) has been investigated 
previously and an inhibitory effect on T-cell and macrophage cytokine production 
was reported (Urasaki et al., 2005).  
Recent drug development has therefore started to focus on macrolide molecules 
without antibiotic properties for the treatment of various non-infectious inflammatory 
conditions (Mencarelli et al., 2011). A recent review (Ogrendik, 2014) has 
summarised the potential benefit of macrolide antibiotics in the treatment of RA and 
we believe that macrolides may also exert their anti-inflammatory properties in 
alphavirus induced arthritis. To our knowledge, no macrolide has previously been 
investigated for the treatment of arthritogenic alphavirus infections. 
Erythromycin (ERY), clarithromycin (CLA) and roxithromycin (RXM) are all 14-
membered ring macrolides with very similar antibiotic profiles (Hardy et al., 1988). 
They are readily available and generally very well tolerated, even when given long 
term for prophylactic treatment (Rubinstein, 2001). To our knowledge, no direct 
antiviral properties have been reported for any of these macrolides.   
1.5.2 Ethyl pyruvate (EP) 
The anti-inflammatory properties of ethyl pyruvate (EP) were firstly reported by Yang 
et al. (Yang et al., 2002), who found modulated cytokine production in EP treated 
mice with haemorrhagic shock. Further investigations (Ulloa et al., 2002) analysed 
the potential use of EP as anti-inflammatory treatment in sepsis and systemic 
inflammation and found, that EP inhibited the release of both TNFα as well as 




mice. Even when administered up to 24 hr after the immediate response EP showed 
significant efficacy and reduced expression of late-phase cytokines.  
EP has been tested in numerous models of septic shock with mostly positive 
outcomes, possibly due to the inhibitory effect on HMGB1 secretion (Dave et al., 
2009; Fink, 2007). HMGB1 has also been suggested as a potential target in arthritic 
conditions (Ulloa et al., 2003) and it is rather surprising that EP has so far not been 
trialled in models of RA. No direct antiviral properties are reported for EP. A more 
recent study (Ong et al., 2012) investigated the effect of EP on dengue virus-
infected monocytes in vitro and found dose-dependent decrease of HMGB1 release. 
As previously outlined, we suggested that HMGB1 may be involved in RRV disease 
as a pro-inflammatory cytokine and therefore investigated EP as a possible 
therapeutic agent.  
1.5.3 Pentoxifylline (PXF) 
Pentoxifylline (PXF) or oxpentifylline is a xanthine derivative with various therapeutic 
effects. It has been shown to decrease blood viscosity and increase blood 
microcirculation and has been approved in Australia for the treatment of intermittent 
claudication caused by peripheral artery disease (Salhiyyah et al., 2012). 
Early investigations into its biological effects have shown that PXF is also a strong 
anti-inflammatory compound, decreasing TNFα production in LPS-stimulated 
macrophages by inhibiting TNFα mRNA accumulation (Han et al., 1990). The TNFα 
inhibitory effect was confirmed for monocytes, however PXF did not reduce but 
rather increase IL-6 production in monocytes exposed to LPS (Schandené et al., 
1992). Further investigations (D'Hellencourt et al., 1996) extended these findings to 
numerous other inflammatory mediators (namely IL-1b, IL-6, IL-8, IL-10 and TNFb) 
and reported that PXF interferes with cytokine production in a rather complex 
manner, strongly depending on type of stimulation and cellular environment.  
Due to the initial reports of TNFα inhibition, PXF was investigated as treatment 
option in rheumatoid arthritis (Maksymowych et al., 1995). PXF decreased the 
number of swollen joints significantly in treated individuals, despite the clinical 
response not consistent with TNFα levels measured in patient blood samples. A 
more recent study however found reduced serum TNFα concentrations in a mouse 




Previous reports have also highlighted the antiviral properties of PXF and found 
inhibition of viral replication in numerous DNA and RNA virus strains, including 
herpes simplex virus, vaccinia virus and rotavirus (Amvros'eva et al., 1993). More 
recent work has confirmed the antiviral properties for Japanese encephalitis virus 
(Sebastian et al., 2009) and reduced symptom manifestation in PXF-treated children 
with dengue virus infection was reported (Salgado et al., 2012). So far no study has 
been published on the effects of pentoxifylline in alphavirus infections. 
1.5.4 Resveratrol (RVT) 
Resveratrol (RVT) has long been known as a cardioprotective constituent in red 
wine and was later associated with prevention of cancer, cardiovascular diseases 
and ischaemic conditions. The molecular processes in which RVT exerts these 
properties are still not fully understood, it is however thought that its cyclooxygenase 
(COX)-inhibiting properties are at least contributing to some of the biological 
activities of RVT (Baur & Sinclair, 2006). COX is an enzyme that catalyses the 
synthesis of pro-inflammatory mediators which may partly explain the anti-
inflammatory properties of RVT.  
Apart from these properties RVT has been investigated for its influence on cytokine 
production in macrophages with inconclusive results. A previous study (Wadsworth 
& Koop, 1999) investigated the effects of resveratrol on LPS-stimulated RAW264.7 
macrophages and found decreased nitrite (NO) release, but increased TNFα mRNA 
expression and induced TNFα secretion. Later investigations with LPS-treated 
RAW264.7 macrophages (Qureshi et al., 2012) showed decreased NO release as 
well as decreased levels of inflammatory cytokines, such as TNFα, IL-1b and IL-6, 
when treated with RVT. An inhibitory effect on IL-6 release from stimulated mouse 
peritoneal macrophages was reported previously (Zhong et al., 1999). These anti-
inflammatory properties were further investigated in a rabbit model of inflammatory 
arthritis (Elmali et al., 2007), which showed significantly decreased cartilage 
destruction in RVT treated animals.  
Previous reports also suggest antiviral activity for RVT, which has been shown to 
inhibit viral replication of most members of the Herpesviridae family, including 
Herpes Simplex virus 1 and 2, Varicella Zoster virus and Eppstein-Barr virus 
amongst others (Campagna & Rivas, 2010). The molecular mechanism in which 
RVT exerts its antiviral properties remains unclear, but may involve inhibition of the 




hosts antiviral response, previous research has also demonstrated that certain 
viruses such as Influenza A and Herpes Simplex virus 1 require activation of that 
same pathway for efficient replication (Santoro et al., 2003).   
More recent work has reported of RVT’s inhibitory effect on respiratory syncytial 
virus replication as well as virus induced IL-6 production in airway epithelial cells 
(Xie et al., 2012).  
Both the antiviral as well as anti-inflammatory properties suggest a suitable role of 
RVT in the treatment of alphavirus infections. To our knowledge, no work has been 
done investigating RVT in the treatment of infections with arthritiogenic viruses. 
1.5.5 Kino extract (KE) 
Kino is a plant exudate formed by some trees upon infections or mechanical injury to 
the bark. In Australia several Eucalyptus species are known to produce this dark 
resin and indigenous people have traditionally used it in aqueous concoctions to 
treat various gastro-intestinal conditions and infections (Locher & Currie, 2010).  The 
high tannin content makes kino a strong astringent with possible antimicrobial 
effects (von Martius et al., 2012). Traditional use of kino used as a tea includes the 
treatment of common colds, which could also indicate possible antiviral properties of 
the extract (Clarke, 2011). Little else is known of the biochemical and 
pharmacological effects of kino, however it has been shown that kino derived from 
Corymbia calophylla may possess anti-inflammatory properties (Martha Y Mungkaje, 
Curtin University, personal communication). Corymbia calophylla or Eucalyptus 
calophylla is commonly referred to as Marri and is a red gum tree native to Western 
Australia (Lim, 2014). So far, no reports have been published regarding the possible 
antiviral effect of its kino exudate.  
Given the potential anti-inflammatory effect of aqueous kino extract we decided to 





2. Methods and Materials 
2.1 Cell culture 
All cell lines were purchased directly from the American Type Culture Collection 
(ATCC) unless stated otherwise. 
2.1.1 Culture conditions 
Cell culture media was purchased from Thermo Scientific (HyClone Laboratories, 
USA) and supplemented with 1% (v/v) Penicillin-Streptomycin solution (P/S) 
(Thermo Scientific, HyClone, 10000 units/ml Penicillin, 10000 µg/ml Streptomycin) , 
unless stated otherwise. For cell line propagation, 5 or 10% (v/v) foetal bovine 
serum (FBS; Serana, Australia) was added to the media. Cells were cultured in a 
humidified incubator (Quantum Scientific, Australia) in 5% (v/v) CO2 at 37°C in T-75 
flasks (NalgeNunc International; Denmark) and subcultured according to ATCC 
protocols. Cells were either manually scraped or detached using 0.25% (v/v) trypsin-
EDTA (Thermo Scientific, HyClone Laboratories, USA) after rinsing twice with sterile 
normal saline (Baxter, Australia). 
2.1.2 Test for mycoplasma  
All cell lines were tested six-monthly for mycoplasma contamination as follows.  
A T75 flask was passaged with 1 ml of 0.25% (v/v) trypsin-EDTA and a 50 µl aliquot 
of this cell suspension was centrifuged at 500 x g for 30 sec (Centrifuge 5417C, 
Eppendorf, Germany). The supernatant was discarded and the cell pellet lysed with 
Easy DNA High Speed Extraction kit (Fisher Biotec, Australia). In brief, 64 µL of 
Solution 1A and 16 µL of Solution 1B were added to each sample and the mixture 
was incubated at 95°C for 20 min. Then 20 µL of Solution 2 was added and this 
mixture containing the extracted DNA was diluted 1/100 (v/v) in PCR grade water 
(Fisher Biotech, Australia) for PCR analysis as usual using primers specific for 
mycoplasma (see 2.5.4). Mycoplasma positive sample cDNA was included as assay 
control. Experimental results were only included in this study when the cell lines 




2.1.3 Culture of RAW264.7 mouse macrophages 
RAW264.7 macrophages (ATCC, TIB-71) were cultured in R-5. At 80-90% 
confluency the cells were manually scraped and split 1/10 for subculture. 
2.1.4 Culture of C2C12 mouse myoblasts 
C2C12 mouse myoblasts (ATCC, CRL-1772; kindly donated by Erin Bolitho, School 
of Pharmacy) were cultured in R-5 or R-10. Cells were grown to a maximum 80% 
confluency to avoid differentiation into myotubes and passaged 1/10 using 0.25% 
(v/v) Trypsin-EDTA. 
2.1.5 Culture and differentiation of 3T3-L1 mouse fibroblasts 
2.1.5.1 Culture of 3T3-L1 mouse fibroblasts 
3T3-L1 fibroblast cells (ATCC, CL-173) were cultured in Dulbecco’s Modified 
Eagle’s Medium containing 4500 mg/l glucose (DMEM, HyClone), 10% (v/v) FBS, 
Glutamax (Gibco, Life Technologies, USA) and antibiotics. Cells were subcultured 
with 0.25% (v/v) trypsin-EDTA before reaching the maximum density of 6x104 cells 
per cm2 as recommended by the ATCC. For differentiation and infection 
experiments, 3T3-L1 pre-adipocytes were only used up to passage number 12.  
2.1.5.2 Differentiation of 3T3-L1 fibroblasts into adipocytes 
Differentiation of 3T3-L1 pre-adipocytes into adipocytes was induced as per method 
of Shepherd et al. (Shepherd et al., 1995) and modified by Zebisch et al. (Zebisch et 
al., 2012). 3T3-L1 cells were cultured to confluence in 6-well plates (Nunclon delta, 
Nalge, UK) in DMEM containing 4500 mg/L glucose, 10% (v/v) FBS, Glutamax and 
P/S. Two days after confluence was reached, the medium was changed to 
additionally contain 0.25 µM dexamethasone (Sigma, Australia), 0.5 µM isobutyl-
methylxanthine (IBMX, Sigma, Australia), 5 µg/mL bovine insulin (Sigma, Australia) 
and 2 µM rosiglitazone (Sigma, Australia). After an additional 2 d in culture, the 
medium was replaced and the cells were maintained in culture medium substituted 
with 5 µg/mL insulin for a further 3 d. After these differentiation steps, the cells were 
maintained in DMEM with 4500mg/L glucose, 10% (v/v) FBS, Glutamax and P/S as 
previously described until the cells fully differentiated into adipocytes. Prior to each 
experiment successful differentiation was confirmed by morphological examination 
of the cells under light microscopy and oil red O (Sigma, Australia) staining to 
visualise lipid droplets. Cells were only used for further experiments when 




2.1.5.3 Staining of 3T3-L1 adipocytes with oil red O 
Oil red O staining solution was prepared freshly by mixing 3 parts of 0.5 % (v/v) oil 
red O in isopropanol (Sigma, Australia) with 2 parts of normal saline and filtering 
through a 0.2 µm filter (Minisart, Sartorius, USA). Adipocytes were fixed in oil red O 
staining solution for 20 min, washed twice with normal saline and examined under a 
light microscope. Adipocytes could be recognised easily by characteristically red 
coloured lipid droplet inclusions whereas pre-adipocytes do not contain lipid droplets 
and hence did not stain (see Figure 1). 
2.1.6 Culture of Vero (African green monkey kidney epithelial) cells 
Vero cells (ATCC, CCL-81, kindly donated by David Williams, School of Pharmacy) 
were cultured in R-5 and grown to around 90% confluency before being passaged 
1/10 using 0.25% trypsin-EDTA. 
2.1.7 Culture of L929 mouse fibroblasts 
L929 cells (ATCC, CCL-81) were cultured in R-10 to around 90% confluency and 




















 unstained  stained with oil red O  
Figure 1: Differentiation of 3T3-L1 cells into adipocytes 
Representative photomicrographs of 3T3-L1 pre-adipocytes prior to differentiation (A 
and B) and at day 10 of differentiation (C to F). (C) and (E) show characteristic 
morphology of unstained adipocytes with visible lipid droplets in the cytosol. 
Treatment with Oil Red O stain coloured the lipids droplets red (D and F). All 
monolayer photographs were taken with an inverse phase contrast microscope at 








2.2 Virus culture 
2.2.1 Ross River Virus strains 
Ross River Virus (RRV) strains DC5692 and DC7194 were sourced from the 
Arbovirus Surveillance group at the Microbiology Department, University of Western 
Australia. RRV DC5692 is one of the early strains derived from Aedes vigilax in 
Western Australia, whereas RRV DC7194 was initially isolated in Queensland but is 
now found throughout Australia (Table 4). Virus was propagated as stated below 
and stocks were kept at -80˚C and thawed immediately before propagation or 
infection assays as needed. 
RRV strain T48 was sourced from Dr David Williams (Curtin University, Western 
Australia). Stocks were grown as described and used for subsequent experiments. 
Early literature suggests to generate the T48 strain RRV by in vitro transcription of 
the plasmid pRR64 which encodes the full-length T48 cDNA clone (Kuhn et al., 
1991), but considering the low divergence of RRV strains over large periods of time 
this was not deemed necessary (Sammels et al., 1995). The strain donated by Dr 
David Williams had initially been derived from the pRR64 plasmid and was 
passaged only few times in Vero cells. 
 
Table 4: Virus strains  
Virus strain Area of initial isolation Source 
RRV DC5692 Western Australia  
(Faragher et al., 1988) 
Arbovirus Surveillance group 
(Microbiology Department, University 
of Western Australia) 
RRV DC7194 Southwest Australia  
(Faragher et al., 1988) 
Arbovirus Surveillance group 
(Microbiology Department, University 
of Western Australia) 
RRV T48 Townsville, Queensland  
(R. Doherty et al., 1963) 






2.2.2 Propagation of Ross River Virus 
For virus propagation, Vero cells were grown in T75 flasks with R-10 until fully 
confluent. The supernatant was removed and 1000 µL of RRV stock with a TCID50 
of 106 or above was added to each tissue culture flask (MOI = 1). The flasks were 
kept at 37°C and gently rocked every 10 min to enhance virus distribution and 
adhesion. After 1 hr a further 8 mL of R-2 was added and the flasks were kept at 
37˚C and 5% (v/v) CO2. When strong cytopathic effect was apparent (usually after 
2-3 d) the supernatant was centrifuged at 1500 x g for 5 min. Aliquots of 1000 µL 
were stored at -80˚C and thawed immediately prior to infection assays or 
determination of the viral titre via tissue culture infective dose assay. 
2.2.3 Tissue Culture Infective Dose 50% assay (TCID50) 
The Tissue Culture Infective Dose 50% (TCID50) assay was used to determine virus 
concentration and viral titre was calculated using a formula established by 
Reed/Munch (Mahy & Kangro, 1996; Reed & Muench, 1938). 
To measure virus concentration, 96 well plates were seeded with 1x105 Vero cells 
per well in 100 µL R-2 and kept at 37˚C in 5% (v/v) CO2 for the cells to adhere. After 
2 hr, 50 µL of a 10-fold serial dilution of virus stock in R-2 was added to each well 
with a minimum of 6 replicates for each dilution step. To an additional 6 wells, 
culture medium without virus was added as negative control. The plates were 
monitored for cytopathic effect (CPE) in the following days and all wells with visible 
CPE were marked. As confirmation, the supernatant was removed after 4 d and 100 
µL of a 0.05% (w/v) solution of crystal violet (Sigma, Australia) in water was added 
to each well. After staining for 20 min the crystal violet solution was aspirated and 
the plates were washed twice with tap water. Wells without CPE were stained dark 
violet. 
According to the number of wells with CPE at each dilution the concentration of 
active virus was calculated using the Reed-Muench method as described by Mahy 
and Kangro (Mahy & Kangro, 1996).  
2.2.4 Virus heat inactivation 
Heat inactivated virus was used in mock infections as a negative control. For 
inactivation, virus stocks were kept in a water bath at 65˚C for 1h and then frozen in 
aliquots. Inactivation efficiency was tested in preliminary experiments to assess a 
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Figure 2: Heat inactivation of RRV DC7194 stock 
RRV DC7194 stock was kept in a water bath at 65˚C and samples were taken at 
regular time intervals and a TCID50 assay was performed on each sample. Non-HI = 
non-heat treated virus stock;  # no CPE was detected; Viral load is expressed as log 
TCID50 and data is shown in mean values ± SEM (n=4). ***(p≤0.001) as determined 





2.3 Infection assays 
Unless stated otherwise, cells were seeded at specified numbers as indicated in 
Table 5 for virus infection assays and kept at 37˚C and 5% CO2 (v/v) in a humidified 
incubator. After 12 hr the media was aspirated and replaced with fresh culture 
medium. Appropriate dilutions of inhibitors and virus were added at the same time 
unless stated otherwise. Some wells only contained media or were challenged with 
heat inactivated RRV as negative controls. Positive control wells were treated with 
lipopolysaccharide (LPS) from E.coli (Sigma, Australia) where appropriate. Inhibitors 
were prepared as stock solution in ethanol (Thermo Fisher Scientific, Australia) or 
dimethyl sulphoxide (DMSO) (Sigma, Australia) and diluted in R-2 as required. A 
vehicle control with ethanol or DMSO only was included in each experiment. 
 
Table 5: Tissue culture plates and cell numbers 
Cell line Culture media Cell number / volume of supernatant 
  6 well plate 12 well plate 24 well plate 
RAW264.7 R-2 8x105 / 2000 µL 4x105 / 1000 µL 2x105 / 500 µL 
C2C12 R-2 4x105 / 2000 µL 2x105 / 1000 µL 1x105 / 500 µL 
3T3-L1 D-10 confluent / 2000 µL - - 
   
2.4 Cell viability assays 
2.4.1 Trypan blue exclusion stain 
Trypan blue exclusion stain was performed routinely for cell counting and 
establishing cell viability prior to experiments. Cells were used at viability rates of ≥ 
90%. 
Prior to seeding, 20 µL of cell suspension was added to 20 µL of 0.4% (w/v) trypan 
blue (Sigma, Australia) solution in sterile saline. Cells were either counted manually 
using a Neubauer haemocytometer under a light microscope or with an automated 




2.4.2 MTT viability assay 
A stock solution of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) (Sigma-Aldrich, Australia) was prepared by dissolving 200 mg MTT 
in 40 mL of phosphate buffered saline (PBS). The solution was filter sterilised and 
stored at 4oC for up to 1 month protected from light. For each assay, three 96 well 
plates were seeded with 100 µL of cell suspension in R-2 at a concentration of 
1x104 cells per well for RAW264.7 or 5x103 cells per well for C2C12. The plates 
were kept at 37˚C and 5% (v/v) CO2 for 24 hr after which 100 µL of test solution was 
added. Either 2- or 10-fold serial dilutions in R-2 were prepared for inhibitors or drug 
diluent and assayed in triplicates. Each plate included a negative control with only 
R-2. 
At times 0, 24, and 48 hr the supernatant of one plate was aspirated and 100 µL of a 
1/5 (v/v) dilution of MTT stock in R-2 was added to each well. After incubation for 1 
hr at 37˚C, the supernatant was aspirated. Cells were then solubilised with 100 µL 
DMSO and the absorbance at 595 nm was determined. Cell viability was calculated 
for each dilution in relation to the untreated control wells. 
2.4.3 Lactate dehydrogenase assay 
To verify cell viability in each experiment a Lactate dehydrogenase (LDH) assay 
(Cayman Chemical Company, LDH Cytotoxicity Assay kit) was performed as per 
manufacturer’s instructions.  
Briefly, LDH reaction buffer was prepared freshly by mixing NAD+, Lactic Acid, INT 
and reconstituted diaphorase in assay buffer. A volume of 100 µL of sample 
supernatant or freshly prepared LDH standard in serial dilution was transferred to a 
96 well plate in duplicate and a further 100 µL of the reaction buffer was added to 
each well. The plate was incubated for 30 min at RT with gentle agitation. After 
incubation the absorbance at 490 nm was measured and LDH levels were 
calculated using the standard curve obtained. 
2.5 Reverse Transcription PCR 
2.5.1 mRNA extraction with TRI Reagent® 
mRNA was extracted from cell monolayers using TRI Reagent® (Sigma-Aldrich, 




of TRI Reagent® were added to tissue culture vessels and the cell lysate was 
homogenised via trituration. For mRNA extraction, a volume of 0.1 mL of 1-bromo-3-
chloropropane (Sigma-Aldrich, Australia) per 1 mL of TRI Reagent® was added to 
the lysate and the mixture was shaken vigorously. After standing for 5 min at RT the 
samples were centrifuged at 12,000 x g for 15 min for complete phase separation. 
The upper aqueous phase was transferred to a new tube containing 0.5 mL 
isopropanol (Sigma, Australia) per 1 mL TRI Reagent® and mixed thoroughly. After 
10 min resting on ice the samples were centrifuged at 12,000 x g for 10 min. The 
supernatant was carefully discarded and the RNA pellet was washed with 1 mL of 
ethanol per 1 mL of TRI reagent® used. After brief air drying at RT the RNA pellets 
were dissolved in water (UltraPure water, PCR grade, Fisher-Biotec, Australia) and 
the RNA concentration was determined with a BioSpec-nano (Shimadzu, Japan). 
2.5.2 DNAse digestion 
Prior to reverse transcription, mRNA was treated with RQ1 DNAse (Promega, USA) 
according to the manufacturer’s instruction to remove contaminating DNA. In brief, 5 
µg of sample RNA was mixed with 1 µL RQ1 DNAse 10x buffer (Promega, USA) 
and 2.5 µL RQ1-DNAse (Promega, USA) and adjusted to a volume of 10 µL with 
PCR grade water. The mixture was kept at 37˚C for 30 min, then 1 µL of RQ1 
DNAse stop solution (Promega, USA) was added to each tube and the samples 
were incubated for a further 10 min at 65˚C.   
2.5.3 Reverse transcription of mRNA 
First strand cDNA synthesis was performed using a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, USA) according to manufacturer’s 
instructions. In brief, 2 µL of digested RNA mix was added to dNTP Mix (4 mM), RT 
buffer, random primers, MultiScribeTM Reverse Transcriptase and PCR grade water 
(Fisher-Biotech, Australia). Reverse transcription was performed by heating the 
mixture for 10 min at 25°C, followed by 120 min at 37°C and 5 min at 85°C. cDNA 
was used immediately for PCR or stored at -20°C. 
2.5.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was performed with 1 µL of cDNA in 12.5 µL 
reactions containing Taq-Ti DNA Polymerase buffer (Fisher Biotec, Australia), 2 mM 
MgCl2 (Fisher Biotec, Australia), 200 µM dNTP (Promega, USA), 200 nM primer mix 




PCR grade water. For each set of reactions one tube without cDNA template was 
added as a non-template control. All newly transcribed cDNA samples were initially 
screened for G3PDH as a house-keeping gene to validate successful RNA 
extraction and transcription. 
PCR amplifications were performed in a Veriti Thermocycler (Applied Biosystems, 
USA) using the conditions outlined in Table 6. The appropriate number of cycles 
was determined for each primer in initial experiments (data not shown). Final cycle 
numbers for each gene are shown in Table 7 (unless stated otherwise). 
 
Table 6: Conditions for RT-PCR 
Step  Time Temperature 
1) Initial denaturation  3 min 95˚C 











3) Final extension  5 min 72˚C 
# Cycle numbers for each gene are given in Table 7 (unless stated otherwise) 
 
2.5.5 Primer design 
Primers were constructed according to references listed in Table 7. Where no 
reference is given, primers were designed using Primer-BLAST (Basic logical 
Alignment Search Tool) provided by the National Centre for Biotechnology 
Information (NCBI) and Primer 3 software (Whitehead Institute and Howard Hughes 
Medical Institute). All self-designed primers were based on mouse mRNA 
sequences derived from the NCBI Genebank database. Primer pairs were chosen to 
give a PCR product with a length of 200-500 base pairs. All primers were 
commercially synthesized by Geneworks Australia, reconstituted in DNAse-free 
water (Fisher-Biotech, Australia) upon arrival and stored at -20˚C. Prior to use the 





2.5.6 Agarose gel electrophoresis 
Amplified PCR products were visualised by agarose gel electrophoresis. 10 µL of 
PCR product was diluted with 2 µL of DNA loading buffer containing 0.25 % (w/v) 
bromophenol blue (Sigma, Australia), 0.25% (w/v) xylene cyanol (Sigma, Australia) 
and 15% Ficoll (type 400) polymer (Sigma, Australia) in ultra-pure water (Fisher 
Biotech, Australia) and pipetted into wells of a freshly prepared 2% (w/v) agarose 
gel (Agarose, Fisher-Biotec, Australia; in Tris-Acetate-EDTA buffer). A 100 base pair 
DNA ladder (Geneworks, Australia) was added to each gel to verify the size of each 
amplified gene product. Gels were run in an electrophoresis chamber (BioRad, 
USA) at 80 V for 55 min in Tris-acetate-EDTA buffer (40 mM 
tris(hydroxymethyl)aminomethane, Fisher Scientific, Australia; 20 mM Acetic acid, 
Fisher Scientific, Australia; 1 mM EDTA, Ajax Laboratories, Australia; adjusted to pH 
8). After electrophoresis, the gel was stained for 30 min in the dark with 0.003% (v/v) 
GelRed® (Biotium, USA) in tris-acetate-EDTA buffer and then photographed with a 
KODAK EDAS DC120 (KODAK, USA) or Quantum ST4 Imaging system (Vilber 
Lourmat, France) under UV light. Unless stated otherwise, all representative 
photographs of agarose gels were derived from conventional RT-PCR. Semi-
quantitative densiometrical analysis was performed using the program ImageJ 
developed by the National Institutes of Health, USA. A ratio of the density of the 
cytokine PCR product to the density of the respective G3PDH product was used to 
compare various samples for semi-quantification. As cycle numbers of cytokines 
often differed from cycle numbers for G3PDH, the densiometric ratio is not absolute 




Table 7: RT-PCR primer sequences and cycle numbers  
Gene 
Primer sequence 





Reference / Genebank 
Accession number 
Mouse G3PDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 452 35 (Paulukat et al., 2001) 
Mycoplasma ACACCATGGGAGYTGGTAAT CTTCWTCGACTTYCAGACCCAAGGCAT 450 35 (Harasawa et al., 2005) 
RRV-E2 GCGCGAATTCGTAGTGTAACAGAGCACTT GCGCGAATTCCTGCGTTCGCCCTCGGTGCG 247 35 
(Mahalingam & Lidbury, 
2002) 
Murine cytokines and chemokines 
HMGB1 ATGGGCAAAGGAGATCCTAA CTCTGTAGGCAGCAATATCC 490 30 NM_031140 
HMGB2 TACCCAGGTGTGGGGATTTA TGCCCTCTCTCTACCTTCCA 228 30 NM_008252.3 
HMGB3 GCGCTGTGATTGACACATCT AATGCCTTGTCACACCAACA 248 30 NM_008253.3 
IL-6 TGCTGGTGACAACCACGGCC GTACTCCAGAAGACCAGAGG 308 30 (Wesselingh et al., 1994) 
IL-10 CAGCCGGGAAGACAATAAC TCATTTCCGATAAGGCTTGG 191 30 NM_010548.2 
IL-18 GACAGCCTGTGTTCGAGGAT TTTCAGGTGGATCCATTTCC 195 30 NM_008360.1 
IL-28β CTCTGTCCCCAAAAGAGCTG GTGGTCAGGGCTGAGTCATT 214 40 NM_177396.1 
IL-33 GCTGCGTCTGTTGACACATT GACTTGCAGGACAGGGAGAC 202 35 NM_001164724.1 
iNOS CCTGTGTTCCACCAGGAGAT GTCCCTGGCTAGTGCTTCAG 249 35 NM_0100927 
MCP-1 CAGCACCAGCCAACTCTCACT AAGGCATCACAGTTCGAGTCA 519 35 NM_011333 
MIF CACCATGCCTATGTTCATCGTGAACA AGCGAAGGTGGAACCGTTCCA 349 40 NM_010798 





2.6 Cytokine Real-time Polymerase chain reaction 
A quantitative analysis of mRNA expression was performed by real time PCR 
analysis using SensiMix SYBR No-ROX Kit (Bioline, Australia) according to the 
manufacturer’s instructions. In brief, 12.5 µL of SensiMix was mixed with 9.25 µL 
nuclease free water, 1.25 µL of 5 µM primer mix (see Table 7) and 2 µL of cDNA as 
prepared in 2.5.3. Two 10 µL aliquots of each reaction mix were analysed in 
duplicate in a Viia 7 (Life Technologies, Thermo Fisher, Australia) under given 
conditions (Table 8). A non-template control (NTC) and a 10-fold serial dilution of 
cDNA were included for each cytokine. G3PDH was used as ‘housekeeping’ gene 
and each cytokine sample was normalised against its corresponding G3PDH value. 
Analysis was performed with Viia 7 software and ratios of mRNA expression were 
calculated with Microsoft Excel 2010. Only normalised values were used to compare 
and calculate up- or down-regulation of cytokine mRNA expression.   
Table 8: Real-time PCR conditions 
Step Time Temperature 
1) Initial denaturation 3 min 95˚C 












3) Final extension 5 min 72˚C 
2.7 ELISA 
ELISA assays (Table 9) were performed according to manufacturer’s instructions. 
Briefly, capture antibody was diluted to the working concentration in PBS, pipetted 
into a 96 well ELISA plate (Nunc Maxisorb, Nunc, Denmark) and kept at RT 
overnight. This step was not necessary for the HMGB1 ELISA since the kit includes 
a pre-coated plate. The ELISA plates were washed three times with 0.05% (w/v) 
Tween 20 (Sigma, Australia) in PBS (ELISA wash buffer) and 100 µl of sample or 
standard were added to the empty wells in duplicate or triplicate. Supplied standards 
were diluted in 1% (w/v) bovine serum albumin (BSA) (Serana, Australia) in PBS 




incubation for 2 hr at RT the plates were washed three times with ELISA wash buffer 
and 100 µL of capture antibody diluted to the working concentration in 1% (w/v) BSA 
in PBS was placed in the well. The plates were incubated for a further 2 hr at RT, 
washed twice with ELISA wash buffer and 100 µL of Horseradish-peroxidase-
streptavidin diluted to the working concentration in 1% (w/v) BSA in PBS was added. 
The plates were kept at RT in the dark for 20 min, washed twice as previously and 
developed with 100 µL of substrate solution (TMB ready-to-use substrate, ELISA 
systems, Australia). After 20 min, 50 µL of 2 N sulphuric acid (Sigma Aldrich, 
Australia) was added to stop development and the plates were read at 450 nm on a 
multi plate reader.   
Table 9: ELISA kits  
Cytokine ELISA kit Cat number 
TNFa R&D Systems -Mouse TNFa ELISA Duo Set DY 410 
IL-6 R&D Systems -Mouse IL-6 ELISA Duo Set DY406 
IL-10 R&D Systems -Mouse IL-10 ELISA Duo Set DY417 
MIF R&D Systems -Mouse MIF ELISA Duo Set DY1978 
HMGB1 Shino-Test HMGB1 ELISA kit ST51011 
PGE2 Cayman Prostaglandin E2 EIA kit – monoclonal 514010 
2.8 Phagocytosis assay 
For the phagocytosis assay, heat inactivated, fluorescein isothiocyanate (FITC) 
(Sigma, Australia) labelled Escherichia coli (ATCC 25922) or Staphylococcus 
aureus (ATCC 29213) bacteria were used. E.coli was chosen as a representative 
gram negative bacteria and S.aureus as a representative Gram positive bacteria.   
2.8.1 Culture of bacteria 
Mueller-Hinton (MH) broth (Oxoid, England) was prepared according to the 
manufacturer’s instructions and autoclaved. Bacterial stock was kept at -80˚C in 
20% (v/v) glycerol (Sigma, Australia) in Mueller-Hinton broth. E.coli or S.aureus 
stocks were thawed as needed and added to 10 mL MH broth and placed on an 
orbital shaker at 37˚C.  Bacterial cultures were grown to an optical density (λ = 
600nm) of approximately 0.8 for E.coli or 1.0 for S.aureus, which indicates an 




2500 x g for 15 min and the supernatant discarded. The bacterial pellet was 
resuspended in 5 mL PBS and the bacteria heat inactivated at 65˚C for 1 hr and 
mixed every 15 min. After heat inactivation the solution was cooled to RT and 
centrifuged. The pellet was washed with 5 mL PBS and resuspended in 1 mL PBS 
and stored at 4˚C. To verify heat inactivation, a 50 µL sample was streaked on 
Mueller-Hinton agar and the plate kept at 37˚C. If no growth was seen after 48 hr, 
the heat inactivated bacteria was labelled with FITC and used for phagocytosis 
assays. 
2.8.2 FITC labelling of heat inactivated bacteria 
Heat inactivated bacteria were incubated with 0.5 mL of 0.1% (w/v) FITC in 50 mM 
NaHCO3 and 100 mM NaCl per 1 mL of bacterial suspension in the dark. After 20 
min at RT, the suspension was centrifuged at 2500 x g for 15 min, the supernatant 
was discarded and the pellet washed twice with 10 mL of cold PBS and re-
suspended in 5 mL of cold PBS. A 20 µL sample was observed under fluorescence 
(Fluorescence microscope Olympus DP71) to verify FITC labelling. Labelled 
bacteria suspension was kept in the dark at 4˚C for up to 1 week. 
2.8.3 Phagocytosis assay – Fluorescent microscopy 
RAW264.7 macrophages were resuspended in R-5 at 1x105 cells/ml. 100 µL of this 
cell suspension was carefully pipetted onto sterile 13mm square glass cover slips in 
6 well plates. Plates were kept in an incubator at 37˚C and 5% (v/v) CO2 for cells to 
adhere and after 1 hr a further 1800 µL of R-5 was carefully added. Cells were 
incubated at 37˚C and 5% (v/v) CO2 and exposed to culture medium or RRV 
suspension at an MOI of 1 for 48, 24 or 0 hr prior to the phagocytosis assay. At the 
beginning of the assay, the supernatant was removed and replaced with 1800 µL of 
fresh R-5. At appropriate times 200 µL of FITC labelled bacteria suspension was 
added to the cells and the plate incubated at 37˚C and 5% (v/v) CO2. After 4 hr the 
supernatant was aspirated and the cells washed twice with 2 mL of cold PBS. 
Samples were fixed on ice with 800 µL/well of 4% (w/v) Paraformaldehyde (Electron 
Microscopy Services, USA) in PBS and the nuclei stained with 10 µL/well of 
propidium Iodide solution (1 mg/mL in water; Sigma, Australia). After 30 min the 
supernatant was discarded and the fixed cells were washed twice with ice cold PBS. 
Cover slips were examined under fluorescence (Olympus IX50) and photos taken 




bacteria were carried out with minimum exposure of the samples to light to prevent 
bleaching. 
2.8.4 Phagocytosis assay – Flow cytometry 
RAW264.7 macrophages were resuspended at 1x106 cells/mL in R-5 and 1000 µL 
of this cell suspension was seeded in 5 mL teflon pots to avoid adhesion. The plates 
were incubated at 37˚C and 5% (v/v) CO2 and 100 µL of culture medium or RRV 
suspension was added 0, 24 or 48 hr prior to the phagocytosis assay. At appropriate 
time points, 200 µL of FITC labelled bacteria suspension was added to the wells and 
the plate was further incubated at 37˚C. After 4 hr the cells were resuspended in the 
supernatant and immediately transferred to 1.5 mL eppendorf tubes on ice. After 
centrifugation at 1000 x g for 10 min at 4˚C the supernatant was aspirated and the 
cells washed with 1 mL of cold PBS. After further centrifugation the supernatant was 
discarded and the cells fixed with 800 µL 4% (w/v) paraformaldehyde (Electron 
Microscopy Services, USA) in PBS. Nuclei were stained with additional 10 µL 
propidium Iodide (1 mg/mL in water). After 30 mins incubation on ice the cells were 
centrifuged and washed with 1 mL of cold PBS and resuspended in 1 mL of PBS. 
Samples were immediately analysed with a flow cytometer (Attune Flow cytometer, 
Applied Biosciences, USA). Analysis of raw data was performed with FlowJo 
(Version X, Tree Star Inc.) flow cytometric data analysis software.  
2.9 L929 bioassay for TNFα  
L929 bioassays were performed to determine bio-concentration and biological 
activity of TNFα (Evans, 2000; Hogan & Vogel, 1988, 2001). L929 fibroblasts were 
cultured to 90% confluence and trypsinised to dislodge. Cells were resuspended in 
R-5 at 5x105 cells/mL and this suspension was seeded to a 96 well plate at 100 
µL/well (i.e. 5x104 cells per well). Plates were incubated at 37˚C and 5% (v/v) CO2 
for 16 hr and supernatant aspirated and replaced with 50 µL/well of fresh R-5. A 50 
µL aliquot of sample supernatant or TNFα standard (recombinant rat TNFα, Sigma, 
Australia) in R-5 were added in triplicate. For samples with high TNFα levels, 
appropriate dilutions of supernatant were also assayed. An aliquot of 50 µL of 4 
µg/mL Actinomycin D (Sigma, Australia) in RPMI was added to each well and the 
plate was incubated at 37˚C. After 24 hr, the supernatant was aspirated and cells 
stained with 100 µL of 0.1% (w/v) crystal violet (Sigma, Australia) in 1% (v/v) acetic 




water and allowed to air dry for 3-4 hr. The cells were solubilised with 100 µL of 1% 
(w/v) SDS in water and absorbance measured at 595 nm on a multi plate reader. 
Preliminary tests showed that RRV present in the sample supernatants did not 
interfere with L929 viability (Figure 3). 
2.10 Measurement of nitrite 
Measurement of nitric oxide (NO) is difficult due to its rapid oxidation in aqueous 
solutions to nitrite (NO2
-) (Ignarro et al., 1993). Nitrite however is more stable and 
can be measured in the supernatant of NO releasing cells using the Griess assay (L. 
C. Green et al., 1982). 
For each assay the Griess reagent (1% (w/v) sulphanilamide (Labchem, Australia) 
and 0.1% (w/v) N-1-naphthylethylenediamine dihydrochloride (ICN Biomedicals Inc, 
USA) in 2.5% (v/v) orthophosphoric acid (Ajax Finchem, Australia)) was prepared 
fresh. An aliquot of 50 µL of supernatant or standard was dispensed into a 96 well 
plate in triplicate and 50 µL of Griess reagent was added to each well. Plates were 
incubated at RT protected from light for 10 min and the absorbance was measured 
within 30 min at 595 nm. The standard curve was prepared using 2-fold serial 
dilutions of a 1 µM sodium nitrite (ChemSupply, Australia) in R-2. 
2.11 Statistical analysis 
Quantitative data is expressed as mean values ± standard error of mean (SEM) 
unless stated otherwise. Statistical analysis was performed with Graphpad Prism 
(Version 6) by one- or two-way analysis of variance (ANOVA). For cytokine assays 
without treatment the values were compared to mock infected samples (negative 
control). Treatment experiments compared values to non-treated infection. A p-value 
≤ 0.05 was considered statistically significant and significance levels are consistently 
expressed as *(p≤0.05), **(p≤0.01), ***(p≤0.001) throughout this thesis.  Dr Richard 










L929 viability for RRV
 
 Actinomycin D + + + - -  
 RRV  (MOI of 0.1) - + - + -  
 RRV  (MOI of 1) - - + - +  
        
Figure 3: L929 cell viability after exposure to Ross River Virus 
An L929 bioassay was performed with RRV DC7194 at an MOI of 0.1 and 1 with 
and without the presence of Actinomycin D. Non treated control cells were assigned 
a cell viability of 100%. Data shown is the relative cell viability compared to non-
treated L929 cells and is expressed as mean value ± SEM (n=4). Statistical analysis 




3. Results I: Differences in the pathology of various RRV 
strains 
3.1 Introduction 
Previous studies (Faragher et al., 1988) have compared the mouse-virulent RRV 
T48 strain and the mouse-avirulent NB5092 strain and showed that small genetic 
differences in the virus are responsible for the difference in virulence. The variation 
of genetic sequences in RRV strains was further investigated by Lindsay et al. 
(Lindsay et al., 1993) who reported that genomic differences were often linked to 
certain geographical regions. Sammels et al. (Sammels et al., 1995) confirmed and 
extended these findings by examining the nucleotide sequences of viral envelope 2 
(E2) and envelope 3 (E3) genes in more detail. Numerous strains and their area of 
isolation were catalogued and it appeared that most genome groups are 
predominant in only small geographic regions. Some strains however could be 
isolated in various parts of the continent, indicating movement of the virus in either 
hosts or reservoirs. A connection between genome mutations and virulence could 
not yet be determined. Only more recently the genetic variations in the sequence of 
E2 and non-structural protein 1 (nsP1) genes were found to be responsible for the 
difference in virulence of RRV strains DC5692 and T48 (Jupille et al., 2013; Jupille 
et al., 2011; Stoermer Burrack et al., 2014). Apart from this work no other RRV 
strains have been investigated and compared in regards to virulence or pathology. 
As reviewed previously (Rulli et al., 2005), both duration and severity of Ross River 
Virus disease (RRVD) can vary considerably and it is possible that genetically 
different virus strains might contribute to this phenomenon.  
In initial experiments we compared three RRV virus strains in order to investigate 
the influence of each strain on cellular pathology. RRV DC7194 and DC5692, kindly 
donated by the Arbovirus Surveillance group (Microbiology Department, University 
of Western Australia), were used with RRV T48 in preliminary investigations to 
determine which RRV strain would be the most appropriate for cytokine inhibitor 
experiments. Comparative tests for the three strains were carried out with regards to 




3.2 Cytopathic effect and viral replication of RRV strains T48, DC7194 
and DC5692   
RRV, like most other alphaviruses, has the ability to infect a variety of arthropod and 
vertebrate cells and cell lines and usually undergoes a cytolytic replication cycle in 
which virus titres increase repidly (Sharkey et al., 2001; Strauss & Strauss, 1994). 
This effect is utilised when growing virus stocks to high titre in Vero cells, resulting in 
cell lysis and virus release. To investigate if different RRV strains show variation in 
this cytopathic effect (CPE) and viral replication numbers, RRV T48, RRV DC7194 
and RRV DC5692 were added to Vero cells at an MOI of 0.1 and cultures were 
observed daily for cytopathic effect. Supernatant was removed 3 d post-infection 
(p.i.) and examined for viral titres by tissue culture infective dose 50% assay 
(TCID50). No visible difference in CPE was observed between the three virus strains 
however a difference was detected in viral titres in the supernatants as shown in 
Figure 4. Titres in the supernatants for T48 and DC7194 expressed in log TCID50 
were 6.72 ± 0.61 and 6.58 ± 0.51 respectively. The viral load in the supernatant for 
DC5692 was significantly (p≤0.05) lower with a log of 5.18 ± 0.55 as determined by 
one-way ANOVA. Both DC7192 and T48 consistently grew to higher titres in Vero 
cells as compared to DC5692. 
3.3 Cytokine response by RAW264.7 macrophages in RRV infection  
Infection of RAW264.7 macrophage cells with RRV results in the secretion of 
several cytokines, such as TNFα (Rulli et al., 2005) and MIF (Herrero et al., 2011). 
In order to examine whether the extent of cytokine release depends on the viral 
strain, RAW264.7 cells were exposed to RRV T48, DC7194 and DC5692 at an MOI 
of 4 and supernatant samples were taken 12 hr post-infection (p.i.) to determine the 
concentration of TNFα and IL-6 by ELISA. As shown in Figure 5, RRV T48 and RRV 
DC7194 induced high TNFα levels at 12 hr p.i. with concentrations reaching 2451 ± 
103 pg/mL and 2140 ± 154 pg/mL respectively. RRV DC5692 induced significantly 
lower levels of TNFα with a concentration of 444 ± 69 pg/mL (p≤0.001) at 12 hr p.i. 
(Figure 5 A). As shown in Figure 5 B, IL-6 levels were analysed in parallel and 
showed that RRV T48 and RRV DC7194 increased IL-6 in the supernatant to 481 ± 
32 pg/mL and 407 ± 18 pg/mL by 12 hr p.i., which was significantly higher than that 
induced by RRV DC5692, reaching 144 ± 18 pg/mL (p≤0.001). Exposure of 
RAW264.7 cells to RRV T48 or DC7194 induced a generally stronger cytokine 
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Figure 4: TCID50 of the supernatant of Vero infected with various RRV strains  
Vero cells were cultured to confluence, exposed to RRV strains T48, DC7194 and 
DC5692 at an MOI of 0.1 and observed daily for CPE. Supernatants were removed 
3 d p.i. to determine viral titres via TCID50 assay. Data shown are mean values ± 
SEM (n=4). *(p≤0.05) as determined by one-way ANOVA compared to T48 or 




















































Figure 5: Cytokine release of RAW264.7 following infection with RRV strains 
RAW264.7 macrophages were inoculated with RRV strains T48, DC7194 and 
DC5692 at an MOI of 4 and levels of TNFα (A) and IL-6 (B) were measured by 
ELISA at 0 hr and 12 hr post-infection. Data is expressed as mean values ± SEM 
(n=3). ***(p≤ 0.001) as determined by one-way ANOVA compared to DC 7192 or 




3.4 Influence of viral titres on cytokine response in infection of 
RAW264.7 macrophages with RRV   
Viral titres in infection experiments are often expressed as multiplicity of infection 
(MOI), which is a numerical statement of the ratio of viruses to the number of target 
cells. The influence of different viral titre on the cellular response has been 
investigated for several viruses (Haas, 2004) and recent work by Chen et al. (W. 
Chen et al., 2014) has briefly investigated the response of osteoblasts exposed to 
RRV at varying MOIs. To examine the influence of virus titres on the magnitude of 
cytokine response from macrophages we infected RAW264.7 cells with RRV T48 at 
an MOI of 0.1, 1 or 10. Supernatant samples were taken at 12 and 24 hr p.i. and 
examined for TNFα concentration by ELISA (Figure 6 A) as well as bioassay (Figure 
6 B). Measured cytokine levels did not show a significant difference between an MOI 
of 1 and an MOI of 10 at any time point for both assays. TNFα levels for an MOI of 
10 and an MOI of 1 at 24 hr p.i. as measured by ELISA were not significantly 
different with 2255 ± 164 pg/mL and 2027 ± 117 pg/mL respectively. RRV at an MOI 
of 0.1 however resulted in significantly lower cytokine concentrations (1624 ± 120 
pg/mL) compared to an MOI of 10 (p≤0.01). The TNFα concentration at 24 hr p.i. as 
determined by bioassay reached 1667 ± 121 pg/mL for an MOI of 10 and 1626 ± 
230 pg/mL for an MOI of 1. An MOI of 0.1 gave a mean value of 1065 ± 132 pg/mL 
at 24 hr p.i., which was again significantly lower than the highest titre used (p≤0.01). 
Cell viability was determined for samples obtained 24 hr p.i. by LDH assay as 
outlined in Methods. Relative viability compared to non-treated cells in percent was 
98.7 ± 1.2 for an MOI of 0.1, 94.7 ± 0.7 for an MOI of 1 and 90.7 ± 1.2 for an MOI of 
10. A lower MOI of 0.1 gave less severe TNFα responses as compare to the higher 

































Figure 6: TNFα release from RAW264.7 infected with differing MOI of RRV T48 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 0.1, 1 or 10. 
Supernatant samples taken at varying times were assayed for TNFα concentrations 
by ELISA (A) and TNFα bioassay (B). Cell viability at 24 hr p.i. was determined by 
LDH assay and expressed as relative viability compared to non-infected cells (C). 




3.5 Discussion of preliminary results 
RRV T48 and RRV DC5692 have previously been compared in a mouse model 
(Jupille et al., 2011) and DC5692 was reported to be mouse avirulent due to 
mutations in its genome sequence in the E2 and nsP1 region. We extended these 
findings in vitro with preliminary experiments showing that RRV DC5692 induces 
only weak cytokine responses in RAW264.7 macrophages as compared to RRV 
T48, as well as reduced characteristics in growth and cytolysis when incubated with 
Vero cells.  
RRV DC7194 and RRV T48, which are both known to be mouse virulent, have 
shown very similar results in regards to viral titres when grown in Vero cells as well 
as TNFα and IL-6 release from infected RAW264.7 macrophages. Little is known 
about the genetic variation between these two strains but it may be assumed that 
their genetic variance in E2 and nsP1 is minimal. Research studies commonly utilise 
the T48 strain, which was one of the earliest RRV isolates, initially collected in North 
Queensland (R. Doherty et al., 1963; Lindsay et al., 1993) and considering the 
strong similarity of T48 and DC7194 in these initial experiments we continued to use 
RRV T48 only. An MOI of 1 was determined as optimal viral titre for infection assays 
with RAW264.7 macrophages since cellular responses were similar to an MOI of 10, 
however cell viability was consistently higher as determined by LDH assay. This 
needed consideration since some experiments were planned to run for up to 72 hr. 
RRV at an MOI of 0.1 produced a delayed response in TNFα release but seemed to 
reach similar cytokine levels as an MOI of 1 lagging approximately 12 hr behind. 
The delay is likely due to initial cytokine response being below the detection level 
and only after early cytolytic replication cycles the viral numbers increase enough to 
initiate a detectable response in the macrophages.  
It was clearly noticeable that TNFα concentrations determined by bioassay showed 
a similar induction pattern although absolute concentrations seemed to be 
considerably lower compared to the results obtained by ELISA. The L929 bioassay 
uses recombinant rat TNFα as standard, which shares 97.4% homology with mouse 
TNFα protein (Kwon Ii et al., 1993). This difference in standard as well as possible 
loss of bioactivity of the samples or standards during storage likely causes that 
discrepancy between the two assays. ELISA assays can often still detect 




It should be noted that cell culture adaptive mutations have been reported for  
Sindbis virus, a member of the alphavirus genus (Klimstra et al., 1999), with 
significant differences in pathogenesis caused by those mutated viruses as 
compared to wild type isolates. To avoid these adaptive processes many 
researchers initially generate the T48 RRV strain by in vitro transcription of a cDNA 
plasmid initially constructed by Kuhn et al. (Kuhn et al., 1991) with further 
propagation in suitable cell lines. The T48 strain used in our experiments was kindly 
donated by Dr David Williams (Curtin University) and had low passage numbers in 
Vero cells after generation from the cDNA plasmid. To minimize the likelihood of 
mutations in the viral genome the initial virus stocks were prepared, aliquoted and 
kept in storage at -80˚C until use. Viral passages were kept to a minimum and did 
not exceed 8 passages in Vero cells. Despite the low divergence over time as 
reported by Sammels et al. (Sammels et al., 1995), adaptive mutations may be 
possible and can therefore not be excluded.  
Another factor to consider is the cell line utilised for propagation of viral isolates. 
Commonly used cell lines for RRV are Vero cells or C6/36 mosquito cells (Jupille et 
al., 2013; Stoermer Burrack et al., 2014). Considering the natural transmission and 
reproduction of RRV in mosquito vectors, the use of C6/36 cells appears suitable, 
especially as it may mimic the naturally occurring step of replication in arthropods. 
Differences of mammalian and mosquito derived Sindbis viruses have been 
reported previously (Klimstra et al., 2003) and similarly Shabman et al. (Shabman et 
al., 2007) showed that mosquito-cell-derived RRV infected dendritic cells more 
efficiently as virus propagated in mammalian cells,  however induced  a less severe 
IFN response. This lack of IFN stimulation is attributed to the high mannose content 
of N-linked glycans on mosquito-derived viral E2 proteins as opposed to the 
complex glycans found on mammalian-derived virus. 
To our knowledge it is not known whether RRV isolates differ in the induction of 
other cytokines which could therefore show variation in virus pathogenesis. 
Mosquito cell culture conditions greatly differ from conditions for most other cell lines 
and due to lack of suitable equipment we performed all virus propagation 




4. Results II: Cellular response and cytokine production of 
RAW264.7 macrophages after RRV infection 
4.1 Introduction: 
As discussed previously, macrophages are known to play a pivotal role in 
inflammatory conditions found in arthritic and rheumatoid disorders and their ability 
to migrate and release pro-inflammatory cytokines is thought to contribute to 
progression of the local inflammation (Burmester et al., 1997; Kinne et al., 2000; 
Nathan, 1987). As an integral part of our innate immune system their general 
involvement in viral infections has been studied (Biron, 1998; Guidotti & Chisari, 
2001) and Lidbury et al. (Lidbury et al., 2008) discussed their important role in the 
immune response to RRV infection. Macrophages can be found extensively in 
synovial linings of infected patients and mice and contribute to the characteristic 
joint inflammation in RRV infections. Considering these findings and the ability of 
macrophages to secrete an array of pro-inflammatory mediators, we decided to use 
RAW264.7 mouse macrophages to further investigate the cytokine network induced 
by RRV with the aim of identifying possible targets for pharmacotherapeutic 
intervention.  
4.2 Infection of RAW cells with RRV 
It has previously been demonstrated that RRV infect RAW264.7 macrophages 
despite the cells ability to produce antiviral cytokines (Lidbury & Mahalingam, 2000b; 
Lidbury et al., 2000). In order to evaluate successful infection under our conditions, 
RAW264.7 macrophages were incubated with RRV T48 at an MOI of 1 and samples 
of the supernatant were taken to be analysed for virus titres via TCID50 assay. As 
shown in Figure 7 A, viral count decreased initially but started to increase again by 
day 2 post-exposure. To confirm that the virus had entered the cells, RNA was 
extracted at each time point and examined for expression of the RRV Envelope 2 
(RRV-E2) gene (Figure 7 B). The primers used in the PCR were chosen to amplify 
the entire region of RRV-E2 (Mahalingam & Lidbury, 2002). A band on the 
electrophoresis gel can be seen in samples from 1 d p.i. onwards and confirmed, 


























    
 B  
RRV 
RRV-E2 
(247 bp)  
    
  G3PDH 
(452 bp)  
    
   
0 24 48 72 
    
    Time p.i.  (hr)      
Figure 7: TCID50 values of supernatant from RRV-infected RAW264.7 
macrophages  
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1. Samples of 
the supernatant were taken at 0 hr, 24 hr, 48 hr and 72 hr post-infection and 
assayed for viral titres via TCID50 assay (A). Values expressed are mean ± SEM 
(n=3). RNA was extracted at the same time points and expression of the viral E2 
gene was determined by RT-PCR. (B) shows a representative photograph of the 




4.3 Cytokine production of RAW264.7 following exposure to RRV  
4.3.1 TNFα response to RRV infection  
Lidbury et al (Lidbury et al., 2008) have shown that macrophages and the cytokines 
they release play an important role in RRV infection. Especially TNFα levels were 
found to be increased in plasma and synovial fluids of mice and humans with acute 
RRV infection (Iwamoto et al., 2008; Rulli et al., 2007). 
In order to further investigate cytokine production of macrophages upon RRV 
infection, RAW264.7 cells were infected with RRV T48 at an MOI of 1 and 
supernatant samples were collected at suitable time intervals to determine TNFα 
concentration by ELISA and L929 bioassay. LPS (from E.coli) is known to induce 
TNFα secretion in RAW264.7 macrophages and was used as positive control 
(Beutler et al., 1985). As shown in Figure 8 A, a strong increase of TNFα 
concentration can be observed in the supernatant of RRV-infected cells in a time 
dependent manner to a level of 1673 ± 152 pg/mL by 12 hr p.i., with no significant 
change thereafter. To assess bioactivity of TNFα and to verify cytokine 
concentration, an L929 bioassay was performed (Figure 8 B). TNFα levels showed 
similar time dependent patterns of induction for the bioassay, however lower 
concentrations were detected with 1277 ± 120 pg/mL at 12 hr p.i. and 1640 ± 225 
pg/mL at 24 hr p.i. As outlined in Methods, the significantly lower concentration of 
the bioassay as compared to the ELISA may result from a loss of bioactivity or the 
use of rat TNFα standard for the L929 assay. Both assays however confirmed an 
increase in TNFα secretion in RRV-infected RAW264.7 macrophages. 
4.3.2 TNFα mRNA induction  
To determine whether RRV infection induced TNFα mRNA expression, RAW264.7 
cells were infected with RRV T48 at an MOI of 1 and mRNA was extracted at 
appropriate time points. Both quantitative real-time RT-PCR as well as conventional 
RT-PCR was performed to investigate expression of TNFα mRNA. Real time PCR 
data (Figure 9 A) shows up-regulation of TNFα mRNA expression in a time 
dependent manner with a maximum 3.24-fold increase at 24 hr p.i. This result was 
confirmed using conventional PCR as shown in Figure 9 B. Induction of TNFα 
mRNA could be detected as early as 4 hr p.i. for RRV and 2 hr post exposure for 
LPS. TNFα mRNA expression increased consistently up to 36 hr p.i. in RRV-






























































Figure 8: Release of TNFα by RAW264.7 macrophages post RRV infection  
RAW264.7 macrophages were exposed to RRV DC7194 at an MOI of 1 or LPS (1 
µg/mL) for varying periods of time and TNFα levels in the supernatant were 
determined via TNFα ELISA (A) and bioactivity of TNFα was tested in a L929-
bioassay (B). Recombinant rat TNFα was used as standard for the bioassay. All 
values are expressed as mean ± SEM (n=4). ***(p≤0.001) as determined by two-
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4.3.3 NO from RAW264.7 macrophages upon exposure to LPS or RRV 
A Griess assay was performed on supernatant collected at appropriate time 
intervals from RRV T48-infected (MOI of 1) or LPS-stimulated (1 µg/mL) RAW264.7 
cells (Figure 10). A significant increase of nitrite (NO2
-) in the supernatant of LPS-
treated macrophages could be detected as early as 12 hr p.i. At 36 hr p.i., NO2
- 
levels were elevated to 30.93 ± 4.89 µM for cells treated with 1 µg/mL LPS (positive 
control). The supernatant of RRV-infected cells showed an slight increase of NO2
- 
levels at 36 hr p.i., which was however not significant. It appears that RRV does not 
significantly induce the release of NO into the supernatant. 
4.3.4 LPS induced NO secretion in RRV-infected RAW264.7 macrophages 
Previous experiments showed that RRV did not induce significant NO secretion in 
RAW264.7 macrophages. In order to examine if RRV affects the ability of 
macrophages to secrete NO upon LPS stimulation, RAW264.7 cells were infected 
with RRV at an MOI of 1 for 0, 24 or 48 hr prior to stimulation with 1 µg/mL LPS. 
NO2
- concentration in the supernatant was determined via Griess assay 24 hr post 
LPS stimulation (Figure 11). HI-RRV was used in mock infections with and without 
24 hr LPS treatment as positive and negative control respectively. Macrophages 
infected with RRV at the start of the experiment (0 hr) and 24 hr prior showed no 
significant change in NO secretion upon LPS stimulation compared to mock infected 
macrophages, with concentrations reaching 40.91 ± 2.70 µM and 39.73 ± 1.92 µM 
respectively. Exposing RAW cells to RRV for 48 hr prior to LPS challenged 
significantly (p≤0.001) decreased NO secretion with levels of NO2
- measured at 
29.24 ± 2.52 µM. This indicates that infection with RRV reduces the NO response 
upon LPS stimulation in RAW264.7 macrophages. 
4.3.5 Transcription of iNOS mRNA in RAW264.7 upon infection with RRV  
To assess whether transcription of iNOS was induced, we performed both 
conventional RT-PCR as well as quantitative real time PCR on extracted mRNA 
using primers specific for iNOS mRNA. Expression levels for non-treated samples 
were below the detection limit of quantitative real-time PCR. Therefore a ratio of 
iNOS mRNA over the corresponding G3PDH mRNA was used in order to graph the 
change of cytokine mRNA transcription (Figure 12 A). Expression of iNOS mRNA 
could be detected as early as 4 hr p.i. with conventional RT-PCR and increased in a 
time dependent manner (Figure 12 B). Compared to NO2
- in the supernatant, the 






























Figure 10: Nitrite concentration in the supernatant of RAW264.7 cells post RRV 
infection 
RAW264.7 cells were exposed to RRV T48 at an MOI of 1 or LPS (1 µg/mL) and 
samples of the supernatant were assayed with Griess reagent for NO2
- 
concentration at 0, 2, 12 and 36 hr post stimulation. Data shown are mean values ± 
SEM (n=4). ***(p≤0.001) for LPS stimulation compared to mock infected RAW264.7 

































Figure 11: NO release from RAW264.7 macrophages infected with RRV prior to 
LPS stimulation 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 for 0, 24 and 
48 hr prior to LPS (1 µg/mL) exposure. Controls were exposed to heat inactivated 
(HI) RRV 48 hr prior to experiment. Positive controls (HI-RRV(+)) were mock 
infected with HI-RRV and stimulated with LPS (1 µg/mL) whereas negative control 
wells (HI-RRV(-)) were mock infected with HI-RRV only. Supernatant samples were 
taken 24 hrs post stimulation with LPS and NO2
- concentration was measured via 
Griess assay. Data is shown in mean values ± SEM (n=5 for RRV 48 hr, RRV 24 hr 
and RRV 0hr, n=4 for HI-RRV (+) and HI-RRV (-)). ***(p≤0.001) Statistical analysis 








































Figure 12: iNOS mRNA expression in RAW264.7 after exposure to RRV or LPS
RAW264.7 macrophages were exposed to RRV T48 
and mRNA was extracted at various times. (A) shows the ratio of iNOS mRNA over 
G3PDH mRNA expression as determined by real time PCR. Expression in control 
samples and treatment at 0 hr p.i. were below the detection level, thus the ratio o
expression at 0 hr p.i. was allocated ‘0’ by default. All data is expressed in mean 
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4.3.6 IL-6 secretion from RRV-infected RAW264.7 macrophages   
IL-6 has been previously reported to be induced in infections with various 
alphaviruses (Assuncao-Miranda et al., 2010; Chow et al., 2011). It appears 
however that it has so far not been investigated in RRV-infected cell lines 
(Assuncao-Miranda et al., 2013). To determine if RRV infection induces IL-6 
secretion, RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 and 
supernatant samples were tested for IL-6 by ELISA (Figure 13). IL-6 could be 
detected in the supernatant from 2 hr p.i. onwards in RRV-infected cells and 
increased in a time dependent manner. By 36 hr p.i. the levels of IL-6 in RRV 
samples reached 567 ± 43pg/mL which was only marginally lower than levels in the 
supernatant of RAW cells stimulated with LPS at 1 µg/mL (644 ± 59 pg/mL). It is 
apparent that RRV significantly induces secretion of IL-6 in a time dependent 
manner. 
4.3.7 Expression of IL-6 mRNA in RAW264.7 macrophages post RRV 
infection 
In order to further investigate the increased production of IL-6, mRNA extracted from 
RRV-infected or LPS-stimulated RAW macrophages was screened for IL-6 mRNA. 
Interestingly, none of the RRV-infected macrophages showed increased IL-6 mRNA 
transcription. LPS stimulated RAW264.7 cells were used as positive control and 
showed significantly increased levels of IL-6 mRNA from 4 hr p.s. onwards peaking 
at 12 hr p.s. and decreasing thereafter (Figure 14), likely due to degradation of IL-6 
mRNA.   
4.3.8 MIF secretion in RAW264.7 macrophages upon RRV infection 
A more recent study (Herrero et al., 2011) with mice highlighted the critical role of 
MIF in RRV induced arthritis in vivo. To investigate if MIF levels are elevated in vitro 
due to secretion of the cytokine by macrophages, we infected RAW264.7 cells with 
RRV and measured MIF concentration in the supernatant at various time points 
post-infection. LPS stimulated RAW cells were used as positive controls. As shown 
in Figure 15, an elevated concentration of MIF in the supernatant was detected by 4 
hr p.i. increasing in a time dependent manner for both RRV- and LPS-treated 
samples with levels at 24 hr p.i. reaching 7765 ± 1657 pg/mL (p≤0.001) and 8230 ± 































Figure 13: IL-6 secretion by RAW264.7 macrophages post RRV infection 
RAW 264.7 macrophages were exposed to RRV T48 (MOI of 1) or LPS (1 µg/mL) 
for 0, 2, 12 or 36 hrs and supernatant was tested for IL-6 by ELISA. Heat inactivated 
RRV was used in mock infections as negative control. Data is expressed as mean 






















Figure 14: IL-6 mRNA expression in RAW264.7 macrophages after exposure to 
RRV and LPS 
RAW264.7 cells were exposed to RRV
mRNA was extracted at 
6 mRNA was determined 
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Figure 15: MIF concentration in RAW264.7 macrophages exposed to RRV or 
LPS 
RAW264.7 macrophage cells were challenged with RRV T48 at an MOI of 1 or LPS 
(1 µg/mL) and supernatant samples were analysed by MIF ELISA at various time 
points post exposure. All data is shown in mean values ± SEM (n=3). **(p≤0.01), 





4.3.9 RRV infection alters transcription of MIF mRNA in RAW264.7  
The mRNA of RAW macrophages infected with RRV T48 was extracted at 
appropriate times p.i. and examined for MIF mRNA expression. Macrophages 
stimulated with 1 µg/mL LPS were used as positive control. MIF mRNA was 
detectable from 12 hr onwards for both RRV-infected as well as LPS treated RAW 
cells as shown in Figure 16. Expression of MIF mRNA continued to at least 36 hr 
post-infection. The rate of expression in RRV induced macrophages however was 
considerably lower compared to the LPS control.  
4.3.10 RRV infection induces secretion of HMGB1 in RAW264.7 macrophages 
HMGB1 is universally expressed in most cells as architectural chromosomal protein, 
however it has also been discovered to function as a pro-inflammatory cytokine 
when released extracellularly (Muller et al., 2001; H. Wang et al., 1999). Stimulation 
with TNFα induces secretion of HMGB1 as a late mediator in inflammation (H. Wang 
et al., 1999). To investigate if RRV induces secretion of HMGB1 in macrophages, 
RAW264.7 cells were exposed to RRV T48 (MOI of 1) for variable amounts of time 
and the supernatant was tested for the presence and concentration of HMGB1 by 
ELISA (Figure 17). Macrophages infected with RRV showed slightly increased 
concentrations of HMGB1 in the supernatant samples by 24 hr p.i. as compared to 
mock infected controls, with levels reaching 6.5 ± 1.3 ng/mL and 12.1 ± 2.7 ng/mL at 
36 hr post-infection. This increase was however not statistically significant. LPS 
treated RAW264.7 cells were used as positive control with HMGB1 concentrations 
significantly increasing to 25.8 ± 6.4 ng/mL (p≤0.001) and 38.6 ± 8.9 ng/mL 
(p≤0.001) by 24 and 36 hr p.i. respectively. 
4.3.11 RRV infection decreases expression of HMGB1 mRNA in RAW264.7  
To study the effect of RRV infection on HMGB1 mRNA expression, RAW264.7 
macrophages were exposed to RRV at an MOI of 1 and mRNA was extracted at 
varying time periods post-infection and analysed by conventional as well as real 
time RT-PCR. As expected, HMGB1 mRNA could be detected at all analysed time 
points and in all samples. Interestingly the expression of HMGB1 mRNA seemed to 
decrease in RRV and LPS stimulated samples at 36 hr post treatment as indicated 
by agarose gel blots. The expression in the control however remained consistent 
(see Figure 18 B). Quantitative real-time data confirmed significant (p≤0.05) down-
regulation of HMGB1 transcription in RRV-infected samples by almost 3.5 times as 







































Figure 16: MIF mRNA expression in RAW264.7 after exposure to 
RAW264.7 macrophages
with LPS (1 µg/mL) and mRNA was extracted at various time
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Figure 17: HMGB1 release of RAW264.7 macrophages upon stimulation with 
LPS or RRV T48 
RAW264.7 macrophages were exposed to with RRV T48 at an MOI of 1 or LPS (1 
µg/mL) and the supernatant was tested for HMGB1 concentration at varying time 
points post-infection by ELISA. Heat inactivated RRV was used in mock infections 
as negative control. Data is shown in mean values ± SEM (n=3). ***(p≤0.001) as 
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4.3.12 RRV increases the transcription of HMGB3 mRNA but does not affect 
HMGB2 mRNA expression in RAW264.7 cells 
In order to determine the effect of RRV on the expression of HMGB2 and HMGB3 
mRNA, RAW cells were infected with the virus at an MOI of 1 and mRNA extracted 
at various time points post-infection. HMGB3 mRNA could be detected in all 
samples and expression gradually increased p.i. in the RRV samples (Figure 19 B). 
LPS challenged samples in contrary showed a decrease in HMGB3 mRNA 
expression in a time dependent manner. Neither RRV nor LPS significantly changed 
the expression of HMGB2 mRNA (Figure 19 A, densiometric data not shown). 
4.3.13 LPS and RRV induce IL-10 secretion in RAW264.7 macrophages 
It has previously been shown that antibody dependent enhancement (ADE) of RRV 
infection can induce the secretion of the anti-inflammatory cytokine IL-10 in RAW 
267.4 macrophages (Mahalingam & Lidbury, 2002) and it was later shown that this 
is also true for naive RRV infection (Morrison et al., 2008). To verify these findings 
for our conditions, RAW264.7 cells were infected with RRV T48 or exposed to LPS 
as a positive control and supernatant was tested for IL-10 by ELISA. As expected, 
LPS significantly (p≤0.001) induced the secretion of IL-10 into the supernatant by 4 
hr post stimulation and peaked at 2244 ± 228 pg/mL by 12 hr post stimulation 
(Figure 20 A). A less pronounced increase of IL-10 levels in the supernatant of RRV-
infected macrophages was noticeable by 12 hr p.i. and significantly (p≤0.05) 
increased by 24 hr p.i. reaching a concentration of 153 ± 25 pg/mL (Figure 20 B). 
For statistical calculation, IL-10 levels were compared to mock infection control. 
4.3.14 RRV does not induce secretion of Prostaglandin E2 in RAW264.7  
The important functions of prostaglandin E2 (PGE2) in inflammatory and immune 
responses have long been established (Kalinski, 2012), however according to our 
literature research no data is available on the role of PGE2 in alphavirus infections. 
To investigate if the regulation of this mediator is altered in RRV infection we 
analysed the supernatant of RAW264.7 macrophages exposed to LPS (1 µg/mL) or 
RRV T48 (MOI of 1). LPS stimulation has previously been shown to induce PGE2 
secretion in RAW264.7 macrophages and was therefore included as positive control 
(Salvemini et al., 1993). As Figure 21 shows, RRV T48 did not stimulate PGE2 
release from macrophages in contrast to LPS stimulation, which significantly 

























Figure 19: HMGB2 and HMGB
after exposure to RRV or LPS
RAW264.7 macrophages
stimulated with LPS (1 
PCR with specific primers for 
are representative photographs of 









0 4 12 24 
 Time p.i. (hr) 
 





0 4 12 24 
 Time p.i. (hr) 
3 mRNA expression in RAW264.7 macrophages 
 
 were infected with RRV DC 7194 at an MOI of 1
µg/mL) and mRNA was extracted at various time
HMGB2 (A) and HMGB3 (B) was performed. 


































   A
LPS























   B 
RRV





















Figure 20: LPS and RRV induces IL-10 secretion in RAW264.7 macrophages 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 (B) or 
stimulated with 1 mg/uL LPS (A) for varying amounts of time. Control cells were 
mock-infected with heat inactivated RRV. IL-10 concentration of the supernatant 
samples was determined by ELISA as outlined in Methods. Data is expressed in 
mean values ± SEM (n=3). Induction of IL-10 secretion is significantly lower in RRV-
infected cells compared to LPS treatment. *(p≤0.05),***(p≤0.001). Statistical 
analysis was performed by two-way ANOVA and compared to mock-infected 

































Figure 21: PGE2 secretion of RAW264.7 macrophages exposed to RRV T48 or 
LPS 
RAW264.7 macrophages were challenged with RRV T48 at an MOI of 1 or LPS (1 
µg/mL) and supernatant samples were analysed by PGE2 ELISA at various time 
points post exposure. All data is shown in mean values ± SEM (n=3), ***(p≤0.001) 





4.3.15 RRV infection induces IL-18 mRNA expression in RAW264.7 
macrophages  
Earlier research has shown that the secretion of the pro-inflammatory cytokine IL-18 
by macrophages plays an important role in rheumatoid arthritis (Gracie et al., 1999), 
and more recently it was reported that plasma IL-18 levels are also increased in 
patients infected with CHIKV (Chirathaworn et al., 2010). To investigate if IL-18 
possibly contributes to inflammatory processes in RRV infections, we exposed 
RAW264.7 macrophages to the T48 strain (MOI of 1) and extracted mRNA at 
various time points post-infection for conventional and real-time RT-PCR analysis. 
LPS was used as positive control (Tone et al., 1997). As shown in Figure 22 A, 
RRV-infected macrophages showed increased transcription of IL-18 mRNA from 12 
hr p.i. onwards. This result was confirmed by real-time PCR analysis, as shown in 
Figure 22 B. The ratio of cytokine mRNA in RRV-infected samples was calculated 
against the mRNA of negative control samples. IL-18 mRNA expression was 
increased 3.1-fold by 12 hr p.i. (p≤0.05) and 4.8-fold by 24 hr p.i. (p≤0.001) as 
compared to mock infection. Exposure to LPS induced IL-18 mRNA in macrophages 
as expected and was detected from 4 hr p.s onwards with conventional RT-PCR. 
Amplicon density appeared to peak at 12 and 24 hr p.s. and decreased again by 36 
hr p.s. (Figure 22 B). 
4.3.16 The expression of IL-33 mRNA is induced in RRV-infected RAW264.7 
macrophages 
IL-33, a member of the IL-1 superfamily has previously been identified as an 
important cytokine in inflammatory conditions (Schmitz et al., 2005). It has been 
shown to contribute to the inflammatory development of rheumatoid arthritis by 
stimulating the release of pro-inflammatory cytokines (Moulin et al., 2007; D. Xu et 
al., 2008). In order to examine a possible role of IL-33 in RRV infections, RAW264.7 
macrophages were exposed to RRV T48 at an MOI of 1 and mRNA was extracted 
at various time points post-infection. Extracted mRNA was analysed with 
conventional and real-time RT-PCR using primers specific for IL-33. LPS treated 
RAW cells showed strong induction of IL-33 mRNA transcription from 4 hr p.s. 
onwards as shown in Figure 23 B. Expression of IL-33 mRNA could be detected in 
RRV-infected cells from 12 hr p.i. onwards, with the density of the amplicons 
decreasing by 36 hr p.i. Due to insufficient expression in controls and 0 hr samples, 
real-time data could not be calculated as relative expression compared to mock 




the corresponding G3PDH mRNA expression (Figure 23 A). This ratio was given the 
arbitrary value of ‘0’ for 0 hr p.i. and is only used to visualise up- or down-regulation 
of mRNA expression. In both RRV as well as LPS treated samples the transcription 
of IL-33 mRNA is induced by 12 hr p.i., increasing in a time dependent manner for 
RRV samples. Expression levels for LPS challenged macrophages at 12 hr p.i. are 
slightly increased compared to RRV infection, however this increase is not 






































Figure 22: IL-18 mRNA expression in RAW264.7 after exposure to RRV
RAW264.7 macrophages
with LPS (1 µg/mL) and mRNA was extracted at various time
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Figure 23: IL-33 mRNA expression in 
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4.4 Inhibitors and stimulants of cytokine release in RRV-infected 
RAW264.7 macrophages 
4.4.1 Inhibition of TNFα in RAW cells post RRV infection 
As mentioned in the Literature Review, many inhibitors for TNFα have been 
identified to this date. NSAIDs and corticosteroids like dexamethasone have been 
shown to inhibit TNFα release in macrophages and both have previously been used 
in the management of RRV induced arthritis (Suhrbier et al., 2012; Suhrbier & 
Mahalingam, 2009). Corticosteroids are however rarely used due to their possible 
immunosuppressive and gastro-intestinal side effects (Mylonas et al., 2004). Zaid et 
al. (Zaid et al., 2011) have trialled etanercept in the treatment of RRV-infected mice, 
but found that complete TNFα inhibition aggravated disease symptoms, likely due to 
impaired antiviral response. It may however be possible that moderate reduction in 
TNFα levels could suppress excessive inflammatory response without impairing 
immune responses to the infection. To our knowledge, apart from the 
aforementioned compounds, no other TNFα inhibitor has so far been examined in 
RRV infection.  
4.4.1.1 Macrolide antibiotics   
Apart from their antibiotic properties several macrolides have been investigated for 
their anti-inflammatory properties (Labro, 1998), however to this date no macrolide 
has been trialled to reduce inflammatory responses in RRV infection. To investigate 
the influence of three commonly used macrolides on cytokine production we infected 
RAW264.7 macrophages with RRV T48 in the presence of varying concentrations of 
macrolides and evaluated the cytokine response. 
4.4.1.1.1 Erythromycin decreases TNFα secretion of RRV-infected 
macrophages 
Early research suggested that Erythromycin (ERY) can reduce TNFα production in 
human monocytes (Iino et al., 1992). To investigate if ERY interferes with RRV 
induced TNFα secretion in macrophages, RAW264.7 cells were exposed to RRV 
T48 at an MOI of 1 with different concentrations of the macrolide present. 
Supernatant samples at various time points were examined for TNFα concentration 
by ELISA (Figure 24 A). Dose-dependent inhibition could be detected as early as 4 
hr p.i. and was significant at 24 hr p.i. for both 10 µM and 100 µM ERY (p≤0.001). At 
36hr p.i. the concentration of TNFα for 10 µM ERY was reduced by approximately 




treated with Erythromycin 10 µM. The decrease of TNFα in the supernatant for 
Erythromycin 100 µM treated cells at 36 hr p.i. was approximately 69.6 % to 369 ± 
69 pg/mL. Lower concentrations (0.1, 1 and 10 µM) of Erythromycin were used in 
separate experiments and TNFα levels were determined by L929 bioassay (Figure 
24 B). Again, inhibition could be detected from 4 hr p.i. onwards for all samples. 
Concentrations of 0.1 µM ERY showed decreased TNFα secretion, which was 
however not statistically significant. At concentrations of 1 µM and 10 µM ERY, a 
significant inhibition could be detected from 12 hr p.i. onwards (p≤0.05 and p≤0.01 
respectively). In samples containing 1 µM ERY, TNFα levels decreased to 448 ± 
126 pg/mL at 24 hr p.i. as compared to 974 ± 86 pg/mL for non-treated cells 
(p≤0.001). This reduction was even more pronounced in 10 µM ERY samples with 
levels dropping to 389 ± 119 pg/mL as determined by L929 bioassay (p≤0.001). 
4.4.1.1.2 Clarithromycin inhibits secretion of TNFα in RRV-infected RAW264.7 
macrophages 
Similar to Erythromycin the macrolide clarithromycin (CLA) has been shown to 
reduce TNFα levels in the sera of LPS stimulated mice (Tkalcevic et al., 2008). In 
order to investigate a possible inhibition of TNFα secretion in RRV infections we 
exposed macrophages RRV T48 (MOI of 1) in the presence of 10 or 100 µM CLA. 
As shown in Figure 25 A, a reduction of TNFα in the supernatant could be detected 
by ELISA from 4 hr p.i. onwards. The maximum inhibitory effect was detected at 24 
hrs p.i. with a reduction of TNFα levels from 1055 ± 90 pg/mL to 640 ± 97 pg/mL for 
10 µM CLA and 380 ± 73 pg/mL for  100 µM CLA respectively. Up to 12 hr p.i. there 
was no significant difference in inhibition for both concentrations, however at 24 hr 
and 36 hr p.i. the increase in inhibition between 10 µM to 100 µM CLA was 
significant (p≤0.05). A TNFα bioassay on supernatant samples from a separate set 
of experiments showed significant reduction of TNFα compared to non-treatment at 
24 hr p.i. for 0.1 µM CLA (p≤0.01), 1 µM CLA (p≤0.001) and 10 µM CLA (p≤0.001). 
The inhibitory effect on TNFα was both time- and dose-dependent as shown in 
Figure 25 B. Cytokine levels at 24 hr p.i. compared to non-treated macrophages 
dropped from 974 ± 86 pg/mL to 649 ± 100 pg/mL (0.1 µM CLA), 432 ± 81 pg/mL (1 




















Figure 24: TNFα secretion of RAW264.7 macrophages after RRV infection and 
concurrent incubation with erythromycin 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 and 
concurrently treated with 0, 0.1, 1, 10 or 100 µM erythromycin. HI-RRV was used as 
negative control. An ELISA (A) and a TNFα bioassay (B) was performed on 
supernatant samples to determine TNFα concentration and bioactivity. All values 
are expressed as mean ± SEM (n=3). *(p≤0.05), **(p≤0.01), ***(p≤0.001) for 















Figure 25: TNFα secretion of RAW264.7 macrophages after RRV infection and 
concurrent treatment with CLA 
RAW264.7 macrophages were incubated with RRV T48 at an MOI of 1 and 
simultaneously treated with 0, 0.1, 1, 10 or 100 µM clarithromycin (CLA). HI-RRV 
was used as negative control. An ELISA (A) or a TNFα bioassay (B) was performed 
on supernatant samples to determine TNFα concentration. All values are expressed 
as mean ± SEM (n=3 for each set of experiments). *(p≤0.05), **(p≤0.01), 




4.4.1.1.3 Roxithromycin alters TNFα secretion in RRV-infected macrophages   
Iino et al. (Iino et al., 1992) reported that Erythromycin as well as Roxithromycin 
(RXM) were able to significantly inhibit TNFα secretion in human monocytes. This 
anti-inflammatory effect was further investigated in arthritic conditions and it was 
found that RXM specifically inhibits progression of collagen induced arthritis and 
suppresses cytokine release in macrophages (Urasaki et al., 2005).  
To examine if this TNFα-suppressive effect can also be utilised in RRV infection we 
exposed RAW264.7 macrophages to RRV T48 (MOI of 1) and various 
concentrations of RXM. Supernatant samples were taken at various time points and 
examined for TNFα concentration by ELISA as shown in Figure 26 A. A reduction of 
TNFα levels was noticeable from 4 hr p.i. onwards for 10 µM RXM but only reached 
significance at 36 hr p.i. (p≤0.05) with TNFα concentrations of 956 ± 105 pg/mL as 
compared to 1213 ± 138 for infected macrophages without treatment. At a 
concentration of 100 µM RXM the reduction was more pronounced (p≤0.001) with 
levels reduced to 556 ± 90 pg/mL at 36 hr p.i. Lower concentrations of RXM were 
trialled in a separate set of experiments and TNFα levels were determined by 
bioassay (Figure 26 B). RXM at a concentration of 0.1 µM reduced TNFα as early as 
4 hr p.i. reaching statistical significance by 12 hr p.i. (p≤0.01) with cytokine 
concentration measuring 286 ± 81 pg/mL as compared to 560 ± 72 pg/mL for non-
treated infection. All samples significantly reduced TNFα secretion (p≤0.001) by 24 
hr p.i. with TNFα concentrations of 648 ± 81 pg/mL (0.1 µM RXM), 576 ± 85 pg/mL 
(1 µM RXM) and 501 ± 67pg/mL (10 µM RXM) respectively as compared to 974 ± 





















Figure 26: TNFα secretion of RAW264.7 macrophages after RRV infection and 
concurrent incubation with Roxithromycin  
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 and 
concurrently treated with or without RXM (0, 0.1, 1, 10 or 100 µM). HI-RRV was 
used as negative control. An ELISA (A) or a L929 bioassay (B) was performed on 
supernatant samples to determine TNFα concentration. All values are expressed as 
mean ± SEM (n=3 for each set of experiments). *(p≤0.05), **(p≤0.01), ***(p≤0.001) 




4.4.1.1.4 Influence of macrolides on transcription of TNFα mRNA in RRV-
infected RAW264.7 macrophages 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 with or without 
concurrent treatment of 100 µM ERY, CLA or RXM. At appropriate time points the 
cells were lysed and quantitative RT-PCR was performed on extracted RNA using 
primers specific for TNFα. Each value obtained was normalised with the 
corresponding G3PDH value and the normalised values were then compared to 
their respective mock infection (control). RRV-infected samples concurrently treated 
with 100 µM ERY showed reduced TNFα mRNA expression at 12 hr and 24 hr p.i. 
as shown in Figure 27 A. Similar to ERY, CLA treatment resulted in reduced TNFα 
mRNA expression at 12 hr p.i. compared to non-treated infection (Figure 27 B). This 
inhibitory effect was still noticeable but less pronounced at 24 hr post-infection. 
Treatment with RXM showed strong inhibition on TNFα mRNA transcription at 12 hr 
p.i. and reached significance by 24 hr p.i. (p≤0.05) as determined by two-way 
ANOVA (Figure 27 C). Treatment with RXM but not ERY or CLA significantly 
reduced transcription of TNFα in RRV-infected RAW264.7 macrophages. 
4.4.1.2 Ethyl pyruvate reduces TNFα secretion in RRV-infected RAW264.7  
Previous research (Ulloa et al., 2002) showed that EP reduces the LPS stimulated 
release of the pro-inflammatory cytokines TNFα and HMGB1 by macrophages in 
vivo and in vitro. To examine if such a reduction in TNFα release is also achievable 
in RRV infection, we infected RAW264.7 macrophages with RRV T48 (MOI of 1) 
and added EP in various concentrations. As shown in Figure 28, both 100 µM and 
1000 µM EP inhibited TNFα secretion significantly (p≤0.05) from 12 hr p.i. onwards 
as compared to non-treated infection. The cytokine levels at 36 hr p.i. were reduced 
by 3.2-fold from 1213 ± 138 pg/mL to 377 ± 98 pg/mL for non-treated cells and 
macrophages treated with 100 µM EP respectively. Interestingly, a 10-fold increase 
in concentration of EP to 1000 µM did not significantly increase inhibition at any 
given time point p.i. with the TNFα concentration in the supernatant reaching 387 ± 



















Figure 27: TNFα mRNA expression in RAW264.7 macrophages after infection 
with RRV and treatment with macrolide antibiotics 
RAW264.7 macrophages were exposed to RRV T 48 at an MOI of 1 and 
concurrently treated with or without 100 µM ERY, CLA or RXM. RNA was extracted 
at different times and examined by quantitative real time PCR. HI-RRV was used as 
negative control. Relative expression was calculated as the normalised values of 
RRV-samples over the normalised values of the corresponding control. Data shown 


















Figure 28: Secretion of TNFα in RRV-infected RAW264.7 macrophages co-
treated with ethyl pyruvate 
RAW264.7 macrophages were incubated with RRV T48 at an MOI of 1 with or 
without the presence of ethyl pyruvate (100 µM and 1000uM). HI-RRV was used in 
mock infections as negative control. A TNFα ELISA was performed on supernatant 
samples taken at various time points. All values are expressed as mean ± SEM 
(n=3). *(p≤0.05), **(p≤0.01), ***(p≤0.001) as determined by two-way ANOVA 





4.4.1.3 Pentoxifylline reduces TNFα release in RRV-infected RAW264.7  
The ability of PXF to inhibit TNFα secretion in macrophages was reported earlier 
and has been investigated in various inflammatory conditions since (G. M. Doherty 
et al., 1991; Loftis et al., 1997; Marques et al., 1999). The beneficial effects of PXF 
in the treatment of refractory rheumatoid arthritis has been reported, the initial 
research however could not give conclusive results in regards to its TNFα inhibiting 
properties (Maksymowych et al., 1995).  To investigate if PXF could reduce TNFα 
secretion by macrophages after RRV infection, RAW264.7 cells were exposed to 
RRV T48 (MOI of 1) with or without the presence of 100 µM or 1000 µM PXF. 
Supernatant samples at varying times were examined for TNFα levels by ELISA and 
graphed in Figure 29. Cells treated with 100 µM PXF showed significantly reduced 
levels of TNFα from 24 hr p.i. onwards (p≤0.001) with concentrations of TNFα in the 
supernatant at 36 hr p.i. decreasing to 434 ± 137 pg/mL as compared to 1213 ± 138 
pg/mL in non-treated samples. Treatment of RRV infection with 1000 µM PXF 
reduced cytokine levels even further at 36 hr p.i. to 300 ± 91 pg/mL (p≤0.001), which 
equates to a 4-fold reduction in TNFα.  
4.4.1.4 Resveratrol alters release of TNFα in RAW264.7 macrophages 
infected with RRV 
Initial investigations on the effect of RVT on LPS challenged macrophages found 
both increased basal TNFα levels as well as TNFα secretion after stimulation, and 
PCR analysis confirmed up-regulation of TNFα mRNA in macrophages exposed to 
RVT (Wadsworth & Koop, 1999). Contrary to these findings a more recent study 
found a decrease in TNFα expression and secretion upon LPS stimulation in 
macrophages treated with RVT (Qureshi et al., 2012). To evaluate if resveratrol 
could have beneficial effects in RRV infection RAW264.7 macrophages were 
exposed to RRV T48 at an MOI of 1 and various concentrations of RVT ranging 
from 0 to 50 µM. Supernatant samples taken at several time points p.i. were 
analysed for TNFα levels by ELISA and the concentration was graphed as shown in 
Figure 30. RVT at concentrations of 5 and 50 µM significantly reduced the secretion 
of TNFα into the supernatant by 12 hr p.i. compared to non-treated infection (p≤0.01 
and p≤0.001 respectively). TNFα concentration at 36 hr p.i. reached 358 ± 96 pg/mL 
for 5 µM RVT as compared to 1213 ± 138 pg/mL in the positive control. 50 µM RVT 
decreased TNFα levels even further to 221 ± 38 pg/mL by 36 hr p.i., which 










Figure 29: The effect of pentoxifylline on TNFα secretion in RRV-infected 
RAW264.7 macrophages  
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 in the 
presence of PXF (100 µM and 1000 µM). Non-treated macrophages were infected 
with RRV in parallel and used as positive control. Supernatant samples were taken 
at various time points and examined for TNFα by ELISA. Data shown above is 
expressed in mean values ± SEM (n=3). **(p≤0.01), ***(p≤0.001) as determined by 





















Figure 30: The effect of resveratrol on TNFα secretion in RRV-infected 
RAW264.7 macrophages  
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 in the 
presence of resveratrol (RVT) (5 µM and 50 µM). Non-treated macrophages were 
infected with RRV in parallel and used as positive control. Supernatant samples 
were taken at various time points and examined for TNFα by ELISA. Data shown 
above is expressed in mean values ± SEM (n=3). **(p≤0.01), ***(p≤0.001) as 






4.4.1.5 Influence of resveratrol, ethyl pyruvate or pentoxifylline on TNFα 
mRNA expression in RRV-infected RAW264.7 macrophages 
RNA extracted from RAW264.7 cells exposed to RRV T48 at an MOI of 1 and 
concurrent treatment with 1000 µM EP, 1000 µM PXF, 50 µM RVT or R-2 was 
examined for expression of TNFα mRNA by quantitative RT-PCR and normalised 
values were compared to respective controls. Concurrent treatment with EP did not 
show a reduction in TNFα transcription at 12 hr p.i. and only a slight down-regulation 
by 24 hr p.i., which was however not significant (Figure 31 A). Stronger inhibition of 
TNFα transcription was observed with PXF, which showed significant reduction at 
12 hr p.i. (p≤0.05). The inhibitory effect however appeared to lessen by 24 hr p.i. as 
shown in Figure 31 B. Co-treatment of RRV infection with 50 µM RVT inhibited 
expression of TNFα in macrophages significantly by 24 hr p.i. (p≤0.05), with 
transcription levels below or similar to negative controls (Figure 31 C). 
4.4.2 Inhibition of IL-6 release of RRV-infected RAW264.7 macrophages 
4.4.2.1 Macrolide antibiotics 
The influence of macrolides on IL-6 expression has been reported with greatly 
varying results in early research, depending on the conditions and cell lines used 
(Labro, 1998). An investigation into macrolide antibiotics as anti-inflammatory 
agents (Ianaro et al., 2000) has reported that several macrolides can reduce IL-6 
expression amongst other cytokines in J774 murine macrophages. This IL-6 
reducing effect was later confirmed for CLA and ERY in LPS stimulated RAW264.7 
macrophages (Sato et al., 2007). To investigate a possible role for macrolide 
antibiotics in the treatment of alphavirus infections we exposed RAW264.7 
macrophages to RRV T48 (MOI of 1) with or without the presence of varying 






















Figure 31: Expression of TNFα mRNA in RRV-infected RAW264.7 
macrophages treated with ethyl pyruvate, pentoxifylline or resveratrol 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 and 
simultaneously treated with 100 µM EP, 1000 µM PXF or 50 µM RVT. RNA was 
extracted at different times and examined by quantitative real time PCR. HI-RRV 
was used as negative control. Relative expression was calculated as the normalised 
values of RRV-samples over the normalised values of the corresponding control. 





4.4.2.1.1 Erythromycin inhibits secretion of IL-6 from RAW264.7 macrophages 
after RRV infection 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 in the 
presence of 10 µM or 100 µM ERY and supernatant at various time points p.i. was 
examined for IL-6 by ELISA (Figure 32). Supernatant levels of treated RAW264.7 
cells were compared to macrophages exposed to RRV without macrolides. At 12 hr 
p.i. an inhibition of IL-6 from 276 ± 81 pg/mL to 165 ± 25 pg/mL was detected for 10 
µM ERY, which was however not significant. The inhibitory effect appeared reduced 
over time with negligible inhibition at 36 hr post-infection for 10 µM ERY. Treatment 
with 100 µM ERY resulted in a stronger inhibition by 5.6-fold (to 49 ± 43 pg/mL) at 
12 hr p.i. (p≤0.01) but decreased to 1.5-fold (360 ± 44 pg/mL) at 36 hr p.i. compared 
to 553 ± 71 pg/mL for non-treated samples (p≤0.05). 
4.4.2.1.2 Clarithromycin inhibits IL-6 release from RRV-infected RAW264.7 
macrophages 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 and 
concurrently treated with 10 µM or 100 µM CLA as previously. Supernatant samples 
at various time points p.i. were screened for IL-6 concentrations by ELISA. Secretion 
of IL-6 into the supernatant was reduced from 12 hr p.i. onwards for both 
concentrations of CLA and inhibition was most prominent at 12 hr p.i. with a 1.8-fold 
and 6.4-fold reduction of IL-6 in 10 µM and 100 µM respectively (Figure 33). IL-6 
levels were still significantly reduced at 36 hr p.i. in samples containing 100 µM 
CLA, however the inhibition was much less pronounced (1.5-fold). From 24 hr p.i. 
onwards the statistical difference between 10 µM and 100 µM was no longer 
significant.  
4.4.2.1.3 Roxithromycin does not inhibit IL-6 secretion of RRV-infected 
RAW264.7 macrophages 
To evaluate the ability of RXM to inhibit IL-6 in RRV infection we exposed 
RAW264.7 macrophages to RRV T48 at an MOI of 1 with or without the presence of 
10 µM  or 100 µM RXM and measured IL-6 concentration in the supernatant by 
ELISA (Figure 34). In contrast to the macrolides tested previously, 10 µM RXM did 
not significantly inhibit IL-6 secretion at any given time point post-infection. 100 µM 
RXM initially inhibited IL-6 release at 12 hr p.i. (p≤0.01) but this effect did not 
continue and no significant reduction in the cytokine concentration was detected at 
24 or 36 hr p.i. It appears that RXM only delayed IL-6 release at 100 µM but did not 










Figure 32: IL-6 secretion of RRV-infected RAW264.7 macrophages treated with 
erythromycin 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 in the presence 
or absence of erythromycin (ERY) (10 and 100 µM). Supernatant samples were 
taken at various time points and examined for IL-6 by ELISA. Data shown above is 
expressed in mean values ± SEM (n=3). *(p≤0.05), **(p≤0.01) was determined by 













Figure 33: IL-6 secretion of RRV-infected RAW264.7 macrophages treated with 
clarithromycin 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 in the presence 
or absence of clarithromycin (CLA) (10 and 100 µM). Supernatant samples were 
taken at various time points and examined for IL-6 by ELISA. Data shown above is 
expressed in mean values ± SEM (n=3). Statistical analysis was performed by two-













Figure 34: Effect on IL-6 secretion in RRV-infected RAW264.7 macrophages 
treated with roxithromycin 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 in the presence 
or absence of roxithromycin (RXM) (10 and 100 µM). Supernatant samples were 
taken at various time points and examined for IL-6 by ELISA. Data shown above is 




















Figure 35: IL-6 concentration in the supernatant of RRV-infected RAW264.7 
macrophages co-treated with ethyl pyruvate 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 in the presence 
or absence of ethyl pyruvate (EP) (100 and 1000 µM). Supernatant samples were 
taken at various time points and examined for IL-6 by ELISA. Data shown above is 





4.4.2.2 Ethyl pyruvate lowers IL-6 secretion in RRV-infected RAW264.7 
macrophages 
The anti-inflammatory effect of EP was previously described (Yang et al., 2002) and 
it was reported that expression of IL-6 mRNA, amongst other cytokines, is inhibited 
in mice subjected to haemorrhagic shock and treated with EP. Further investigations 
(Song et al., 2004) in LPS-stimulated RAW264.7 macrophages showed strong 
reduction of IL-6 secretion when treated with EP. To examine if release of IL-6 can 
also be reduced in RRV infection, the supernatant of RAW264.7 macrophages 
exposed to RRV and co-treated with varying concentrations of EP was analysed by 
IL-6 ELISA. As shown in Figure 35, the inhibitory effect of EP was both time- and 
dose-dependent. Significant reduction of IL-6 was detectable from 12 hr p.i. onwards 
for macrophages treated with 1000 µM EP (p≤0.05). At 36 hr p.i. inhibition was more 
pronounced with IL-6 concentration lowered from 496 ± 27 pg/mL (non-treated 
infection) to 130 ± 25 pg/mL and 68 ± 18 pg/mL for 100 µM EP and 1000 µM EP 
respectively (p≤0.001). This translates to a 3.8-fold (100 µM EP) and 7.2-fold (1000 
µM EP) reduction of IL-6 secretion. 
4.4.2.3 Influence of pentoxifylline on IL-6 release in RRV-infected RAW264.7 
Early research with PXF has revealed its anti-inflammatory properties in endotoxin 
challenged volunteers by reducing serum TNFα levels without affecting IL-6 
concentrations (Waage et al., 1990). Later reports (D'Hellencourt et al., 1996) 
confirmed these results, but highlighted that the effect of PXF on IL-6 secretion 
varies between whole blood culture and peripheral blood mononuclear cells 
(PBMCs). Further studies have shown the IL-6 inhibiting properties of PXF on 
alveolar macrophages in pulmonary sarcoidosis and in pig-serum-stimulated rats 
(Toda et al., 2009; Tong et al., 2003). Considering these variable findings we trialled 
PXF in our infection assay and examined its effect on IL-6 production. RAW264.7 
macrophages were exposed to RRV T48 at an MOI of 1 with or without different 
concentrations of PXF and supernatant samples were analysed by IL-6 ELISA at 
various time points p.i. (Figure 36).  Both 100 µM and 1000 µM PXF showed 
inhibition of IL-6 from 24 hr p.i. onwards, which was however not significant as 
compared to non-treatment.  
PXF had shown a strong inhibitory effect on TNFα secretion earlier (4.4.1.3) but had 
no significant influence on IL-6 secretion. Comparable results were reported  for 
endotoxin challenged PBMCs previously (Waage et al., 1990) and we were able to 





The inhibitory effect of RVT on IL-6 release from peritoneal mouse macrophages 
has been previously reported (Zhong et al., 1999) and was confirmed in LPS-
stimulated RAW264.7 macrophages later (Capiralla et al., 2012). To investigate a 
possible IL-6 inhibiting effect in RRV infection we exposed RAW264.7 macrophages 
to RRV T48 at an MOI of 1 in the presence or absence of 5 µM and 50 µM RVT and 
analysed the supernatant by IL-6 ELISA (Figure 37). A time- and dose-dependent 
inhibition was detected immediately and reached significant levels for both 
concentrations by 12 hr p.i. (p≤0.001). Non-treated samples infected with RRV 
showed IL-6 levels of 496 ± 27 pg/mL by 36 hr p.i., whereas co-treatment with 5 µM 
RVT reduced the concentration 1.7-fold to 279 ± 32 pg/mL. Samples treated with 50 











Figure 36: IL-6 release from RRV-infected RAW264.7 macrophages co-treated 
with PXF 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 in the presence 
or absence of pentoxifylline (PXF) (100 and 1000 µM). Supernatant samples were 
taken at various time points and examined for IL-6 by ELISA. Data shown above is 
expressed in mean values ± SEM (n=3).  No significant inhibition was detectable for 












Figure 37: Effect of RVT on IL-6 release from RRV-infected RAW264.7 
macrophages 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 with or without 
resveratrol (RVT) (5 and 50 µM). Supernatant samples taken at various time points 
p.i. were analysed by IL-6 ELISA. Data shown is expressed in mean values ± SEM 





4.4.3 Macrolides increase in the secretion of the anti-inflammatory cytokine 
IL-10 in RAW264.7 macrophages 
The therapeutic potential of macrolides as anti-inflammatories has previously been 
reviewed and the potential of some macrolides to increase levels of Interleukin 10 
(IL-10) has been highlighted (Labro, 1998). These effects might be beneficial in the 
treatment of rheumatic diseases (Keystone et al., 1998), however are possibly not 
beneficial in RRV infection, as increased IL-10 levels are thought to result in 
reduced anti-viral responses (Rulli et al., 2005). As shown in earlier experiments 
(4.3.13), IL-10 is up-regulated in RRV infection and considering the potential of 
macrolide antibiotics to interfere with cytokine expression, we investigated the 
influence of macrolides on RRV-infected macrophages. RAW264.7 macrophages 
were infected with RRV T48 at an MOI of 1 and concurrently treated with 100 µM of 
ERY, CLA or RXM. Supernatant samples were taken at appropriate times and IL-10 
levels determined by ELISA. All macrolide antibiotics tested resulted in elevated IL-
10 levels by 4 hr p.i. compared to non-treated RRV-infected macrophages (Figure 
38), however this increase was not significant for ERY. CLA treatment showed a 
significant 3.2-fold increase in IL-10 to 147 ± 22 pg/mL at 4 hr p.i. compared to 46 ± 
15 pg/mL for non-treated samples (p≤0.01). This effect was even greater for RXM 
with IL-10 concentrations of 239 ± 42 pg/mL, which equates to a 5.2-fold increase 
(p≤0.001). At 12 hr p.i. and after there was no significant difference between RRV-
infected non-treatment samples and ERY or CLA treated samples. The up-
regulation of IL-10 secretion was significant for RXM at 4, 12 and 24 hr p.i., but 
dropped below significance levels at 36 hr p.i. For better comparison, IL-10 
concentrations of the supernatant at 24 hr p.i. are shown in Table 10. 
 
Table 10: Macrolide antibiotics alter IL-10 release in RAW264.7 macrophages 
IL-10 levels were measured at 24 hr p.i. by ELISA. Data is expressed as mean value 
± SEM (n=3 independent experiments).  
Macrolide antibiotic IL-10 levels (pg/mL) x-fold increase 
no macrolide 153 ± 25 - 
Erythromycin 126 ± 12 0.8 
Clarithromycin 167 ± 22 1.1 


































Figure 38: The effect of macrolide antibiotics on IL-10 secretion in RRV-
infected RAW264.7 macrophages  
 RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 in the 
presence of 100 µM erythromycin, clarithromycin or roxithromycin. Non-treated 
macrophages were infected with RRV in parallel and used as positive control. 
Supernatant samples were taken at various time points and examined for IL-10 by 
ELISA. Data shown above is expressed in mean values ± SEM (n=3). *(p≤0.05), 
***(p≤0.001) as determined by two-way ANOVA for macrolide treatments compared 





4.4.4 Inhibition of MIF in RRV-infected RAW264.7 macrophages 
A previous study (Herrero et al., 2011) has highlighted the important role of MIF in 
RRV infection and it was reported that treatment with the established MIF-inhibitor 
ISO-1 significantly reduced symptom manifestation in RRV-infected mice. More 
recently research has focused on MIF as a therapeutic target for inflammatory 
diseases and investigated several synthetic MIF inhibitors for possible therapeutic 
use (L. Xu et al., 2013). Our previous experiments with TNFα inhibitors have shown 
a strong effect on cytokine release from macrophages for several tested 
compounds. To assess if these agents also modulate MIF secretion in infected 
macrophages we exposed RAW264.7 cells to RRV T48 (MOI of 1) in the presence 
of various compounds and measured MIF concentration in the supernatant collected 
at different time points post-infection. 
4.4.4.1 Macrolide antibiotics 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 in the presence 
of 100 µM ERY, CLA or RXM and supernatant samples were collected at 
appropriate time points p.i. and analysed by MIF ELISA. None of the macrolide 
antibiotics tested showed significant reduction of MIF secretion at 12 or 24 hr p.i. 
(Figure 39). ERY treated samples showed a reduction of MIF concentration, which 
was however not significant (as determined by two-way ANOVA). 
4.4.4.2 Ethyl pyruvate, pentoxifylline and resveratrol do not significantly 
reduce MIF secretion in RRV-infected macrophages 
Similarly to previously tested macrolide antibiotics we analysed supernatants of 
RAW264.7 macrophages exposed to RRV and concurrent treatment with 1000 µM 
EP, 1000 µM PXF or 50 µM RVT. EP-treatment resulted in lower concentrations of 
MIF in the supernatant at 12 hr and 24 hr p.i., whereas RVT appeared to generally 
increase MIF secretion from macrophages (Figure 40). PXF had no influence on 
MIF concentration in the supernatant of treated cells. None of the effects was 

































Figure 39: MIF concentration in the supernatant of RRV-infected macrophages 
with concurrent exposure to macrolide antibiotics 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 with or without 
100 µM erythromycin (ERY), clarithromycin (CLA) or roxithromycin (RXM). Samples 
collected at 0, 12 and 24 hr p.i. were analysed by MIF ELISA. Infection with HI-RRV 
was used as negative control (Control), non-treated RRV infection served as 
positive control (RRV). Data is expressed as mean value +- SEM (n=3). Statistical 
































Figure 40: MIF concentration in the supernatant of RRV-infected macrophages 
treated with ethyl pyruvate, pentoxifylline or resveratrol 
RAW264.7 macrophages were exposed to RRV T 48 at an MOI of 1 and 
concurrently treated with or without 1000 µM ethyl pyruvate (EP), pentoxifylline 
(PXF) or resveratrol (RVT). Samples collected at varying time points post-infection 
were analysed by MIF ELISA. HI-RRV was used as negative control in mock 
infection with (Control), non-treated RRV infection served as positive control (RRV). 
Data is expressed as mean value +- SEM (n=3). Statistical analysis was performed 





4.4.5 Inhibition of IL-18 in RRV-infected macrophages 
The important role of IL-18 in CHIKV infection has been highlighted previously 
(Chirathaworn et al., 2010) and inhibition of IL-18 was suggested as a possible 
target for the treatment of CHIKV disease. To our knowledge, no compounds have 
however so far been investigated for their influence on IL-18 production in 
alphavirus infections. In order to determine if any of the previously trialled 
compounds has a regulatory effect on IL-18 synthesis in macrophages we analysed 
extracted mRNA by quantitative real time PCR using primers specific for IL-18. 
Tested samples included treatment with 100 µM ERY, 100 µM CLA, 100 µM RXM, 
1000 µM EP, 1000 µM PXF or 50 µM RVT. The normalised values were compared 
to the corresponding normalised control values and graphed as shown in Figure 41. 
From the tested compounds, EP and RVT exhibited a noticeable inhibitory effect on 
IL-18 mRNA transcription at 12 hr p.i. (Figure 41 D and F). At 24 hr p.i. significant 
inhibition as compared to non-treated infection was present in samples treated with 
ERY (p≤0.01), EP (p≤0.01) and RVT (p≤0.05). RXM and PXF showed some 
exhibitory effect, however not at a significant level. CLA appeared to have very little 
or no effect on IL-18 mRNA expression. 
4.4.6 Inhibition of HMGB1 mRNA expression in RRV-infected RAW264.7 
macrophages 
Similar to previous experiments we investigated a possible inhibitory effect of 
various compounds on HMGB1 mRNA transcription in RRV infection. Again, mRNA 
extracted from RAW264.7 macrophages exposed to RRV T48 at an MOI of 1 was 
treated with either 100 µM ERY, 100 µM CLA, 100 µM RXM, 1000 µM EP, 1000 µM 
PXF or 50 µM RVT. Quantitative real time PCR analysis was performed with 
HMGB1-specific primers and the derived values were normalised with the 
corresponding G3PDH values as previously. Normalised values were graphed as a 
ratio to their corresponding negative control values. Only EP had a noticeable effect 
with HMGB1 mRNA expression similar to controls by 24 hr p.i. (Figure 42 D). None 
of the other compound showed significantly differing HMGB1 mRNA expression at 

























































































































































Figure 41: IL-18 mRNA expression in RRV-infected RAW264.7 with inhibitors 
RAW264.7 macrophages infected with RRV T48 at an MOI of 1 were treated with 
100 µM ERY, 100 µM CLA, 100 µM RXM, 1000 µM EP, 1000 µM PXF or 50 µM 
RVT. Non-treated infection served as positive control (RRV) whereas infection with 
HI-RRV was used as negative control (control). mRNA was analysed by quantitative 
RT-PCR and normalised values were graphed against their respective controls. 
Values are expressed as mean + %CV (n=3). *(p≤0.005). **(p≤0.01) as determined 
by two-way ANOVA.  
A           B 
C           D 























































































































































Figure 42: HMGB1 mRNA expression in RRV-infected RAW264.7 treated with 
inhibitors 
RAW264.7 macrophages were exposed to RRV T48 at an MOI of 1 with or without 
the presence of 100 µM ERY, 100 µM CLA, 100 µM RXM, 1000 µM EP, 1000 µM 
PXF or 50 µM RVT. Non-treated infection was used as positive control (RRV), HI-
RRV served as negative control (control). RNA was quantified by real time RT-PCR 
and normalised values were plotted against respective controls. Values are 
expressed as mean + %CV (n=3). Statistical analysis as per two-way ANOVA. 
A           B 
C           D 




4.5 Phagocytic activity of RAW cells after RRV infection 
Early studies have shown a link between phagocytic activity of macrophages and 
the severity of symptoms in rheumatoid arthritis (Burmester et al., 1997) and it was 
later reported that persistent RRV infection causes an increase in phagocytic activity 
in murine macrophages (Way et al., 2002). No studies have been conducted on 
acute RRV infection in macrophages and the influence on phagocytosis. To 
investigate if phagocytic activity is altered in acute RRV infection, RAW264.7 
macrophages were exposed to RRV for varying times prior to a phagocytosis assay. 
Heat inactivated and FITC labelled bacteria were utilised to visualise and quantitate 
phagocytosis. Both Gram positive (Staphylococcus aureus) as well as gram 
negative bacteria (Escherichia coli) were used in the assay. 
4.5.1 Analysis of phagocytic activity in RRV-infected RAW264.7 by 
fluorescence microscopy 
To investigate the influence of acute RRV infection on macrophages we exposed 
RAW264.7 cells to RRV T48 (MOI of 1) for 24 and 48 hr prior to the phagocytosis 
assay. HI-RRV was used in a mock infection 48 hr prior to the assay and used as 
control. FITC-staining of the bacteria was confirmed by fluorescence microscopy 
prior to addition (Figure 43). To ensure that phagocytosis was evaluated 
independently, both a Gram positive (S.aureus) as well as a gram negative (E.coli) 
bacterial strain was used in separate experiments. As pictured in Figure 44 (A and 
C), no difference in phagocytosis was visible for any of the samples at 1 hr post 
exposure to labelled E.coli. At 4 hr post exposure the RAW264.7 cells infected with 
RRV 24 hr prior to the assay consistently showed increased phagocytic activity 
(Figure 44 B and D). The macrophages had taken up more labelled bacteria 
compared to non-treated samples and it also appeared that more cells were 
showing phagocytosis. The effect was even more pronounced in RAW264.7 
macrophages that were infected with RRV 48 hr prior to the assay (Figure 44 E and 
F). A similar result was obtained with S. aureus, with an increased phagocytic 
activity already apparent at 1 hr post exposure to labelled bacteria for RAW264.7 
cells infected with RRV (Figure 45 A, C and E). Again, at 4 hr post exposure an 
increase in phagocytic activity was observed for RRV-infected macrophages 
compared to mock infected controls. There was no clear visual difference between 














     FITC labelled S.aureus 
 
Figure 43: FITC labelled E.coli and S.aureus  
Heat inactivated E.coli or S.aureus were incubated with FITC as described in 
Methods. Prior to the phagocytosis assay fluorescent labelling was confirmed by 
microscopy under UV light. Above are representative pictures of FITC labelled E.coli 
























Figure 44: Phagocytosis of FITC-labelled E.coli by RAW264.7 macrophages 
after RRV infection 
RAW264.7 macrophages were exposed to RRV T48 for 24 or 48 hr prior to addition 
of FITC labelled E.coli. HI-RRV was added to control wells 48 hr prior to the 
phagocytosis assay. Cells were fixed and stained with PI as described in Methods. 
Photographs were taken under fluorescence after 1 hr (A, C and E) and 4 hr (B, D 
and F) of exposure to FITC labelled bacteria. Shown are representative 

























Figure 45: Phagocytosis of FITC-labelled S.aureus by RAW264.7 cells after 
RRV infection 
RAW264.7 macrophages were exposed to RRV T48 for 24 or 48 hr prior to addition 
of FITC labelled S.aureus. HI-RRV was added to control wells 48 hr prior to the 
phagocytosis assay as control. Cells were fixed and stained with PI as described in 
Methods. Photographs were taken under fluorescence after 1 hr (A, C and E) and 4 
hr (B, D and F) of exposure to FITC labelled bacteria. Above are representative 




4.5.2 Flow cytometric analysis of phagocytic activity in RRV-infected 
RAW264.7 macrophages 
Due to the limitations of fluorescence microscopy in regards to quantitation, the 
phagocytosis experiments were repeated and the RAW264.7 macrophages were 
examined in an Attune flow cytometer using a 488 nm excitation laser to quantify 
phagocytic activity. To avoid adherence of the macrophages to tissue culture 
vessels, all cells were grown in teflon culture vessels and further processed as 
outlined in Methods. Both E.coli and S.aureus were used to confirm the previously 
observed increase in phagocytic activity. 
In brief, similar to the previous assay, RAW264.7 macrophages were exposed to 
RRV T48 at an MOI of 1 for 24 or 48 hr prior to the start of the assay. Mock infection 
with heat–inactivated RRV was performed on additional samples 48 hr prior to the 
experiment and used as negative control. Macrophages were exposed to FITC-
labelled E.coli or S.aureus for 0, 1 or 4 hrs and washed, fixed and stained before 
being analysed on an Attune flow cytometer.  
4.5.2.1 Compensation 
Initial experiments determined emission levels at the appropriate wave lengths for 
both flouorophores in the assay. Propidium iodide (PI) was used to stain the nuclei 
of the macrophages and its emission was measured through a 574/26 nm filter, 
whereas bacteria was labelled with fluorescein isothiocyanate (FITC) and detected 
with a 530/30 nm emission filter. To ensure that any ‘spillover’ fluorescence could be 
compensated, initial samples were run for FITC positive samples without PI stain 
(macrophages at 4 hr post exposure to FITC labelled E.coli or S.aureus without 
further stain) as well as PI labelled macrophages that were not exposed to labelled 
bacteria (Figure 46 A and C). Since FITC only samples showed spillover signals at 
higher emission and vice versa, an automated compensation was run on the Flojo 
analysis software to accommodate for this shift in emission (Figure 46 B and D). 
Automatic compensation was always manually confirmed for FITC- and PI-only 
samples and adjusted if required. Compensation was performed for each separate 
experiment and further samples were analysed under compensated settings. 
4.5.2.2 Gating strategy 
To select only RAW264.7 macrophages but exclude debris or unbound bacteria, an 
initial gate was set for the desired population (‘cells’) and applied to all samples 
(Figure 47 A).  Gate settings were confirmed for each specimen population 




graphed in a histogram of forward scatter (height) (FSC-H) over forward scatter 
(area) (FSC-A) as shown in Figure 47 B. Single cells show a linear relationship 
between FSC-H and FSC-A and were separately gated to avoid detection of 
doublets or larger cell clumps, which appeared mostly at the top edge of the 
histogram. The unstained ‘single cells’ sample was further graphed as PI- and FITC-
detection plot (Figure 47 C) and separate gates were drawn for PI-only, FITC-only 
and PI+FITC containing populations and again applied to all samples. 
4.5.2.3 RRV infection increases the number of macrophages showing 
phagocytic activity  
Analysis with Flowjo software showed a time dependent rise in the numbers of 
FITC+PI positive cells out of all detected cells, which indicates an increased number 
of cells with phagocytic activity. This was observed for both E.coli and S.aureus and 
in all samples, however RAW264.7 cells that had been exposed to RRV prior to the 
assay generally showed higher percentages of cell numbers with phagocytic activity 
(see Figure 48). This increase was significant for S.aureus samples at 1 hr post 
exposure to bacteria for macrophages infected with RRV for 24 hrs (p≤0.01) and 48 
hrs (p≤0.05) prior to the assay (Figure 48B). There was no significant difference in 
cell numbers between 24 hr and 48 hr pre-exposure to RRV. 
4.5.2.4 RRV infection increases the mean phagocytic activity in RAW264.7 
macrophages 
For further analysis, the mean fluorescent intensity (MFI) for FITC+PI positive cell 
populations was compared in order to determine whether an increase in phagocytic 
activity was detectable. As expected, the MFI increased in a time dependent manner 
in all samples, meaning each detected cell had adsorbed an increasing number of 
bacteria over time (Figure 49). Samples exposed to RRV prior to the experiment 
showed generally higher MFI for both bacteria strains at 1 hr post exposure and 
reached significantly higher levels at 4 hr post exposure. Again, no significant 
difference was detectable between the 24 hr and 48 hr RRV samples, although it 
appeared that samples with 48 hr pre-infection showed slightly increased phagocytic 
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Figure 46: Compensation strategy for FACS analysis
Samples containing macrophages with FITC
only) and macrophages stained with PI only (PI
compensation of ‘spillover’ emission.  Shown above are representative emission 
plots of non-compensa
compensation was performed for each experiment with FloJo X software and 
manually adjusted as required
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Figure 47: Gating strategy for flowcytometry analysis
A side scatter (SSC) over forward scatter (FSC) plot of unstained macrophages was 
graphed and cell population (‘cells’) was gated to exclude debris as shown in (A). 
This population was graphed in a forward scatter (FSC) height over area plot and 
gated for a ‘single cells’ subpopulation
FITC-detection and gates were drawn for PI
(C). Shown above are representative plots as graphed with Flojo X software.
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Figure 48: Percentage of cells showing phagocytic activity in RAW264.7 
macrophages with and without pre-exposure to RRV T48 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 for 24 or 48 hr 
prior to the phagocytosis assay and exposed to FITC-labelled E.coli (A) or S.aureus 
(B) for varying time points. Macrophages were washed, fixed and stained as 
outlined in Methods and analysed by flow cytometry. Graphed above is the 
percentage of the FITC+PI-positive population out of all PI-positive cells. Data is 
expressed in mean values ± SEM (n=3 independent experiments). *(p≤0.05), 
**(p≤0.001) as determined by two-way ANOVA. Note the non-linear scale for time 










































Figure 49: Phagocytic activity of RAW264.7 macrophages with or without pre-
exposure to RRV 
RAW264.7 macrophages were infected with RRV T48 at an MOI of 1 for 24 or 48 hr 
prior to the phagocytosis assay and exposed to FITC-labelled E.coli (A) or S.aureus 
(B) for varying time points. Macrophages were washed, fixed and stained as 
outlined in Methods and analysed by flow cytometry. The graphs above show the 
mean fluorescent intensity (MFI) of the FITC+PI positive population, i.e. only cells 
that have shown some degree of phagocytosis. MFI is expressed in arbitrary values 
as mean ± SEM (n=3 independent experiments). *(p≤0.05), **(p≤0.001) as 










Figure 50: Phagocytic activity of RAW264.7 macrophages with our without 
pre-exposure to RRV  
Data derived from the phagocytosis experiments with S.aureus was graphed as a 
histogram over FITC detection to visualise the change in phagocytic activity with 
pre-exposure to RRV T48 at an MOI of 1. Above diagram shows a representative 
overlay of samples exposed to S.aureus at 4 hr post exposure to the bacteria. 
Specimen RAW – no RRV – 4h.fcs = RAW264.7 macrophages without exposure to 
RRV T48, Specimen RAW – RRV24h – 4h.fcs = RAW264.7 macrophages with 24 hr 
pre-exposure to RRV T48, Specimen RAW – RRV48h – 4h.fcs = RAW264.7 





4.6 Discussion of RAW264.7 results 
A recent study (Taylor et al., 2013) has once more confirmed the important role of 
macrophages in RRVD progression and the release of macrophage-derived 
mediators is now considered to be a major contributing factor to the development of 
inflammatory joint conditions during infection (Assuncao-Miranda et al., 2013). With 
our experiments, we could confirm and further investigate the increased expression 
and secretion of several of those cytokines from macrophages during RRV infection 
in vitro, including TNFα (Lidbury et al., 2008) and MIF (Herrero et al., 2011). 
Although elevated IL-6 levels have been reported in CHIKV infections (Ng et al., 
2009), its role in RRVD has so far not been investigated. We could show that the 
release of IL-6 but not the expression of IL-6 mRNA is increased in RAW264.7 
macrophages upon RRV infection in vitro. It has previously been suggested that 
altered IL-6 mRNA degradation may occur during viral infection of airway epithelial 
cells (Lutter et al., 2000) and it remains to be determined whether RRV interferes 
with the decay of IL-6 mRNA during infection. Furthermore, increased expression of 
IL-18 mRNA has previously been recognized for CHIKV infections (Chirathaworn et 
al., 2010) and we established a comparable stimulation pattern for the expression of 
IL-18 mRNA in RRV infections. We were able to show an increase of IL-33 and IL-
10 mRNA expression during infection and established the non-involvement of PGE2 
in macrophage regulated processes during RRV infection. 
The role of HMGB1 in RRV-infected macrophages remains unclear and further 
investigations are necessary. Release of HMGB1 was increased in infected 
RAW264.7 macrophages but did not reach significant levels. Considering the 
function of HMGB1 as a ‘late response mediator’ (Harris et al., 2012) more long term 
experiments are necessary to investigate whether delayed HMGB1 release is 
significantly altered in RRV infection. Apart from its function as an inflammatory 
cytokine HMGB1 may also be involved in the elimination of viral particles, as a 
recent study (W. Wang et al., 2014) suggested. Knock-out mice with HMGB1-
depleted dendritic cells showed increased and more effective clearance of vaccinia 
virus. Due to the cost of HMGB1 ELISA kits however we decided to focus on other 
cytokines. 
Contrary to previous reports we found only low levels of NO in the supernatant of 
RRV infected cells despite transcription of iNOS  mRNA  (K. Burrack et al., 2014). 
Production of iNOS upon infection is likely an antiviral response and it has been 




effect on iNOS transcription in LPS-stimulated macrophages during antibody 
dependent enhanced infection. We could show that RRV was able to inhibit the NO 
response from LPS challenged macrophages independent of the infection pathway. 
Exposure of RAW264.7 cells to RRV for 48 hr prior to stimulation resulted in a 
significant reduction of NO release, which indicates that RRV interferes with the 
cellular antiviral response. It remains to be clarified how RRV induces iNOS 
expression without increasing nitrite levels. Stimulation with LPS gave positive NO 
results and served as assay control.  
With this more comprehensive understanding of cytokine regulation during RRV 
infection we investigated possible inhibitors to target these inflammatory mediators. 
The anti-inflammatory properties of macrolides have been reported numerous times 
and more recent data attributes this effect to the inhibition of cytokines (Zarogoulidis 
et al., 2012). We could show that erythromycin strongly inhibits TNFα and IL-6 but 
not IL-10 release from RRV-infected macrophages. A reduction of IL-18 and MIF 
mRNA transcription was detected, although MIF inhibition did not reach significant 
levels. Clarithromycin similarly reduced TNFα and IL-6 secretion and slightly 
increased the concentration of IL-10 in the supernatant of infected RAW264.7 
macrophages. No significant effect was detected for IL-18 or MIF mRNA expression. 
Roxithromycin exhibited a slight inhibitory effect on TNFα but did not reduce 
secretion of IL-6 or mRNA expression of MIF. A significant increase in IL-10 was 
however detected for RXM, while expression of IL-18 mRNA was reduced. 
We could show for the first time that macrolide treatment on RRV-infected 
macrophages has varying inhibitory effects on the regulation of pro-inflammatory 
cytokines, such as TNFα, MIF, IL-6 and IL-18 as well as the anti-inflammatory 
cytokine IL-10. Interleukin 10 is an important mediator in the host’s antiviral 
response and also possesses anti-inflammatory properties, however it has been 
suggested that a decrease in IL-10 secretion might be desirable in RRV infection 
(Rulli et al., 2005). It remains to be determined whether this decrease is in fact 
beneficial in vivo or if the anti-inflammatory effect of IL-10 outweighs it. From the 
tested macrolides RXM appears to induce IL-10 secretion in RRV infected 
macrophages. Future research projects are needed to determine if RXM-induced 
increase of IL-10 interferes with the replication cycle of RRV in macrophages or 
other cell types such as Vero or C2C12 cells.  
ERY has shown very promising results in these in vitro experiments and future 




these experiments confirm the anti-inflammatory effect of ERY it may be considered 
as a treatment option in an established mouse model of RRV (Taylor et al., 2014). 
The concentration levels of ERY in the inhibitor experiments were similar to the peak 
plasma concentration levels in standard antibiotic therapy with 500 mg ERY four 
times daily (Krasniqi et al., 2012). 
Ethyl pyruvate has previously been recognised as an anti-inflammatory agent (Fink, 
2007) and our experiments indicated an anti-inflammatory effect of EP on RRV-
infected macrophages. TNFα secretion into the supernatant was reduced in a dose-
independent manner, consistent with previous findings (Nativel et al., 2013) that 
reported of a dose-independent reduction of IL-6 secretion in an LPS-challenged 
human liposarcoma cell line when treated with similar concentrations of EP. Further 
investigations are necessary to expose the molecular processes and pathways 
involved in this inhibitory effect. We could also show that EP significantly reduces IL-
6 secretion and expression of both MIF and IL-18 mRNA in RRV infected RAW264.7 
macrophages. These results and the well documented inhibitory effect on HMGB1 
secretion indicate a possible role of EP in the treatment of RRV infections. Future 
research projects need to establish if the aforementioned cytokines are inhibited in 
human macrophages and whether EP should be tested as treatment option in a 
mouse model. 
Anti-TNFα therapy with pentoxifylline has previously been reported to reduce 
inflammatory symptoms in a mouse model of antigen-induced arthritis (Queiroz-
Junior et al., 2013). We could show that PXF similarly reduces TNFα release from 
macrophages in RRV infection but has no or little effect on IL-6 secretion. No 
significant effect on MIF or IL-18 mRNA was detected. Similarly to the previously 
tested inhibitors, resveratrol reduced levels of TNFα and IL-6 in the supernatant of 
infected RAW264.7 macrophages, and did inhibit IL-18 mRNA but not MIF mRNA 
expression. A rat model recently confirmed the anti-inflammatory effect of RVT in 
arthritic conditions (Riveiro-Naveira et al., 2014).  
An increase in the phagocytic activity of macrophages persistently infected with 
RRV was previously reported (Way et al., 2002). Our experiments could show that 
this increase in phagocytic activity is also occurring in acutely infected RAW264.7 
macrophages and it appears to be independent of the phagocytic stimuli. A Gram 
positive, as well as a gram negative bacterial strain were used in the assay with both 
situations confirming increased phagocytic activity of RRV infected macrophages. 




The increased phagocytic activity indicates activation of the macrophages upon 
infection. 
Other assay setups that were considered and may be included in future studies are 
plate based fluorescence assays. This would reduce the steps involved in the 
sample preparation, however likely give less sensitive results as compared to flow 




5. Results III: C2C12 cells after RRV infection  
5.1 Introduction 
Early investigations into the pathogenesis of Ross River Virus infection in mice have 
revealed rapid viral growth in muscle tissue, with viral titres peaking at 4 d post-
infection (p.i.), as well as severe muscle fibre damage from 7 d p.i. onwards  
(Murphy et al., 1973). Further studies (Eaton & Hapel, 1976) however gave contrary 
results and found that RRV could persistently infect primary mouse muscle cells in a 
non-cytolytic way. Lidbury et al. (Lidbury et al., 2000) concluded from these two 
opposing findings that the cytopathic effect RRV exerts on mouse muscles in vivo 
must be caused by host response mechanisms which had not been recognized yet. 
In their studies a strong infiltration of macrophages into infected mouse muscle 
tissue was identified and it was proposed that macrophages likely are the major 
contributor to the pathological symptoms observed in RRV infection. These findings 
were summarised in a review (Rulli et al., 2005), and it was suggested that 
specifically macrophage derived chemokines may be responsible for the observed 
muscle pathology. Later investigations (Morrison et al., 2007) confirmed the 
infiltration of inflammatory cells and found the involvement of complement as a host-
specific response to contribute to tissue destruction in vivo as compared to in vitro 
infections. Most research in the pathology of RRV disease focused on macrophages 
and macrophage-derived cytokines since (Lidbury et al., 2008). However, with 
reports of myocytes secreting an array of pro-inflammatory cytokines (Pedersen et 
al., 2007) we considered re-investigating the possible role of muscle cells in RRV 
infection. 
5.2 RRV propagates in a cytolytic replication cycle in C2C12 myoblast 
cells 
To investigate the effect of RRV on muscle cells we decided to use C2C12 myoblast 
cells, as they have previously been shown to be susceptible to infection in studies 
with alphavirus vectors (Wahlfors et al., 2000). Initial experiments were conducted to 
establish if RRV does infect the cell line under our conditions. C2C12 cells were 
exposed to RRV T48 at an MOI of 1 and observed for cytopathic effects under a 
light microscope. Morphological changes were visible in infected cells from 12 hr p.i. 




p.i. most cells had lysed and detached from the tissue culture plate with only very 
few cells appearing viable.  
RNA extracted at various time points post-infection was analysed by conventional 
PCR using primers specific for the RRV-E2 RNA sequence. As shown in Figure 52, 
virus RNA was detectable from 4 hr p.i. onwards showing a very faint band which 
increased in intensity by 12 and 24 hr post-infection. This indicates that viral RNA is 
synthesized in C2C12 cells upon infection with RRV. Supernatant samples taken at 
the same time points were examined by LDH assay as described in Methods to 
determine cell viability (Figure 53). As expected, reduced viability, expressed in 
increased LDH levels, was observed from 12 hr p.i. (p≤0.01) onwards and most 
pronounced by 36 hr p.i. (p≤0.001) compared to non-infected cells. Exposure to LPS 
did not affect cell viability. These results were confirmed with an MTT assay as 
shown in Figure 54. C2C12 cells were infected 36, 24, 12 and 0 hr before 
performing a MTT assay as outlined in Methods. Cell viability was calculated as 
relative viability to non-infected cells which was given the arbitrary value of 100% 
viability. Cells that had been infected 0 hr and 12 hr before the MTT assay did not 
show any significant change in viability (Figure 54). C2C12 cells that had been 
exposed to RRV 24 hr prior to the assay showed significant reduction in viability to 
79.6 ± 9.1 % (p≤0.001). Exposure to RRV for 36 hr reduced relative cell viability to 
26.0 ± 10.8 % (p≤0.001). This data confirmed the viability results obtained by LDH 
assay previously. 
It appeared that cell death was due to a cytolytic replication cycle of the virus in 
C2C12 myoblasts. To investigate if this was true, we exposed C2C12 cells to RRV 
T48 in culture medium adjusted to a TCID50 of 1x104 and took supernatant samples 
daily to determine viral titres. Some wells contained no cells but culture medium and 
virus only and were used as control samples. As expected, viral titres in controls 
decreased over time and by day 4 no active virus was detectable by standard 
TCID50 assay (Figure 55). RRV appears to slowly degrade over time at 37˚C. 
Interestingly, viral titres significantly increased within 1 d p.i. (p≤0.05) and reached 
peak levels at 2 d p.i. (p≤0.001) in samples that contained C2C12 myoblasts. Viral 
titres thereafter slowly decreased but still showed significantly higher levels 
compared to controls (p≤0.001). Observations under the light microscope confirmed 
increasing cell damage and lysis of C2C12 myoblasts over time and by 2 d p.i. only 





























Figure 51: C2C12 cells exposed to RRV T48  
C2C12 cells were exposed to RRV T48 or HI-RRV at an MOI of 1 for various times 
and then stained with 0.1 % (w/v) crystal violet to visualise viable cells. 
Representative photographs taken under 40x magnification are shown above for 
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Figure 52: Expression of RRV-E2 mRNA in C2C12 cells post-infection 
C2C12 myoblasts were exposed to RRV T48 at an MOI of 1 and RNA was extracted 
at various time points post-infection. After transcription in to first strand cDNA the 
samples were analysed by RT-PCR with primers specific for the RRV-E2 sequence. 
Shown above are representative photograph of the agarose gels under UV light 

























Figure 53: Cell viability of C2C12 myoblasts post RRV exposure 
Supernatant of C2C12 myoblasts exposed to RRV was examined by LDH assay for 
cell viability. As outlined in Methods, increased LDH levels indicate cell lysis and 
therefore correlate to cell death. C2C12 cells were exposed to HI-RRV and used as 
control. LPS was tested as a stimulant for further experiments. All data is expressed 
in mean values ± SEM (n=6). **(p≤0.01), ***(p≤0.001) as determined by two-way 











Figure 54: MTT assay on C2C12 after RRV infection for varying time periods 
C2C12 cells were pre-treated with media containing RRV T48 at an MOI of 2 for 0, 
12, 24 or 36 hr and a MTT assay was performed to determine cell viability. Non-
infected cells were used as controls and given the arbitrary value of 100%. Viability 
of the samples was calculated as relative viability compared to controls. Data shown 
above are mean values ± SEM (n=3). ***(p≤0.001) as determined by one-way 













Figure 55: Virus titres after infection of C2C12 cells with RRV T48 
C2C12 cells were exposed to RRV T48 (in culture medium with virus at a TCID50 of 
1x104) and supernatant samples taken daily were examined for viral titres by 
standard TCID50 assay. RRV T48 at the same concentration was used in control 
wells without any cells and kept under the same conditions at 37˚C and 5% (v/v) 
CO2 in a humidified incubator.  Data shown is expressed in log TCID50 as mean 
values ± SEM (n=3 independent infection experiments). *(p≤0.05), ***(p≤0.001) # 





5.3 Cytokine production  
As reviewed earlier, muscle cells have previously been shown to release an array of 
cytokines (often labelled ‘myokines’) that can contribute to inflammatory processes. 
To investigate if the release of these myokines could potentially play a role in RRV 
infection, we exposed C2C12 myoblasts to RRV T48 at an MOI of 1 and examined 
supernatant samples for cytokine levels. Considering our findings of a cytolytic 
replication cycle in C2C12 cells we investigated cytokine release for up to 24 hr p.i. 
only, since cell viability seemed to significantly decrease thereafter and mediators 
might be released due to cell lysis rather than active secretion as cytokines. 
5.3.1 RRV induces TNFα secretion in infected C2C12 myoblasts 
Supernatant samples of RRV-infected C2C12 cells were taken at appropriate times 
p.i. and assayed for TNFα concentrations by ELISA. C2C12 cells mock infected with 
heat inactivated RRV (HI-RRV) were used as control. LPS exposure does stimulate 
expression of both TNFα and IL-6 in C2C12 cells and was therefore included as 
positive control (Frost et al., 2002). As expected, TNFα concentrations for LPS 
samples increased in a time dependent manner and reached 317 ± 82 pg/mL by 24 
hr post stimulation (p≤0.001) (Figure 56). Supernatant of RRV-infected C2C12 cells 
did show a time dependent increase in TNFα concentrations detectable from 4 hr 
p.i. onwards to 340 ± 89 pg/mL by 24 hr p.i. (p≤0.001). 
5.3.2 RRV induces expression of TNFα mRNA in C2C12 myoblasts 
To examine expression of cytokine mRNA in RRV-infected C2C12 myoblasts, RNA 
was extracted at varying times p.i. and PCR analysis was performed using primers 
specific for TNFα. Gel electrophoresis of the PCR amplicons confirmed that 
expression of TNFα mRNA is induced by RRV, increasing in a time-dependent 
manner (Figure 57). LPS challenged C2C12 cells were used as positive control and 
showed a similar pattern of mRNA expression, with induction of TNFα mRNA 
detectable by 4 hr p.i. increasing in a time-dependent manner. Very weak bands 












Figure 56: TNFα secretion of C2C12 exposed to RRV or LPS 
C2C12 myoblasts were treated with RRV T48 at an MOI of 1 or LPS (1µg/mL) and 
supernatant samples taken at varying time points were analysed by TNFα ELISA. 
HI-RRV was used as negative control sample (Control). All data is expressed in 
mean values ± SEM (n=4). **(p≤0.01), ***(p≤0.001) as determined by two way 























Figure 57: TNFα mRNA in RRV and LPS treated C2C12 myoblast cells
C2C12 myocytes were exposed to RRV T48 
RRV for varying amounts of time and extracted RNA was analysed
using primers specific for TNF
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5.3.3 RRV does not induce NO-secretion in infected C2C12 myoblasts 
To examine if RRV induces the release of nitric oxide (NO), we assayed the 
supernatant of infected C2C12 cells with Griess reagent for nitrite, a stable oxidation 
product of nitric oxide. Our experimental setup mostly used LPS as a positive control 
to stimulate cytokines in C2C12 cells, however it has previously been shown that 
LPS alone does not induce the secretion of NO in C2C12 myoblasts (G. Williams et 
al., 1994). Supernatant derived from LPS stimulated RAW264.7 macrophages were 
included as assay control. As Figure 58 shows, neither LPS, nor RRV altered the 
concentration of nitrite in the supernatant of exposed C2C12 myoblasts. 24 hr pre-
exposure to RRV T48 at an MOI of 1 followed by LPS stimulation (1 µg/mL) was 
trialled as well but failed to induce NO by 24 hr post exposure. 
5.3.4 iNOS mRNA is induced in RRV-infected C2C12 myoblasts 
RNA was extracted at certain time points post stimulation from C2C12 cells exposed 
to RRV or LPS and screened for inducible nitric oxide synthase (iNOS) mRNA by 
RT-PCR. Despite the lack of significant NO release into the supernatant, iNOS 
mRNA is induced in C2C12 exposed to RRV (Figure 59). The PCR amplicons were 
visible by 4 hr p.i. and density increased in a time-dependent manner. LPS 
challenged samples showed similar patterns. As expected, no iNOS mRNA was 
detectable in control samples. 
As samples for various cytokine assays were often obtained from the same 
experiments, we did not have a positive control for this particular assay. NO 
stimulation assays however showed similar results in other cell lines with iNOS 
mRNA being increasingly expressed but no NO detectable in the supernatant of 
RRV-infected cells. Supernatant from LPS-challenged RAW264.7 macrophages 
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Figure 58: Nitrite concentration in supernatant of C2C12 exposed to RRV 
and/or LPS 
C2C12 myoblasts were exposed to RRV T48 at an MOI of 1, LPS (1 µg/mL) or HI-
RRV and supernatant samples were taken at varying time points and analysed for 
nitrite concentrations by Griess assay. Other samples were exposed to RRV T48 at 
an MOI of 1 for 24 hr prior to stimulation with 1 µg/mL LPS (24h RRV + LPS). All 
data is expressed in mean values ± SEM (n=6 for control, RRV and LPS, n=4 for 
24h RRV + LPS). Supernatant taken from RAW264.7 macrophages challenged with 
LPS (1ug/mL) for 24 hr was used as positive assay control ((+)control). Statistical 
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Figure 59: iNOS mRNA expression in C2C12 myoblasts exposed to RRV or 
LPS 
C2C12 myocytes were exposed to RRV T48 at an MOI of 1, LPS (1 µg/mL) or HI-
RRV at an MOI of 1 for varying amounts of time and extracted RNA was analysed 
by RT-PCR using primers specific for iNOS. The figure above shows representative 





5.3.5 RRV induces IL-6 secretion in infected C2C12 cells 
It has previously been reported that LPS and various cytokines stimulate the release 
of IL-6 from C2C12 myoblasts (Frost et al., 2003). To investigate if RRV also 
induces secretion of IL-6 we analysed the supernatant of infected C2C12 at various 
times p.i. by ELISA. Stimulation with LPS (1 µg/mL) was used in positive control 
samples. As Figure 60 shows, exposure to RRV sharply increased IL-6 levels in the 
supernatant by 4 hr p.i. to 316 ± 91 pg/mL and reached 341 ± 83 pg/mL by 24 hr p.i. 
(p≤0.001). LPS induced IL-6 release at a lower rate but reached similar levels by 24 
hr p.i., with concentrations of 356 ±70 pg/mL (p≤0.001). Mock infection with heat 
inactivated RRV did not significantly increase IL-6 concentration in the supernatant 
at any time. 
5.3.6 IL-6 mRNA expression is induced in C2C12 after exposure to LPS or 
RRV T48 
RNA was extracted at the same time points the supernatant samples were taken 
and analysed by RT-PCR using primers specific for IL-6. Expression of IL-6 mRNA 
was detectable from 12 hr post exposure onwards for RRV samples, with 
transcription increasing in a time-dependent manner (Figure 61). LPS samples 
generally showed earlier induction of IL-6 mRNA with faint bands detectable by 4 hr 
post stimulation. The intensity of the bands also increased in a time-dependent 
manner indicating up-regulation of IL-6 mRNA expression. No IL-6 mRNA was 
































Figure 60: IL-6 concentration in the supernatant of C2C12 exposed to RRV or 
LPS 
C2C12 myoblasts were exposed to RRV T48 at an MOI of 1 or LPS (1 µg/mL) and 
supernatant was analysed by IL-6 ELISA. Mock infection with heat inactivated RRV 
was used as negative control. Data is expressed in mean values ± SEM (n=6). 
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Figure 61: IL-6 mRNA expression in C2C12 muscle cells exposed to RRV or 
LPS 
C2C12 myocytes were exposed to RRV T48 (MOI of 1), LPS (1 µg/mL) or HI-RRV 
(MOI of 1) for varying amounts of time and extracted RNA was analysed by RT-PCR 
using primers specific for IL-6 or G3PDH. The figure above shows representative 





5.3.7 RRV and LPS stimulate MIF secretion in C2C12 myoblasts but do not 
induce MIF mRNA transcription 
Challenge of L6 rat myoblasts with TNFα stimulates secretion of macrophage 
migration inhibitory factor (MIF) (Benigni et al., 2000) and more recently a mouse 
model has revealed the crucial role of MIF in the pathogenesis of RRV infection 
(Herrero et al., 2011). Considering these reports together with previous findings 
(Lidbury et al., 2000) of macrophage migration into the muscle of RRV-infected 
mice, we decided to investigate if MIF is secreted from muscle cells during RRV 
infection. C2C12 myoblasts were exposed to LPS (1 µg/mL) or RRV T48 (MOI of 1) 
and supernatant samples were taken and analysed for MIF concentrations by ELISA 
(Figure 62). It appears that C2C12 show some basal secretion of MIF since levels in 
control wells varied between 257 ± 28 pg/mL and 414 ± 47 pg/mL at 4 h and 24 hr 
p.i. respectively. Exposure to LPS increased MIF concentrations in the supernatant 
in a time dependent manner to 2736 ± 787 pg/mL by 24 hr p.s. (p≤0.01). MIF 
release was detectable from 4 hr p.i. onwards for samples exposed to RRV and 
reached concentrations of 2871 ± 730 pg/mL by 12 hr p.i. (p≤0.001) and 4332 ± 864 
pg/mL by 24 hr p.i. (p≤0.001). RNA extracted from the samples at the same time 
points was analysed by RT-PCR for expression of MIF mRNA (Figure 63). MIF 
mRNA expression was below the detection limit for control and RRV samples, but 
showed the respective amplicon for LPS challenged myoblasts at 24 hr p.i. MIF 
positive cDNA samples were run in parallel as RT-PCR control. 
5.3.8 Neither RRV nor LPS induce secretion of IL-10 in C2C12 myoblasts 
Increased interleukin-10 (IL-10) levels have previously been reported for 
macrophages in antibody-dependent enhanced infection of Ross River virus (ADE-
RRV) (Mahalingam & Lidbury, 2002). To investigate if IL-10 is also released by 
infected muscle cells we exposed C2C12 myoblasts to RRV T48 at an MOI of 1 and 
analysed the supernatant at various time points post-infection by IL-10 ELISA. 
Exposure to 1 µg/mL LPS was used in previous experiments as stimulant control 
and the same supernatant samples were analysed for IL-10. Neither RRV nor LPS 
increased inteleukin-10 levels at any time point post stimulation in C2C12 (Figure 
64). RNA extracted at the same time points was analysed by RT-PCR and 





























Figure 62: MIF concentration in the supernatant of C2C12 myoblasts exposed 
to RRV or LPS 
MIF levels in the supernatant of C2C12 exposed to RRV T48 at an MOI of 1 or LPS 
(1 µg/mL) were determined by ELISA at appropriate time points post stimulation. 
Exposure to HI-RRV was used as negative control (Control). All data is expressed in 
median values ± SEM (n=5). **(p≤0.01), ***(p≤0.001) determined by two-way 





















Figure 63: MIF mRNA expression in C2C12 myoblast cells upon exposure to 
RRV or LPS 
C2C12 myocytes were exposed to RRV T48 
RRV for varying amounts of time and extracted RNA was analysed
using primers specific for 
RAW264.7 stimulated with 1 µg/mL LPS was used as positive RT
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Figure 64: IL-10 concentration in the supernatant of RRV- or LPS-stimulated 
C2C12 
C2C12 cells were exposed to RRV T48 at an MOI of 1, LPS (1µg/mL) or HI-RRV 
and supernatant samples were examined for IL-10 concentration by ELISA. All data 






5.3.9 Transcription of HMGB-protein mRNAs is down-regulated by RRV and 
up-regulated by LPS in C2C12 myoblast cells 
As mentioned earlier, HMGB1 protein has been investigated as a pro-inflammatory 
cytokine and recent research identified it as a possible target for inflammation 
control (Nogueira-Machado & de Oliveira Volpe, 2012). The other members of the 
HMGB-family, HMGB2 and HMGB3, have previously also been identified as 
regulatory elements in inflammation and immunity (Yanai et al., 2012). To determine 
if expression of these modulators is altered in RRV infection, we extracted RNA from 
C2C12 myoblasts after exposure to RRV T48 (MOI of 1) or LPS (1 µg/mL) and 
analysed it by RT-PCR using specific primers for the members of the HMGB-protein 
family (Figure 65). Considering the ubiquitous function of HMGB1 as an architectural 
DNA-stabilising protein as well as a cytokine it was not surprising to see basal 
expression of mRNA in all samples and increased transcription of mRNA at 24 hr 
post exposure in LPS stimulated samples (Andersson et al., 2002). Exposure to 
RRV T48 however decreased transcription of HMGB1 by 4 hr p.i. and expression 
stayed reduced thereafter. Similar patterns were detected for HMGB2 and HMGB3 
(Figure 65 B and C). Exposure to RRV T48 down-regulated transcription of the 
specific mRNA whereas stimulation with LPS up-regulated its expression.  
5.3.10 Expression of IL-18 mRNA in C2C12 myoblasts is induced by RRV T48 
or LPS 
Previous studies (Frost et al., 2002) have identified numerous cytokines released by 
LPS stimulated C2C12 myoblasts and reported of an initial increase followed by a 
decrease of IL-18 mRNA transcription post stimulation. We have analysed RNA 
samples extracted from RRV-exposed (MOI of 1) or LPS stimulated (1 µg/mL) 
C2C12 myoblasts by RT-PCR for expression of IL-18 mRNA. Contrary to previous 
findings we could see a strong increase in IL-18 mRNA transcription post exposure 
to LPS (Figure 66). Infection with RRV T48 also resulted in up-regulation of IL-18 
mRNA from 4 hr p.i. onwards, increasing in a timely manner. Cells exposed to HI-
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Figure 65: HMGB mRNA expression in RRV
C2C12 were exposed to RRV T48 
various times and extracted 
HMGB1 (A), HMGB2 (B) or HMGB3 (C)
G3PDH RT-PCR as shown in previous figures (
the PCR amplicons was performed with Image
at each time point over the respective 
mean values ± SEM (n=3)
two-way ANOVA compared to negative controls.


































































































- or LPS treated C2C12 cells
at an MOI of 1, LPS (1 µg/mL
RNA was analysed by RT-PCR with primers specific for 
. Equal RNA loading was validated with 
Figure 63). Densiometric analysis of 
J and graphed as the ratio 
expression at 0 hr. Data is expressed as 
. *(p≤0.05), **(p≤0.01), ***(p≤0.001) 

















) or HI-RRV for 
expression 








     
 
RRV 
IL-18 (195 bp)  
 




IL-18 (195 bp) 
 
 




IL-18 (195 bp) 
 
 
 G3PDH (452 bp) 
 
 
  0 4 12 24  
  Time p.i. (hr)  
Figure 66: IL-18 mRNA expression in C2C12 macrophages stimulated with 
RRV or LPS 
C2C12 myocytes were exposed to RRV T48 at an MOI of 1, LPS (1 µg/mL) or HI-
RRV for varying amounts of time and extracted RNA was analysed by RT-PCR 
using primers specific for IL-18. Pictured above are representative photographs of 





5.3.11 RRV and LPS induce expression of IL-33 mRNA in C2C12 myoblasts 
IL-33, a rather novel cytokine of the IL-1 family has been identified as a pro-
inflammatory mediator in rheumatoid arthritis (D. Xu et al., 2008).  The expression of 
IL-33 in skeletal muscle of canines had been reported long before its role as 
cytokine was reported (Onda et al., 1999). To investigate if RRV possibly affects IL-
33 expression in muscle cells we exposed C2C12 myoblasts to RRV T48 (MOI of 1) 
or LPS (1 µg/mL) and extracted RNA at varying times post stimulation. Conventional 
RT-PCR was performed with primers specific for IL-33. Interestingly, exposure to 
LPS induced IL-33 mRNA expression in a time-dependent manner from 4 hr p.s. 
onwards (Figure 67). A similar, but even stronger inducing effect was apparent for 
RRV-infected C2C12 myoblasts, with mRNA expression detected by 4 hr p.i. with 
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Figure 67: IL-33 mRNA expression in C2C12 myoblasts post exposure to LPS 
or RRV   
C2C12 myoblast cells were infected with RRV T48 at an MOI of 1 or stimulated with 
LPS (1 µg/mL) and RNA was extracted at varying time points post exposure. HI-
RRV was used in mock infections as negative control. Shown above are 





5.4 Inhibition of cytokine production in C2C12 cells 
5.4.1 Introduction 
Febbraio et al. (M. A. Febbraio et al., 2010) reviewed the role of muscle derived IL-6 
in inflammatory diseases like rheumatoid arthritis and evaluated the therapeutic 
potential of IL-6 receptor blockers as anti-inflammatory agents. Considering this 
proposed anti-inflammatory effect of IL-6 receptor blocking antibodies, we suggest 
that inhibition of IL-6 release may potentially decrease the inflammatory response 
commonly observed in RRV infection. As shown in previous experiments, several 
compounds decreased IL-6 release in RRV-infected RAW264.7 macrophages.  
In order to see if a similar reduction of IL-6 secretion can also be observed in mouse 
myoblasts we infected C2C12 cells in the presence of these agents and measured 
IL-6 concentration in the supernatant at appropriate times post-infection. Initial MTT 
viability assays with C2C12 cells showed no cytotoxicity at the previously used 
maximum concentration except for pentoxifylline (PXF) (data not shown). PXF was 
therefore excluded in further experiments with C2C12 myoblasts.  
5.4.2 Macrolide antibiotics do not significantly reduce IL-6 release in RRV-
infected C2C12 myoblasts 
Erythromycin (ERY) and Clarithromycin (CLA) but not Roxithromycin (RXM) have 
previously shown an inhibitory effect on IL-6 release in RRV-infected RAW264.7 
macrophages. To investigate the influence of these macrolide antibiotics on the IL-6 
release of muscle cells in RRV infection, we exposed C2C12 myoblast cells to RRV 
T48 at an MOI of 1 with or without the presence of 100 uM ERY, CLA or RXM and 
analysed the supernatant at appropriate times p.i. by IL-6 ELISA. As Figure 68 
shows, IL-6 levels in the supernatant of RRV-infected C2C12 were generally lower 
for all three macrolides in comparison to non-treated RRV infection, however this 












Figure 68: IL-6 secretion of RRV-infected C2C12 in the presence of macrolides 
C2C12 myoblasts were exposed to RRV T48 at an MOI of 1 in the presence or 
absence of 100 µM ERY (A), CLA (B) or RXM (C) and the supernatant was 
analysed at various times p.i. by IL-6 ELISA. Infection with HI-RRV was used as 
negative control, non-treated infection was used as positive control (RRV). Data is 
expressed in mean values ± SEM (n=3). Statistical analysis was performed by two-




5.4.3 Ethyl pyruvate does not reduce IL-6 secretion in RRV-infected C2C12 
mouse myoblasts 
Previous experiments with RRV-infected RAW264.7 macrophages have shown 
significant reductions of IL-6 release in the presence of ethyl pyruvate (EP). To see 
if EP also reduces IL-6 secretion in RRV-infected myoblasts we infected C2C12 
cells with RRV T48 at an MOI of 1 in the presence of 1000 uM EP and analysed the 
supernatant at 12 and 24 hr p.i. by IL-6 ELISA. Non treated infection was used as 
positive control and compared to treatment. EP did not significantly reduce IL-6 
release from C2C12 myoblasts into the supernatant during RRV infection (Figure 
69). 
5.4.4 Resveratrol does not significantly alter IL-6 release in C2C12 myoblasts 
during RRV infection 
Similarly to the previous compounds, resveratrol (RVT) showed strong inhibitory 
effects on the IL-6 release of RAW264.7 macrophages during RRV infection. To 
investigate a possible effect on C2C12 we infected mouse myoblasts with RRV with 
or without the presence of 50 µM RVT and analysed the supernatant at various 
times post exposure to the virus (Figure 70). RVT did not significantly alter IL-6 
release of RRV-infected C2C12 myoblasts at any time point p.i. (Table 11). 
Table 11: IL-6 concentration of RRV-infected C2C12  
Inhibitor 
IL-6 (pg/mL)  
at 24 hr p.i. 
Significance 
No inhibitor 283±48  
ERY (100 µM) 198±24 ns 
CLA (100 µM) 264±31 ns 
RXM (100 µM) 241±16 ns 
EP (1000 µM) 261±27 ns 
RVT (50 µM) 266±33 ns 
IL-6 levels in C2C12 supernatant were measured at 24 hr p.i. with RRV T48 (MOI of 
1) with or without the presence of ERY, CLA, RXM, EP or RVT. Data is expressed 
as mean values ± SEM (n=3); ns = not significant (as determined by two-way 



























Figure 69: IL-6 concentration of RRV-infected C2C12 in the presence of ethyl 
pyruvate 
C2C12 myoblasts were exposed to RRV T48 at an MOI of 1 in the presence or 
absence of 1000 uM EP and supernatant samples were taken at 12 and 24 hr p.i. 
and analysed by IL-6 ELISA. Mock infection with HI-RRV was used as negative 
control, non-treated infection (RRV) was used as positive control. Data is expressed 
in mean values ± SEM (n=3). Statistical analysis was performed by two-way ANOVA 




























Figure 70: IL-6 concentration in the supernatant of RRV-infected C2C12 
myoblasts co-treated with resveratrol (RVT) 
C2C12 myoblasts were infected with RRV T48 at an MOI of 1 in the presence or 
absence of 50 uM RVT and supernatant samples taken at 12 and 24 hr p.i. were 
analysed by IL-6 ELISA. Non-treated infection was used as positive control (RRV) 
whereas mock infection with HI-RRV served as negative control. All data is graphed 
in mean values ± SEM (n=3). Statistical analysis was performed by two-way ANOVA 





5.5 Inhibition of virus reproducibility with kinos extract 
5.5.1 Introduction 
Locher and Currie (Locher & Currie, 2010) previously published a review on the 
chemistry and pharmacological properties of kinos, a characteristical plant exudate 
often derived from trees of Australian Eucalyptus species. Kinos are strong 
astringents with a high content of polyphenolic tannins and aqueous kino extracts 
(KE) have traditionally been used as antiviral and antibacterial preparations, mainly 
in gastro-intestinal infections. Martha Y. Mungkaje (School of Pharmacy, Curtin 
University, Australia) has investigated kinos extract for its anti-inflammatory 
properties and found that aqueous KE derived from Eucalyptus calophylla reduced 
TNFα and NO release in LPS stimulated macrophages (personal communication).  
Considering these findings we decided to investigate kino for its possible antiviral 
and anti-inflammatory properties in RRV infection. Aqueous kino extract was 
obtained by cold maceration of raw kino in water followed by sterile filtration and 
adjustment to a stock solution containing 33 mg/mL of raw kino. The extracts were 
prepared and kindly donated by Martha Y. Mungkaje (Curtin University, Western 
Australia). Initial viability studies were conducted to examine cytotoxicity of the 
extract on C2C12 myoblast cells. An MTT assay was performed with aqueous KE at 
a maximum concentration of 0.5 mg/mL and two-fold serial dilutions thereof (Figure 
71). Relative viability was calculated against the respective controls of untreated 
C2C12 cells. Viability was not compromised for kino concentrations of up to 0.125 
mg/mL. At concentrations of 0.25 mg/mL and higher cell viability was significantly 
compromised by 48 hr post exposure (p≤0.01).   
5.5.2 RRV infection in C2C12 myoblasts and Vero cells with concurrent 
incubation with kino extract 
The next step after determining cytotoxicity was to investigate if RRV does infect 
C2C12 cells as previously established in the presence of KE. C2C12 muscle cells 
were incubated with 0.1 mg/mL KE and concurrently infected with RRV T48 at an 
MOI of 1. Supernatant samples were taken at regular time intervals and examined 
for the presence of active viral particles. The supernatant of C2C12 cells treated 
with 0.1 mg/mL KE showed significantly reduced viral load at 1 d (p≤0.001) and 3 d 




Photographs of the cells were taken daily p.i. and a progressive cytopathic effect 
was observed in RRV-infected C2C12 myoblasts (Figure 73 B and D) as compared 
to non-infected controls (Figure 73 A and C). Samples exposed to RRV and 
concurrently treated with 0.1 mg/mL KE showed no CPE by 1 d post exposure 
(Figure 73 F) and reduced CPE by 3 d post exposure (Figure 73 H) when compared 
to non-treatment. C2C12 mock infected with HI-RRV (MOI of 1) showed increasing 
morphological changes by 3 d post exposure to kino, with cells presenting more 
rounded and formation of vacuoles within the cytosol (Figure 73 G). 
To examine if the reduction in viral titres upon kino exposure is specific to C2C12 
myoblasts or if it also occurs in other cell lines we exposed Vero cells to 0.1 mg/mL 
KE and determined viral load in the supernatant at appropriate time points post-
infection (Figure 74). Viral titres showed a similar pattern with significantly lower viral 
titres at 1 and 3 d p.i. compared to non-treated infection (p≤0.001). Observation 
under the light microscope confirmed the reduced cytopathic effect in KE-treated 
Vero cells (Figure 75). Exposure to 0.1 mg/mL of kino extract resulted in increased 
vacuolisation within the cytoplasm of the cells for both infected and non-infected 
samples (Figure 75 E-H). Cell lysis in RRV-infected samples appeared however 
reduced with concurrent kino treatment as compared to samples without KE, which 
was most evident by 3 d p.i. (Figure 75 D and H). Cell viability of Vero cells was not 










Figure 71: Cell viability of C2C12 myoblasts after exposure to different 
concentrations of KE 
A MTT viability assay was performed on C2C12 myoblasts using aqueous kino 
extract (KE) at concentrations of 0.5 mg/mL (KE 0.5) and two-fold serial dilutions 
thereof (KE 0.25, KE 0.125 and KE 0.063) for 24 and 48 hr. Relative viability was 
calculated against non-treated control wells, which were given the arbitrary value of 
100% viability. All data shown are mean values ± SEM (n=3). Statistical analysis 
was performed by two-way ANOVA and compared to the respective control for 24 











Figure 72: Virus titre of C2C12 supernatant post RRV infection with and 
without concurrent treatment with kino extract 
C2C12 myoblasts were infected with RRV at an MOI of 1 with or without the 
presence of 0.1 mg/mL kino extract. Supernatant samples were taken at various 
days post-infection and viral titres were determined by TCID50 assay. All data is 
graphed as mean values ± SEM (n=3). Statistical analysis was performed by two-
















   
Figure 73: C2C12 cells
C2C12 cells were inoculated
(B,D) of 0.1 mg/mL kino extract. 
(A,C,E,G). Shown are representative photographs at 1 d (A,B,E,F) and 3 d 
(C,D,G,H) post-infection
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 infected with RRV and concurrent treatment with kino
 with RRV ( MOI of 1) in the presence (F,H) or absence 
Infection with HI-RRV was used as 
















































Figure 74: Virus titre of Vero supernatant post RRV infection with and without 
concurrent treatment with kino extract 
Vero cells were infected with RRV at an MOI of 1 with or without the presence of 0.1 
mg/mL kino extract. Supernatant samples were taken at various days post-infection 
and viral titres were determined by TCID50 assay. All data is graphed as mean 
values ± SEM (n=3). Statistical analysis was performed by two-way ANOVA 
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Figure 75: Vero cells infected with RRV and concurrent treatment with kino  
Vero cells were infected with RRV T48 at an MOI of 1 in the presence (F,H) or 
absence (B,D) of 0.1 mg/mL KE. HI-RRV was used as control (A,C,E,G). Shown 
above are representative photographs of the cells taken at 40x magnification by 1 d 




5.5.3 Kino extract does not have direct antiviral properties 
In order to investigate if the decrease in viral titres is due to reduced viral replication 
or due to direct antiviral activity of KE we incubated RRV T48 stock with kino extract 
and determined viral titres as previously. RRV T48 stock solution with a TCID50 
adjusted to 106.5 was incubated at 4˚C with or without 0.1 and 1 mg/mL KE for 24 or 
48 hr and the number of active virus particles was determined by TCID50 assay. As 
shown in Figure 76, virus titres were not significantly reduced upon incubation with 
0.1 or 1 mg/mL KE as compared to the appropriate control, thus ruling out a direct 
antiviral effect. As expected, the number of active viruses in 48 hr samples show 
lower titres as compared to 24 hr samples due to progressive virus degradation over 
time. 
5.5.4 Virus replication in C2C12 and Vero cells after 24hr pre-treatment with 
aqueous kino extract 
Considering the effect of kino extract on viral replication in both C2C12 and Vero 
cells, we decided to investigate whether prophylactic treatment with KE can 
successfully inhibit viral replication.  
C2C12 or Vero cells were incubated with 0.1 mg/mL aqueous kino extract for 24 hr, 
washed twice with PBS and then exposed to RRV at an MOI of 1 in the absence of 
KE. Supernatant samples were taken daily and virus titres were determined by 
TCID50 assay as previously. As shown in Figure 77, pre-exposure to 0.1 mg/mL KE 
significantly reduced viral titres in the supernatant of infected C2C12 myoblasts in 
the days post exposure (p≤0.001). Low titres were still detectable at 1 d p.i. but by 3 
d p.i. no active virus could be detected by TCID50 assay. Initial experiments 
included 0.5 mg/mL KE samples but were omitted due to the cytotoxicity as shown 
previously (see 5.5.1). In samples pre-treated with 0.5 mg/mL KE no virus was 
detected at 1 or 3 d p.i. (data not shown).  
Photographs taken at the time of sample collection show increasing cytopathic effect 
(CPE) in non-treated infection, with characteristic CPE foci visible from 1 d p.i. 
(Figure 78 B and D). Extensive CPE and cell lysis was observed at 3 d post-
infection. Samples treated with 0.1 mg/mL KE showed reduced growth compared to 
non-treated cells at day 1 and 3 of the experiment with increasing morphological 
changes and rounded cells in both infected as well as mock infected samples. 
Otherwise no obvious difference could be observed between infected and mock 




Similar results were obtained for pre-treatment of Vero cells with 0.1mg/mL kino 
extract followed by RRV infection. Viral load as determined by TCID50 assay showed 
virus levels below the calculation minimum at 1 d p.i. for Vero cells pre-treated with 
0.1 mg/mL KE (Figure 79). No active virus was detected in any of the KE pre-treated 
samples at 3 d p.i. 
Visual observation of the cells under a light microscope showed again progressive 
CPE for RRV-infected samples without KE-pre-treatment at 1 and 3 d p.i. (Figure 80 
B and D) compared to mock-infected control (A and C). Pre-exposure to 0.1 mg/mL 
KE shows morphological changes with cells forming vacuoles within the cytoplasm 
(Figure 80 E-H). This effect was observed for all samples pre-treated with aqueous 
KE. RRV infection shows reduced cytopathic effect and cytolysis in pre-treated 
samples as compared to samples without prior KE exposure. This is especially 






























Figure 76: Virus titres after incubation of RRV T48 with various concentrations 
of KE 
RRV T48 stock solution (TCID50 = 106.801) was incubated with or without KE (0.1 
and 1 mg/mL) for 24 and 48 hrs and virus titres were determined as previously by 
TCID50 assay. Data shown above is graphed as mean values ± SEM (n=3). 
Statistical analysis by two-way ANOVA showed no significant differences between 


































Figure 77: Virus titre in the supernatant of C2C12 myoblasts pre-treated with 
kino extract upon RRV infection  
C2C12 myoblasts were exposed to 0.1 mg/mL aqueous kino extract (KE) for 24 hr 
prior to infection with RRV T48. Viral load in the supernatant was determined by 
TCID50 assay and graphed as log TCID50. # (no virus detected at day 3 p.i. for 
C2C12 pre-treated with KE). Data is shown as mean value ± SEM (n=3). Statistical 
analysis was performed by two-way ANOVA and compared to non-treatment 
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Figure 78: RRV infection of C2C12 cells after pre-treatment with kino extract 
C2C12 were exposed to 0.1 mg/mL aqueous kino-extract (E-H) or R-2 (A-D) for 24 
hr. The supernatant was replaced with R-2 prior to inoculation with RRV T48 (MOI of 
































Figure 79: Viral load in the supernatant of RRV-infected Vero cells after pre-
treatment with 0.1 mg/mL aqueous kino extract 
Vero cells were exposed to 0.1 mg/mL kino extract (KE) for 24 hr prior to infection 
with RRV T48 at an MOI of 1. Viral titres in the supernatant samples were 
determined by TCID50 assay and graphed as log TCID50. Data is shown as mean 
values ± SEM (n=3). # (number of infected wells for pre-treated KE samples at 1 d 
p.i. below calculation limit), ## (no virus detected at day 3 p.i. for C2C12 pre-treated 
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Figure 80: RRV infection in Vero cells after pre-treatment with kino extract 
Vero cells were exposed to 0.1 mg/mL aqueous kino-extract (E-H) or R-2 (A-D) for 
24 hr prior to inoculation with RRV T48 (MOI of 1) (B,D,F,H) or HI-RRV (A,C,E,G). 
Cells were observed daily for morphological changes and CPE. Formation of 




5.6 Discussion of C2C12 results 
The role of muscle cells during RRV infection has still not been fully identified. Initial 
reports gave varying cellular responses for in vivo and in vitro infections and it was 
concluded, that other host factors must be contributing to the necrotic muscle 
pathology in infected mice (Lidbury et al., 2000).  
We were able to show that RRV can undergo a replication cycle in C2C12 mouse 
myoblasts which leads to significantly increased viral numbers and lysis of infected 
cells. Only recently another study was published independently with similar reports 
of C2C12 being suitable cells for RRV propagation (Stoermer Burrack et al., 2014). 
We believe, and our findings support this idea, that the initial spike in viral titres and 
the tissue destruction found in muscles during acute infections are partially caused 
by exponential cytolytic virus replication in muscle cells. With these necrotic 
processes during initial infection, the symptomatic myalgia and myositis would be 
expected. It is however also important to emphasize that we do not doubt the 
significant role of infiltrating macrophages and other leukocytes into the muscle 
during RRVD. Numerous studies have shown that various immune responses such 
as macrophage cytokines or complement activation contribute to the inflammatory 
myopathy of infected mice (Morrison et al., 2007; Morrison et al., 2006) and a recent 
study by Burrack et al. (K. S. Burrack et al., 2015) has highlighted the regulatory 
function of T-cells on virus infection and inflammation in the skeletal muscle tissue.  
We could show that initial infection of C2C12 muscle cells with RRV triggers the 
production of a variety of cytokines. The transcription and/or secretion of the pro-
inflammatory mediators TNFα, MIF, IL-6, IL-18 and IL-33 were clearly up-regulated 
after exposure to RRV. This could explain early macrophage migration and 
activation into the muscle as observed in RRV infected mice. Early research (G. 
Williams et al., 1994) has suggested that LPS alone is not able to induce nitrite 
release from C2C12 myoblasts and a combination of TNFα and IFNγ was required 
for successful induction of NO secretion. Frost et al. (Frost et al., 2004) however 
reported of increased iNOS production and nitrite secretion in LPS challenged 
C2C12 myoblasts. Similar to these results we could show that iNOS mRNA was 
transcribed in both LPS- and RRV-challenged myoblast cells. Despite induction of 
iNOS however, no elevation in supernatant nitrite levels was detected in infected 
C2C12 cells. Initially the increasing lysis of RRV infected cells was considered to be 
a contributing factor to this phenomenon as cell destruction may occur before 




induction of iNOS mRNA transcription without elevated nitrite levels. It remains to be 
determined whether iNOS is translated in insufficient amounts or if the NO response 
is delayed compared to iNOS induction. Due to excessive cytolysis no time points 
past 24 hr post-infection were analysed for cytokine secretion.  
Inhibitors that were previously trialled in macrophages were tested for their effect on 
IL-6 secretion in infected C2C12 myoblasts. IL-6 is recognized as one of the major 
regulatory cytokines released from muscle cells and it has been shown previously 
that IL-6 contributes to macrophage activation (Chomarat et al., 2000; Mark A. 
Febbraio & Pedersen, 2002). Of the tested compounds, little or no inhibitory effect 
was detected for CLA, RXM, EP and RVT. ERY showed some inhibition on IL-6 
release in muscle cells. This together with the results from macrophage experiments 
makes ERY an interesting compound for further investigation as a treatment option 
for RRVD.  
It should be noted that cytokines released from muscle cells function as regulatory 
mediators likely only within the first 12 to 24 hr of infection. Increasing cytolysis 
could result in uncontrolled release of various cytoplasmic compounds and therefore 
macrophage infiltration and activation would be inevitable.  
A second set of experiments focused on the biological effects of aqueous 
Eucalyptus calophylla kino extract (KE) in RRV infected muscle cells. We were able 
to show that treatment with kino extract reduced virus propagation in both C2C12 as 
well as Vero cells. Pre-treatment with KE seemed to completely inhibit the 
replication cycle in both cell lines. KE does not have any direct antiviral properties 
on RRV but chemical analysis has revealed large amounts of tannins in the kino 
exudate (Locher & Currie, 2010). These astringent compounds may precipitate 
surface proteins including integrins, which are considered crucial for successful virus 
adhesion to the cell (La Linn et al., 2005). At the correct KE concentration virus entry 
may be inhibited without impairing cell viability.  
While kino extract seems not suitable as a therapy option in the treatment of RRV 
infections, it does highlight the importance of cell surface structures for alphavirus 
infections, which could potentially offer a target for treatment or prevention of RRV 
disease. It remains to be determined whether KE interacts with specific surface 
structures to interfere with virus adhesion or whether the effects are non-specific 
due to the astringent properties of the extract. Due to its physicochemical properties 
KE is poorly absorbed (Locher & Currie, 2010). A possible future research project 




investigate KE as a possible protective agent against enteric virus infections. It also 
remains to be investigated whether the astringent effect is reversible in C2C12 cells 
or whether cell viability is impaired after prolonged periods of time. The formation of 
vacuoles in the cytoplasm, similar to what we could observe, has previously been 
linked to statin-induced cell damage and apoptotic processes in muscle cells 
(Sakamoto & Kimura, 2013) and therefore more long term viability experiments are 
needed to fully assess cytotoxicity. 
Future research projects could focus on following questions: 
- Are macrophages attracted to infected muscle tissue due to the active 
release of chemokines or due to necrotic processes after infection of RRV? 
- Does the avirulent strain RRV DC5692 show similar cytolytic effects on 
C2C12 myoblast cells? Does it induce the same cytokine response? 
- Is the vacuolisation caused by KE in C2C12 cells a reversible effect? Does 




6. Results IV: Cytokine production of 3T3-L1 adipocytes after  
exposure to Ross River Virus T48 
6.1 Introduction 
Previous studies on the pathogenesis of murine RRV infections in various tissues 
found extensive viral growth in brown adipose tissue (Murphy et al., 1973). Despite 
these findings, no further investigations were undertaken to investigate RRV 
infection in adipocyte cells. Adipocytes are known to produce a wide array of 
cytokines upon stimulation – often labelled adipokines – and their role in many 
inflammatory conditions has been acknowledged (Berg & Scherer, 2005; Coppack, 
2001).  A review of the involvement of adipose tissue in rheumatoid arthritis (Tarner 
et al., 2007) has highlighted a possible role of adipokines as targets for future 
treatments. Considering these findings we decided to investigate a potential role of 
adipocytes in RRV infection. The fibroblast-like pre-adipose cell line 3T3-L1 can be 
differentiated to adipocytes as outlined previously and is commonly used in 
adipocyte research (Poulos et al., 2010). We therefore decided to use differentiated 
3T3-L1 adipocytes in our infection experiments.  
6.2 Infection of 3T3-L1 adipocytes with RRV T48 
6.2.1 3T3-L1 pre-adipocytes do not show CPE upon exposure to RRV 
Even in optimized conditions, differentiation rates of 3T3-L1 pre-adipocytes to 
adipocytes are not likely to reach 100% (Mehra et al., 2007). Hence preliminary 
experiments were conducted to examine the effect of RRV on 3T3-L1 pre-
adipocytes first. To ensure sufficient viral loading the concentration of virus dilution 
was adjusted to MOI = 4 since culture vessel surface was increased. Non-
differentiated 3T3-L1 cells were exposed to RRV T48 (MOI of 4) and observed daily 
for up to 4 d. No cytopathic effect was visible and no morphological changes were 
detected by day 4 (Figure 81 A). Supernatant taken immediately after addition of 
RRV as well as 2 and 4 d p.i. was examined for viral titres by TCID50 assay (Figure 
81 B). Viral load in the supernatant expressed as log TCID50 dropped from 4.88 ± 
0.08 to 2.35 ± 0.55 by day 2 p.i. and no virus could be detected by day 4 p.i. This 
indicates that RRV does not undergo a cytolytic replication cycle in 3T3-L1 pre-
















   
 
 
Figure 81: 3T3-L1 pre-adipocytes exposed to RRV T48 
3T3-L1 pre-adipocytes were exposed to RRV for up to 4 d and examined under a 
light microscope for CPE or morphological changes. Shown in (A) are representative 
photographs of 3T3-L1 pre-adipocytes immediately after infection (Day 0) and 4 d 
p.i. (Day 4). Viral titres of the supernatant were determined as usual and graphed as 
log TCID50 values. All data shown is expressed as mean values ± SEM (n=3). 
Statistical analysis was performed by one-way ANOVA and compared to Day 0. 




6.2.2 3T3-L1 adipocytes do not show CPE upon exposure to RRV 
The next aim was to investigate if RRV does infect 3T3-L1 adipocytes and cause 
cytolysis upon virus replication, similar to Vero or C2C12 cells. In order to test this, 
3T3-L1 pre-adipocytes were differentiated into adipocytes as outlined in Methods 
and exposed to RRV T48 (MOI of 4). Photographs were taken at 36 hr p.i. and 
adipocytes were examined for cytopathic effect. None of the infected cells showed 
cytolysis or any other morphological changes (Figure 82). 
6.2.3 RRV mRNA is expressed in 3T3-L1 adipocytes upon exposure to RRV 
In light of the initial findings that RRV does not immediately undergo a replication 
cycle that leads to lysis of the host cell, we examined if RRV can enter adipocytes in 
a non-cytolytic infection as reported for synovial cells previously (Journeaux et al., 
1987). Differentiated 3T3-L1 adipocytes were exposed to RRV T48 at an MOI of 4 
and RNA was extracted at various time points post-infection. A conventional RT-
PCR was performed to investigate if RRV RNA (viral RNA coding the entire region 
of the viral E2 protein) can be detected within the first 36 hr post-infection. As shown 
in Figure 83, at 18 hr p.i. a very faint band could be detected for adipocytes exposed 
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Figure 82: 3T3-L1 adipocytes after exposure to RRV T48
3T3-L1 adipocytes were exposed to RRV T48 (MOI of
Shown are representative photographs of the adipocytes at 0 hr (A) and 36 hr (B) 
post-infection. Photographs were taken with 






 4) and examined for CPE. 
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Figure 83: RRV RNA can be detected in 3T3-L1 adipocytes post exposure 
3T3-L1 adipocytes were exposed to RRV T48 (MOI of 4) and RNA was extracted at 
various time points post-infection and transcribed into a first strand cDNA as 
outlined in Methods. A PCR was performed to evaluate the expression of viral E2 
RNA with G3PDH used as control gene on the same samples. Shown above are 






6.3 Cytokine production in 3T3-L1 adipocytes in RRV infection 
6.3.1 Neither RRV nor LPS induce TNF-α release in 3T3-L1 adipocytes  
After confirming that RRV does enter 3T3-L1 adipocytes we explored the cellular 
response of infected cells in regards to cytokine production. To examine if RRV 
induces secretion of TNFα in adipocytes we infected differentiated 3T3-L1 with RRV 
T48 and analysed the supernatant by ELISA. Samples taken at any time point p.i. 
did not show increased levels of TNFα (Figure 84). LPS successfully induces TNFα 
secretion in macrophages and was trialled as alternative stimulant, however failed to 
induce TNFα secretion in 3T3-L1 adipocytes. It has previously been reported that 
LPS stimulation induces several pro-inflammatory cytokines in human adipocytes 
but not TNFα (Hoch et al., 2008). RNA extracted at the same time points was 
screened for TNFα mRNA but did not show gene expression in RRV samples or 
LPS samples (data not shown) despite previous reports of LPS induced TNFα 
transcription in 3T3-L1 (Ajuwon & Spurlock, 2005). 
6.3.2 RRV does not induce secretion of NO however induces transcription of 
iNOS mRNA in 3T3-L1 adipocytes 
3T3-L1 adipocytes were exposed to RRV T48 (MOI of 4) and supernatant samples 
were taken after 0, 6, 18 and 36 hr  post-infection and examined by Griess-assay for 
nitrite, a stable oxidation product of biologically released NO. Neither LPS-
stimulated nor RRV-infected 3T3-L1 adipocytes showed increased levels of nitrite in 
the supernatant at any time (Figure 85). RNA extracted at the same time was 
reverse transcribed and analysed by PCR with gene-specific primers for inducible 
iNOS. Transcription of iNOS mRNA was significantly induced in RRV (p≤0.05) and 
LPS (p≤0.01) samples by 6 hr post exposure and gene expression continued in both 










Figure 84: TNFα secretion of 3T3-L1 adipocytes post RRV infection 
3T3-L1 adipocytes were exposed to RRV T48 (MOI of 4) and supernatant samples 
taken at appropriate time points p.i. were tested for TNFα concentration by ELISA. 
Data shown are mean values ± SEM (n=4). Statistical analysis was performed by 
























Figure 85: NO production of 3T3-L1 adipocytes upon RRV infection or LPS 
stimulation 
3T3-L1 adipocytes were exposed to RRV at an MOI of 4, LPS (1 µg/mL) or culture 
media and supernatant samples were taken at appropriate time points. Nitrite 
concentration was determined by Griess assay as outlined in Methods. Data above 
is expressed in mean values ± SEM (n=4). No significant change in nitrite 








































Figure 86: iNOS mRNA expression in 
or LPS 
3T3-L1 adipocytes were exposed to RRV
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6.3.3 3T3-L1 adipocytes secrete IL-6 after infection with RRV 
Previous reports (Fasshauer et al., 2003) have shown that 3T3-L1 adipocytes 
secrete IL-6 upon LPS challenge. To investigate if this pro-inflammatory cytokine is 
also released in RRV infection we exposed adipocytes to RRV T48 and examined 
supernatant samples at different times for IL-6 by ELISA (Figure 87). IL-6 could be 
detected in significant concentrations as early as 6 hr post stimulation with levels 
increasing in a time-dependent manner to 1464 ± 194 pg/mL by 36 hr p.i. (p≤0.001). 
LPS at 1 µg/mL induced IL-6 in a similar way with levels reaching 1575 ± 177 by 36 
hr post stimulation.  
6.3.4 RRV induces expression of IL-6 mRNA in 3T3-L1 adipocytes 
To further investigate the increase of IL-6 secretion, 3T3-L1 adipocytes were 
exposed to RRV or LPS and RNA was extracted at various times post stimulation. A 
RT-PCR with IL-6 specific primers was performed and the obtained gel blots were 
analysed densiometrically as outlined in Methods. Expression of IL-6 mRNA can be 
detected in RRV at 6 hr p.i. increasing in a time-dependent manner (Figure 88 A). 
LPS stimulation similarly shows a significant induction of IL-6 mRNA by 6 hr 
(p≤0.05) with expression still strongly increased after 36 hrs. The semi-quantitative 
densiometric analysis did not show a significantly higher level of expression for RRV 
samples, however photographs of the agarose gels clearly visualised an increase in 
IL-6 mRNA expression (Figure 88 B). 
6.3.5 IL-18 mRNA expression in 3T3-L1 is not influenced by RRV or LPS 
It was previously reported (Sun et al., 2009) that 3T3-L1 adipocytes can secrete IL-
18 and considering the role of IL-18 as one of the pro-inflammatory cytokines in 
rheumatoid arthritis we investigated a possible increase in IL-18 expression during 
RRV infection (Gracie et al., 1999). In order to examine IL-18 mRNA expression, 
3T3-L1 adipocytes were infected with RRV or stimulated with LPS and RNA was 
extracted at various time points. A PCR with IL-18 specific primers was performed 
after reverse transcription and agarose gels were photographed and analysed as 
previously. IL-18 was expressed in RRV-, LPS- as well as non-treated control-
samples equally and no significant change in gene expression was detected over 
































Figure 87: IL-6 concentration in supernatant of 3T3-L1 adipocytes exposed to 
RRV  
3T3-L1 adipocytes were exposed to RRV an MOI of 4, LPS (1 µg/mL) or culture 
media and supernatant samples taken at 0, 6, 18 and 36 hr p.i. were tested for IL-6 
by ELISA. Data above is expressed in mean values ± SEM (n=4). ***(p≤0.001) as 
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Figure 88: IL-6 mRNA expression in 3T3-L1 adipocytes after exposure to RRV 
or LPS 
3T3-L1 adipocytes were exposed to RRV T48 an MOI of 4 or LPS (1 µg/ml) and 
mRNA was extracted at various times. The mRNA expression of the cytokine IL-6 
and G3PDH were determined by densiometric analysis and the ratio of cytokine 
mRNA over G3PDH mRNA is graphed in (A). Data shown are mean values ± SEM 
(n=3 for RRV, LPS and control, n=4 for G3PDH). *(p≤0.05),**(p≤0.01),***(p≤0.001) 
as determined by two-way ANOVA compared to control.  (B) shows representative 
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Figure 89: IL-18 mRNA expression in 3T3-L1 adipocytes after exposure to RRV 
or LPS 
3T3-L1 adipocytes were exposed to RRV T48 an MOI of 4 or LPS (1 µg/mL) and 
mRNA was extracted at various times. mRNA expression of IL-18 and G3PDH was 
determined by densiometric analysis and the ratio of IL-18 mRNA over G3PDH 
mRNA is graphed in (A). Data is expressed in mean values ± SEM (n=4 for RRV 
and G3PDH, n=3 for LPS and control). Analysis by two-way ANOVA compared to 





6.3.6 RRV induces transcription of IL-33 mRNA in 3T3-L1 adipocytes in a 
time dependent manner 
IL-33 has been investigated as a possible contributing factor in rheumatoid arthritis 
and it is known that adipose tissue can release IL-33 (Schaffler & Scholmerich, 
2010; D. Xu et al., 2008). To examine if RRV infection increases expression of this 
cytokine, 3T3-L1 adipocytes were infected with RRV T48 or challenged with LPS as 
previousl and RNA was extracted at several time points post-infection. Transcription 
levels of IL-33 mRNA were determined by RT-PCR and densiometric analysis of gel 
photographs was performed with ImageJ. As shown in Figure 90 B, RRV induces IL-
33 mRNA by 6 hr p.i. and expression increases in a time-dependent manner. At 18 
hr (p≤0.05) and 36 hr (p≤0.01) p.i. the levels of IL-33 mRNA were significantly higher 
compared to non-treated controls. LPS also seems to stimulate IL-33 mRNA 
transcription, however levels were considerably lower compared to RRV samples 
(Figure 90 B). 
6.3.7 HMGB1 mRNA transcription in 3T3-L1 adipocytes during RRV infection 
As mentioned earlier in this thesis, the function of HMGB1 as a cytokine has been 
recognised and it has recently been shown that pre-adipocytes can release HMGB1 
upon stimulation (Nativel et al., 2013). HMGB1 has been identified as a novel 
adipokine that induces IL-6 secretion in SW872 pre-adipocytes and contributes to 
inflammatory processes in adipose tissue. To investigate the role of HMGB1 in 
RRV-infected adipocytes we exposed differentiated 3T3-L1 cells to RRV T48 (MOI 
of 4) and extracted RNA at various times post-infection. RT-PCR was performed 
with primers specific for HMGB1 and agarose gels were photographed and analysed 
with ImageJ as previously. There was a small decrease in HMGB1 transcription for 
RRV-infected samples as compared to control samples, which was however not 
statistically significant as determined by two-way ANOVA (Figure 91). Exposure to 
LPS (1 µg/mL) induced transcription of the HMGB1 gene in 3T3-L1 adipocytes, 
which reached significance by 36 hrs post-infection (p≤0.05) as compared to mock 
infected control.  
6.3.8 Basal HMGB2 expression in 3T3-L1 adipocytes exposed to RRV or LPS 
Similar to HMGB1 we analysed expression of HMGB2 mRNA upon exposure of 
3T3-L1 adipocytes to RRV or LPS. A RT-PCR of extracted RNA samples with 
HMGB2 specific primers indicated a basal HMGB2 expression in 3T3-L1 adipocytes. 
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Figure 90: IL-33 mRNA expression in 3T3-L1 adipocytes after exposure to RRV 
or LPS 
3T3-L1 adipocytes were exposed to RRV T48 (MOI of 4) or LPS (1 µg/mL) and RNA 
extracted at various times. Expression of IL-33 and G3PDH mRNA was determined 
by densiometric analysis and the ratio of IL-33 over G3PDH mRNA was graphed in 
(A). Data shown are mean values ± SEM (n=3 for RRV, LPS and control, n=4 for 
G3PDH). *(p≤0.05), **(p≤0.01) as determined by two-way ANOVA. (B) shows 
representative photographs of agarose gels. Contrast for IL-33 gel photographs was 










































Figure 91: HMGB1 
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Figure 92: HMGB2 mRNA expression in 3T3-L1 adipocytes after exposure to 
RRV or LPS 
3T3-L1 adipocytes were exposed to RRV T48 an MOI of 4 or LPS (1 µg/mL) and 
mRNA was extracted at various times. The mRNA expression of HMGB2 and 
G3PDH was determined by densiometric analysis and the ratio of  
HMGB2 mRNA over G3PDH mRNA is graphed in (A). Data shown are mean values 




6.3.9 RRV reduces transcription of HMGB3 mRNA in 3T3-L1 adipocytes 
Further investigations examined the influence of RRV on HMGB3 transcription in 
3T3-L1 adipocytes. Previously obtained cDNA samples were tested for HMGB3 
mRNA with specific primers. As graphed in Figure 93, densiometric analysis showed 
reduction of HMGB3 mRNA expression in a timely manner in RRV-infected cells 
compared to controls and reached statistical significance by 18 hr p.i. (p≤0.05). 
Exposure of 3T3-L1 adipocytes to LPS did not change the rate of HMGB3 mRNA 
expression. 
6.3.10 MIF mRNA is not expressed in 3T3-L1 adipocytes and neither LPS nor 
RRV induce MIF gene transcription or MIF release 
Increased MIF secretion from 3T3-L1 adipocytes upon TNFα challenge has been 
reported previously (Hirokawa et al., 1997) and more recentrly the crucial role of MIF 
in RRV induced arthritis was established (Herrero et al., 2011). To investigate MIF 
mRNA transcription in adipocytes we exposed 3T3-L1 cells to RRV or LPS and 
extracted mRNA at various time points post exposure. A RT-PCR with MIF specific 
primers was performed on samples and agarose gels were photographed as 
previously. In our conditions, 3T3-L1 adipocytes did not show basal MIF mRNA 
expression and transcription was neither induced by RRV nor by LPS (Figure 94). 
MIF expression in human adipocytes has been examined previously and it was 
reported that basal expression of MIF is not influenced by exposure to LPS (Skurk et 
al., 2005). An ELISA on supernatant samples confirmed that no MIF was secreted 
by 3T3-L1 adipocytes upon exposure to RRV (data not shown).  
6.3.11 LPS and RRV induce MCP-1 gene expression in 3T3-L1 adipocytes 
Inflammatory stimulation has been reported to induce MCP-1 secretion from 3T3-L1 
adipocytes (Sun et al., 2009) and since MCP-1 is a regulatory cytokine in RRV 
infection (Mateo et al., 2000) we investigated its expression in RRV-infected 
adipocytes. RNA was extracted from 3T3-L1 adipocytes at various times post 
exposure to RRV or LPS and RT-PCR was performed with primers specific to the 
MCP-1 gene. Photographs of PCR amplicons were analysed and plotted as shown 
in Figure 95. There was no detectable expression of the MCP-1 gene in control 
samples. LPS-challenged 3T3-L1 adipocytes showed induced transcription of MCP-
1 as early as 6 hr p.s. (p≤0.05), with transcription levels increasing in a time-
dependent manner. Similarly, MCP-1 expression increased in RRV-infected 3T3-L1 
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Figure 93: HMGB3 mRNA expression in 3T3-L1 adipocytes after exposure to 
RRV or LPS 
3T3-L1 adipocytes were exposed to RRV T48 an MOI of 4 or LPS (1 µg/mL) and 
mRNA was extracted at various times. The mRNA expression was determined by 
densiometric analysis and the ratio of cytokine mRNA over G3PDH mRNA was 
graphed in (A). Data shown are mean values ± SEM (n=4 G3PDH, n=3 for RRV, 
LPS and control). (B) shows representative photographs of agarose gels. *(p≤0.05), 
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Figure 94: MIF mRNA expression in 3T3-L1 adipocytes after exposure to RRV 
or LPS 
3T3-L1 adipocytes were exposed to RRV T48 an MOI of 4 or LPS (1 µg/mL) and 
mRNA was extracted at various periods of time. A RT-PCR with specific primers 
was performed and PCR amplicons were photographed. No MIF mRNA was 
detected in any sample in 3 independent experiments. MIF positive samples from 
RAW264.7 cells treated with LPS were included in the PCR to verify assay 
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Figure 95: MCP-1 mRNA expression in RAW264.7 macrophages after exposure 
to RRV or LPS 
3T3-L1 adipocytes were exposed to RRV T48 an MOI of 4 or LPS (1 µg/mL) and 
mRNA was extracted at various times. The mRNA expression of MCP-1 and 
G3PDH were determined by densiometric analysis and graphed as the ratio of 
cytokine mRNA over G3PDH mRNA (A). Data shown are mean values ± SEM (n=4 
for RRV and G3PDH, n=3 for LPS and control). (B) shows representative 




6.4 Discussion of 3T3-L1 results 
As mentioned in the literature review, only Murphy et al. (Murphy et al., 1973) have 
previously described the cytolytic replication cycle of RRV in adipose tissue of 
infected mice. Apart from these early findings, no further information is available on 
the effect of RRV or CHIKV on adipocytes. With our experiments we have shown 
that RRV successfully infects 3T3-L1 adipocytes in a non-cytolytic way in vitro, 
similar to the non-destructive infection previously reported for RRV in human 
synovial cells (Journeaux et al., 1987). These observations seem to stand in 
contrast to previous reports of severe necrosis and cytolysis found in adipose tissue 
of RRV-infected mice (Murphy et al., 1973). The differences in the pathological 
mechanisms of infection and replication however may be caused by various other 
host factors that initiate the cytolytic processes in vivo. Previous studies on RRV 
infected muscle cells have similarly given conflicting reports for in vivo and in vitro 
experiments and it is now recognised that involvement of the complement and 
infiltrating macrophages contribute to the pathological processes in the host 
response (Lidbury et al., 2000; Morrison et al., 2007).  
Our experiments showed that viral mRNA was expressed for more than 6 d p.i. 
without any noticeable cytopathic effect or visible morphological changes. This 
indicates a persistent asymptomatic infection of RRV in adipocytes, comparable to 
the persistent infection found in macrophages (Linn et al., 1996). Whether the 
infection persists over longer periods of time in adipose tissue (e.g. weeks or 
months) is still to be determined. Considering the prolonged duration of RRVD with 
serum viral titres dropping below detection levels these results could indicate a 
possible role of adipocytes as reservoir cells that harbour the virus.  
The potential of adipocytes to release pro-inflammatory cytokines has been reported 
extensively and adipose tissue is considered to be an important contributor to 
inflammatory processes (Berg & Scherer, 2005). Our experiments could show that 
RRV induces various inflammatory and immune mediators in 3T3-L1 adipocytes 
upon infection. An increase in transcription or secretion of the pro-inflammatory 
cytokines IL-6, IL-33 and MCP-1 was observed. Especially the latter has been 
shown to facilitate the recruitment of monocytes and macrophages into the tissue 
and could possibly be a contributing mediator to macrophage infiltration in RRV 
infection as hypothesized earlier (Mateo et al., 2000). IL-18 was not induced in 3T3-
L1 adipocytes after exposure to RRV T48, despite previous reports of its important 




mRNA was detected in all samples but there was no significant difference between 
RRV samples and mock infected samples. Adipocytes may therefore not be the 
primary sources for systemic IL-18 in alphavirus infections.  
Continuous low level expression of MIF has previously been reported in adipocytes 
(Hirokawa et al., 1997) and a more recent study showed the crucial role of MIF in 
alphavirus infections (Herrero et al., 2011). Despite these findings we could not 
detect any basal or induced transcription of MIF mRNA in 3T3-L1 adipocytes or 
secretion of MIF into the supernatant. It is possible, although unlikely, that basal 
expression of MIF mRNA was below our detection level for conventional PCR. It 
appears that adipose tissue does not release MIF upon RRV infection. 
Neither RRV nor LPS induced transcription or secretion of TNFα in 3T3-L1 
adipocytes. Previous reports indicated that LPS-challenge alone does not stimulate 
release of TNFα from adipocytes and our experiments confirmed this. It must be 
noted at this point that no suitable positive stimulator was available at the time of our 
adipocyte experiments and LPS was only trialled as it has previously been shown to 
induce the transcription and release of various cytokines in an array of cells and cell 
types. Future experiments need to include a suitable positive control. Similarly the 
induction of NO-release was not confirmed by positive control stimulation. Neither 
RRV nor LPS induced significant release of nitric oxide from 3T3-L1 adipocytes, 
despite increased transcription of iNOS as detected by RT-PCR. As summarised in 
the literature review, iNOS is an enzyme with a high throughput catalysing 
production of NO and considering the early onset of iNOS induction, an increase of 
nitrite in the supernatant was expected. A similar pattern of early increase in iNOS 
transcription but delayed release of nitric oxide into the supernatant was observed 
for RAW264.7 macrophages. It remains to be investigated if iNOS itself is fully 
synthesized after transcription and whether nitric oxide is produced and released at 
a later stage. 
Basal expression of HMGB1 and HMGB2 were detected as expected but did not 
change upon LPS or RRV stimulation whereas HMGB3 mRNA transcription 
appeared down-regulated in RRV infected adipocytes. The release of HMGB 
proteins as potential extracellular cytokines in RRV infection was investigated, 
however it seems that adipocytes do not show increased synthesis of these 
mediators.  
It is noteworthy that conventional RT-PCR blots were used for semi-quantitative 




against its corresponding G3PDH blot to normalise the value. The data derived 
should however only be used to visualize an increase or decrease of transcription. It 
is strictly semi-quantitative and would require quantitative real-time PCR for 
confirmation. In order to save time and cost we decided not to proceed with real-
time analysis as the initial focus was on identifying genes that are influenced during 
RRV infection. Further experiments with possible inhibitors should include 
quantitative real time PCR analysis.  
Future investigations for RRV infection in adipocytes should focus on following 
questions: 
- Can persistent infection be confirmed with detection of viral mRNA in 3T3-L1 
adipocytes even after longer periods of times (e.g. weeks or months)?  
- Do 3T3-L1 adipocytes show CPE after longer periods of time or with higher 
MOIs?  
- Can Western blots or similar assays detect the transcription of viral proteins 
in 3T3-L1 adipocytes post exposure to RRV? 
- Do adipose tissue samples from RRV mouse models show signs of 
infection? Can the virus be reactivated from adipose tissue or adipocyte cell 
lines if persistent infection was confirmed? 
- Why is iNOS transcription induced within hours after infection with RRV 
without increasing nitrite levels in the supernatant? Is nitric oxide released 
from 3T3-L1 adipocytes at a delayed stage? Is iNOS synthesized after 
transcription of iNOS mRNA? 
- Can these results be repeated with primary adipocytes? 




7. General discussion 
RRV is the most common arbovirus in Australia with up to 5000 infections recorded 
annually. While this number may seem to be small in comparison to the country’s 
population, the impact on people’s health as well as the economy is substantial. In 
addition, case numbers appeared to have increased in the last few years and a 
recent report by the Queensland Health Department (Queensland Health, 2015) 
confirms this trend. By March 2015, Queensland alone recorded more than 3000 
cases which is 8.1 times the five year mean. 
Furthermore, alphaviruses such as RRV or CHIKV present a considerable risk for 
larger outbreaks in the future. A variation in the gene sequence of the viral nsP1 and 
pE2 has been reported to be the cause of the difference in virulence between RRV 
DC5692 and RRV T48 (Jupille et al., 2011). In accordance with these findings our 
preliminary experiments confirmed a significantly reduced cytokine response from 
RRV DC5692-infected macrophages as compared to infection with RRV T48. RRV 
DC7294 showed similar virulence to the T48 strain and it can be assumed that there 
is no or very little difference in the gene sequence coding the nsP1 and pE2. Small 
mutations in these regions however could turn a previously avirulent or 
asymptomatic strain into a virulent strain causing severe symptoms in infection. 
Thus the number of affected patients would increase drastically as current non-
symptomatic infections are generally not noticed and recorded. 
Mutations in the genome of an alphavirus have previously also facilitated vector-
specific adaption. A change in the sequence of the viral E1 gene of CHIKV resulted 
in increased infectivity to the vectors Aedes albopictus and Aedes aegypti and 
thereby contributed to the rapid global spread of CHIKV (Tsetsarkin et al., 2007), 
with outbreaks affecting up to 1.5 million people, such as the 2006 outbreak in India. 
It can be assumed that similar mutations in the genome of RRV may potentially 
cause vector adaption to a wider spectrum of mosquito species or more efficient 
transmission, as reported for CHIKV (de Lamballerie et al., 2008), which would 
undoubtedly increase the risk of large outbreaks in Australia. A recent review (Claflin 
& Webb, 2015) has highlighted the increasing range of suitable RRV vectors within 
Australia, which now includes several brackish and fresh water mosquitoes.   
Lastly, with increasing global travel the risk of introducing CHIKV to Australia is 




travellers returning from affected areas (Viennet et al., 2013) and with suitable 
mosquito vectors such as Aedes alpopictus present throughout the country, it 
appears inevitable that CHIKV will be introduced and established in Australia. In this 
case, the impact on health and economy would be considerably larger as disease 
symptoms are generally more severe and longer lasting. Similar circumstances have 
previously led to a small CHIKV outbreak in Italy in 2007 (Rezza et al., 2007). The 
virus was introduced by a visiting traveller from India and had quickly spread in a 
small region through established mosquito vectors.  
In light of these possible threats and a lack of antiviral therapy it is necessary to 
investigate alternative treatment options for the management of alphavirus 
infections, such as RRVD or CHIKVD. Current treatment options only target 
symptomatic relief with NSAID and analgesic drugs but often lead to severe adverse 
effects when used long term (Suhrbier et al., 2012). It is therefore important to 
further investigate the pathological processes during alphavirus infections and to 
find more effective and economic treatment options. This study aimed to investigate 
the pathogenesis in alphavirus infection and identify targets for pharmacotherapeutic 
intervention. It has previously been suggested that findings in RRV research may 
contribute to the understanding of CHIKV disease (Srivastava et al., 2008) and we 
have therefore decided to use RRV in our experiments, as it poses a lower safety 
hazard compared to CHIKV. The results obtained in this study are however possibly 
applicable to other alphavirus infections, such as CHIKV or BFV. 
After the initial replication and distribution within the host, alphaviruses are known to 
infect a variety of cells and tissues triggering pathological and inflammatory 
processes. Most research has focused on the infection of macrophages and their 
role in the pathogenesis of RRV arthritis is undisputed (Atkins, 2013). Macrophages 
have been shown to migrate into the synovial lining and secrete various cytokines 
during RRV infection which contribute to the local joint inflammation (Lidbury et al., 
2008). To understand the regulatory processes, we investigated which cytokines are 
altered during infection. 
In accordance with other reports we could detect an increase in TNFα (Lidbury et 
al., 2008) and MIF (Herrero et al., 2011) secretion in RRV infected macrophages. 
Our experiments showed induction of iNOS expression, however without increasing 
supernatant NO levels. RRV has been reported to inhibit the iNOS/NO pathway 
previously (Lidbury & Mahalingam, 2000b) but more research is needed to highlight 




reduced NO secretion from LPS-challenged macrophages after 48 hr pre-exposure 
to RRV. Similar results were reported previously in infections with the Venezuelan 
equine encephalitis virus, which further suggests the interference of alphaviruses 
with the NO pathway (Schoneboom et al., 2000). 
The role of IL-6 in CHIKVD has been highlighted before and a correlation between 
IL-6 plasma levels and the severity of arthritic symptoms had been reported (Ng et 
al., 2009). It appears however that the role of IL-6 in RRV infection has not been 
fully investigated yet and we could show increased IL-6 secretion from macrophages 
during infection. Similarly, the role of IL-18 has been recognised in CHIKV 
(Chirathaworn et al., 2010) and we were able to also show increased IL-18 mRNA 
transcription in RRV-infected macrophages respectively. To our knowledge this 
study has for the first time shown that transcription of IL-33 mRNA is increased in 
RRV infected macrophages, indicating a contributing role in the pathogenesis. 
Further we were able to show that PGE2 secretion is not altered in RRV infection. 
HMGB-1 levels in the supernatant were increased, however more research is 
necessary to investigate its role in RRV infection, including more long term infection 
assays to assess whether HMGB1 acts as a possible late mediator in the host’s 
response to the virus. Lastly, in accordance to previous reports (Mahalingam & 
Lidbury, 2002) we could show an increased secretion of IL-10 from RRV-infected 
macrophages. 
With this more detailed knowledge of cytokine expression and secretion from RRV-
infected macrophages we were able to test several compounds for their ability to 
alter cytokine expression and thereby possibly reduce inflammatory responses. 
Apart from non-specific macrophage depletion (Lidbury et al., 2008) or anti-TNFα 
therapy (Zaid et al., 2011) only few other cytokine inhibitors have been trialled 
previously in RRV infection, such as the MCP-1 inhibitor Bindarit (Rulli et al., 2009) 
and more recently the glycosaminoglycan-like molecule Pentosan Polysulfate 
(Herrero et al., 2015). 
As outlined in section 4.4, we tested the macrolide antibiotics erythromycin, 
clarithromycin and roxithromycin as well as ethyl pyruvate, pentoxifylline and 
resveratrol for their ability to reduce pro-inflammatory cytokine expression in RRV-
infected macrophages. Especially ERY and EP showed promising results which 
warrant further investigation. ERY reduced secretion or transcription of TNFα, MIF, 
IL-6 and IL-18, but did not alter the IL-10 response from RRV-infected 




symptoms as it inhibits excessive host responses to clear the virus (Rulli et al., 
2005). It is however not known whether the anti-inflammatory effect of IL-10 would 
outbalance these properties and reduce symptom manifestation during infection. 
Our results suggest a possible role for ERY in the treatment of RRV or other 
alphavirus infections. The highest concentration used in the experiments was similar 
to peak plasma levels in humans treated with a standard antibiotic therapy of 4 
times 500 mg ERY per day (Krasniqi et al., 2012). The safety of ERY has been 
established at this dose and a small clinical trial could assess whether ERY reduces 
the inflammatory symptoms during acute RRV infection. In addition, the results from 
chapter 4.4 indicate a possible role of EP in the treatment of inflammatory symptoms 
during RRV-infection. Treatment with EP reduced the release of TNFα, IL-6 and MIF 
and inhibited transcription of IL-18 mRNA in infected macrophages. A dose-
independent inhibitory effect of EP on IL-6 production has been reported previously 
and our results indicated a similar effect on TNFα during RRV infection (Nativel et 
al., 2013). Further investigations are needed to identify the molecular mechanisms 
of inhibition.  
It should be noted that the results from the inhibitor experiments were derived from 
in vitro conditions only. It remains to be investigated if the inhibitory effect on various 
cytokines does occur in vivo. It has previously been shown that, apart from 
macrophages, many other factors are involved in the progression of RRVD. The 
activation of complement during the host immune response is undoubtedly a major 
contributor to the disease pathology (Morrison et al., 2008) and recent research in a 
RRV mouse model has revealed an important role of T-cells in the control of RRV 
infection in muscle tissue (K. S. Burrack et al., 2015). 
The inhibitors in these experiments have been tested on RRV-infected 
macrophages and their pharmacological effect on other cells during infection is 
largely unknown. We have suggested the involvement of muscle cells in the 
pathogenesis of RRV and several experiments of this study focused on muscle cells 
as possible target for pharmacotherapy intervention in RRV.  
After an incubation period of approximately 3-11 days patients generally start to 
develop symptoms of RRV infection in an initial acute phase with flu like symptoms, 
fever and severe myalgia, mostly lasting for around 4-10 days (Assuncao-Miranda et 
al., 2013). This time frame coincides with a spike in viral titres found in the plasma of 
infected patients (Suhrbier et al., 2012), indicating that rapid viral propagation occurs 




virus propagation involves specific cell types. We believe that RRV undergoes a 
cytolytic replication cycle in muscle cells, which may explain the exponential 
increase in viral numbers as well as the severe myalgia during the acute phase of 
infection. Necrosis of the muscle has been reported previously in RRV infections, 
however infiltrating macrophages or activation of complement has been suggested 
as the causative factor (Lidbury et al., 2008; Morrison et al., 2008). Our experiments 
show a rapid cytolytic replictation of RRV in muscle myoblast cells, which may 
contribute to the intial phase myopathies concurrent with peak virus titres.  
To further investigate the role of muscle cells in RRV infection we focused on a 
possible involvement of myokines, such as IL-6. Our experiments showed that 
several cytokines are released by C2C12 muscle cells during RRV infection, 
including TNFα, MIF and IL-6 and in addition, the transcription of the pro-
inflammatory cytokines IL-18 and IL-33 was induced. Considering the early onset of 
cytokine release it can be assumed that these mediators are actively secreted rather 
than passively released from necrotic or apoptotic cells. We believe that these 
cytokines contribute to the local inflammation and possibly initiate the excessive 
infiltration of macrophages into the muscle tissue.  
This may offer an interesting therapeutic target and we therefore tested the 
inhibitors from previous macrophage experiments on C2C12 cells, focussing on the 
myokine IL-6. The role of muscle derived IL-6 in inflammatory conditions has been 
reviewed previously and the IL-6 signalling pathway has been suggested as a 
possible therapeutic target in anti-inflammatory treatment (M. A. Febbraio et al., 
2010).  
Of the tested compounds only ERY showed an inhibitory effect on IL-6 secretion 
during RRV infection. This effect was however not statistically significant and further 
investigations are necessary to evaluate a possible therapeutic role of ERY. Our 
experiments showed increasing cytolysis of muscle cells within 24 hr of infection in 
vitro and therefore cytokine levels were only analysed for up to 24 hr p.i. The 
inhibitory effect of ERY might however reach significance at a later stage during 
infection, which possibly progresses slower in muscle tissue in vitro due to antiviral 
host response mechanisms. Our data further supports a possible role of ERY in the 
treatment of RRV infection and warrants the use of ERY in a mouse model of 
RRVD. 
In a separate set of experiments the anti-inflammatory effect of kino extract (Martha 




myoblasts. Concurrent exposure of C2C12 and Vero cells to KE and RRV showed a 
reduction of cytolysis and virus titres in the supernatant. Pre-treatment of both 
C2C12 and Vero cells appeared to completely inhibit viral replication, with virus 
titres falling below detectable levels by 3 d post-infection. RRV requires certain cell 
surface proteins, such as integrins, for successful binding and possibly to facilitate 
virus entry. It is possible that the tannins found in kinos precipitate surface structures 
including these proteins and therefore inhibit binding of the virus to the cell surface. 
Unbound RRV would then slowly degrades into an inactivated form over time, 
possibly involving oxidative processes. High concentrations of KE showed 
cytotoxicity on C2C12 myoblasts but at concentrations of 0.125 mg/mL and below it 
appeared that the astringent effect was sufficient to inhibit virus entry without 
affecting cell viability. As previously described, long term experiments are necessary 
to assess prolonged viability of C2C12. Prolonged exposure to 0.125 mg/mL KE 
initiated the formation of vacuoles in the cytoplasm of both Vero cells as well as 
C2C12 cells. It has previously been shown that similar vacuolisation can indicate 
apoptotic processes in muscle cells (Sakamoto & Kimura, 2013), however it remains 
to be investigated whether this is also true for KE treated cells. As mentioned 
previously, initial cytotoxicity assays showed no reduced viability at the given 
concentrations within 3 days. 
The final part of this study briefly investigated a possible involvement of adipocytes 
in RRVD. Early investigations (Murphy et al., 1973) reported of necrotic lesions in 
the fat tissue of RRV-infected mice, but to our knowledge no further study 
considered a possible involvement of adipose tissue or adipocytes in the 
pathogenesis of RRVD. Our experiments indicate that RRV can infect differentiated 
3T3-L1 adipocytes in vitro inducing a non-cytolytic replication, with viral RNA 
detectable for more than 6 days post-infection in the adipocytes. No morphological 
changes or cytolytic foci were visible, in contrast to the observed necrosis in the 
adipose tissue of mice within days of infection with RRV (Murphy et al., 1973). It 
appears that host-mediated immune responses contribute to the severe destruction 
of adipose tissue in vivo, similar to how it was suggested for muscle tissue 
previoulsy (Rulli et al., 2005). Infiltrating immune cells such as macrophages might 
further exacerbate the immune reaction and possibly initiate the necrotic tissue 
destruction. Due to the non-cytolytic infection, adipocytes may act as reservoir cells 
for RRV in vivo and therefore possibly contribute to the prolonged infection. A recent 
study (Couturier et al., 2015) has reported of similar mechanisms with adipose 




term studies are necessary to clarify whether cytolysis occurs at a later stage during 
infection or whether virus replication subsides without lysis of the cell. 
In addition, it has previously been reported that numerous viruses such as 
cytomegalovirus and respiratory syncitial virus can infect human adipocytes and 
induce secretion of pro-inflammatory cytokines such as IL-6 (Bouwman et al., 2008). 
In line with these reports we could show that RRV initiated the transcription and 
expression of numerous cytokines in 3T3-L1 adipocytes in vitro. Both transcription of 
IL-6 mRNA as well as secretion of IL-6 into the supernatant were significantly 
induced in RRV infection. Similarly, the expression of IL-33 mRNA was induced in 
adipocytes exposed to RRV or LPS. Contrary to the cytokine response from infected 
macrophages we could not detect increased transcription of IL-18, MIF, HMGB1 or 
HMGB2 mRNA, it appeared however that expression of HMGB3 mRNA was down-
regulated in RRV-infected adipocytes. MCP-1 has previously been recognised as a 
regulatory cytokine in RRV infection (Mateo et al., 2000) and we could show for the 
first time that adipocytes also exhibited increased transcription of MCP-1 mRNA 
when challenged with LPS or RRV. TNFα secretion and transcription was neither 
induced by RRV- nor by LPS-stimulation. Due to limited availability of other 
inflammatory stimulants LPS was trialled as a possible inducer of TNFα but failed to 
initiate secretion or transcription. This set of experiments was therefore lacking a 
positive control. Each assay did however include an internal control with TNFα-
positive samples from experiments with other cell lines in order to validate the assay 
procedure. Similarly, nitrite was below the detectable level in RRV-treated samples, 
despite increased transcription of iNOS mRNA. These findings are consistent with 
previous experiments in in RAW264.7 and C2C12 cells and further suggest that 
RRV interferes with NO production. More long term experiments are needed to 
investigate whether the NO response is delayed or otherwise inhibited. 
In conclusion, this study could uncover the contribution of several macrophage-
derived cytokines in the pathogenesis or RRV infections. We have shown that 
several compounds were able to inhibit cytokine expression from macrophages and 
especially ERY and EP may be suitable alternatives for the treatment of RRVD. The 
therapeutic potential of these compounds however needs to be further evaluated in 
a RRV mouse model. A recent review has concluded that numerous models of 
alphaviral disease adequately mimic the pathological processes observed in 
alphavirus infections in humans (Taylor et al., 2014) and could therefore examine 
the effects to these compounds beyond macrophages. The involvement of muscle 




replication cycle in muscle cells to be a contributory factor to the development of 
myalgia during RRV infection. We were able to show for the first time that RRV can 
infect adipocytes in what appears to be a non-cytolytic way in vitro and induce 
secretion of pro-inflammatory cytokines and chemokines. The non-cytolytic infection 
indicates a possible role of adipose tissue as a reservoir and further investigations 
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